[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 111
6. Dalton AK, Murray PS, Murray D, Vogt VM: Biochemical characterization of rous sarcoma virus MA protein interaction with membranes. J Virol; 2005 May;79(10):6227-38
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biochemical characterization of rous sarcoma virus MA protein interaction with membranes.
  • We have used an in vitro flotation assay to directly measure Rous sarcoma virus (RSV) MA-membrane interaction in the absence of host cell factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1996 Apr;70(4):2664-8 [8642704.001]
  • [Cites] Biochemistry. 1996 Apr 2;35(13):3933-43 [8672424.001]
  • [Cites] Biophys J. 1996 Aug;71(2):561-75 [8842196.001]
  • [Cites] J Virol. 1996 Dec;70(12):8540-8 [8970978.001]
  • [Cites] Virology. 1972 Nov;50(2):550-7 [4344196.001]
  • [Cites] J Mol Biol. 1979 Jul 15;131(4):819-37 [229234.001]
  • [Cites] J Biol Chem. 1980 Oct 10;255(19):9044-50 [6251073.001]
  • [Cites] Biochim Biophys Acta. 1982 Jul 28;689(2):393-402 [6288099.001]
  • [Cites] Protein Eng. 1998 Sep;11(9):739-47 [9796821.001]
  • [Cites] Cell. 1998 Dec 11;95(6):847-58 [9865702.001]
  • [Cites] J Virol. 1999 Mar;73(3):1902-8 [9971769.001]
  • [Cites] J Virol. 1999 Apr;73(4):2604-12 [10074105.001]
  • [Cites] J Virol. 1999 May;73(5):4136-44 [10196310.001]
  • [Cites] Biochemistry. 1999 Jun 22;38(25):8056-63 [10387050.001]
  • [Cites] J Virol. 1999 Aug;73(8):7050-5 [10400808.001]
  • [Cites] Biophys J. 1999 Dec;77(6):3176-88 [10585939.001]
  • [Cites] Virology. 2000 Feb 15;267(2):289-98 [10662624.001]
  • [Cites] J Mol Biol. 2000 Feb 25;296(3):887-98 [10677289.001]
  • [Cites] J Virol. 2000 Mar;74(6):2855-66 [10684302.001]
  • [Cites] J Virol. 2000 Apr;74(7):3264-72 [10708443.001]
  • [Cites] J Virol. 2000 Jun;74(11):5142-50 [10799589.001]
  • [Cites] J Virol. 1997 May;71(5):3474-83 [9094619.001]
  • [Cites] J Virol. 1997 Jun;71(6):4425-35 [9151833.001]
  • [Cites] J Virol. 1997 Sep;71(9):6582-92 [9261380.001]
  • [Cites] Structure. 1997 Aug 15;5(8):985-9 [9309215.001]
  • [Cites] Biophys J. 1997 Oct;73(4):1717-27 [9336168.001]
  • [Cites] Science. 1997 Oct 31;278(5339):849-53 [9346481.001]
  • [Cites] Pac Symp Biocomput. 1996;:53-72 [9390223.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2580-5 [9482929.001]
  • [Cites] Biochemistry. 1998 Feb 24;37(8):2145-59 [9485361.001]
  • [Cites] J Mol Biol. 1998 Mar 27;277(2):161-9 [9514761.001]
  • [Cites] J Virol. 1998 Apr;72(4):2723-32 [9525590.001]
  • [Cites] EMBO J. 1998 May 1;17(9):2699-708 [9564051.001]
  • [Cites] J Mol Biol. 1998 Jun 19;279(4):921-8 [9642071.001]
  • [Cites] Biophys J. 1998 Aug;75(2):769-76 [9675178.001]
  • [Cites] J Virol. 1998 Sep;72(9):7659-63 [9696871.001]
  • [Cites] J Virol. 2003 Apr;77(8):4805-17 [12663787.001]
  • [Cites] Traffic. 2003 Apr;4(4):201-13 [12694559.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5795-800 [12721375.001]
  • [Cites] J Biol Chem. 2003 Jul 25;278(30):27923-9 [12761222.001]
  • [Cites] J Cell Biol. 2003 Sep 29;162(7):1233-44 [14517204.001]
  • [Cites] Proteins. 2003;53 Suppl 6:430-5 [14579332.001]
  • [Cites] Traffic. 2003 Nov;4(11):785-801 [14617360.001]
  • [Cites] Traffic. 2003 Dec;4(12):902-10 [14617353.001]
  • [Cites] Cell. 2003 Nov 14;115(4):377-88 [14622593.001]
  • [Cites] J Mol Biol. 2004 Jan 2;335(1):275-82 [14659756.001]
  • [Cites] J Virol. 2004 Feb;78(3):1552-63 [14722309.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):517-22 [14699046.001]
  • [Cites] Physiol Rev. 2004 Jul;84(3):699-730 [15269334.001]
  • [Cites] J Virol. 2004 Sep;78(17):9560-3 [15308748.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14889-94 [15465916.001]
  • [Cites] Virology. 1971 Oct;46(1):106-16 [4108030.001]
  • [Cites] Anal Biochem. 1972 Jun;47(2):614-9 [4338619.001]
  • [Cites] J Mol Biol. 2000 May 19;298(5):841-57 [10801353.001]
  • [Cites] J Mol Biol. 2000 Jun 2;299(2):499-520 [10860755.001]
  • [Cites] J Mol Biol. 2000 Jun 30;300(1):103-12 [10864502.001]
  • [Cites] Bioinformatics. 2000 Apr;16(4):404-5 [10869041.001]
  • [Cites] J Mol Biol. 2000 Aug 4;301(1):173-90 [10926500.001]
  • [Cites] J Virol. 2000 Dec;74(23):11222-9 [11070020.001]
  • [Cites] J Virol. 2001 Mar;75(6):2753-64 [11222698.001]
  • [Cites] Virus Res. 2001 Jul;76(1):103-13 [11376850.001]
  • [Cites] J Mol Biol. 2001 Jun 29;310(1):243-57 [11419950.001]
  • [Cites] J Virol. 2001 Sep;75(17):7913-24 [11483736.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10875-9 [11526217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13925-30 [11717449.001]
  • [Cites] J Virol. 2002 Feb;76(4):1876-83 [11799182.001]
  • [Cites] Mol Cell. 2002 Jan;9(1):145-54 [11804593.001]
  • [Cites] Proteins. 2002 May 1;47(2):228-35 [11933069.001]
  • [Cites] J Clin Invest. 2002 Sep;110(5):597-603 [12208858.001]
  • [Cites] Structure. 2002 Dec;10(12):1627-36 [12467570.001]
  • [Cites] J Virol. 2003 Mar;77(5):3058-66 [12584331.001]
  • [Cites] Methods Biochem Anal. 2003;44:427-40 [12647398.001]
  • [Cites] J Virol. 1984 Oct;52(1):145-53 [6090691.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(2):523-7 [2405382.001]
  • [Cites] AIDS. 1991 Jun;5(6):639-54 [1883539.001]
  • [Cites] Proteins. 1991;11(4):281-96 [1758883.001]
  • [Cites] Biochemistry. 1992 Feb 18;31(6):1767-73 [1737030.001]
  • [Cites] Nature. 1992 Mar 5;356(6364):83-5 [1538787.001]
  • [Cites] Proteins. 1992 Apr;13(2):112-9 [1620693.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5181-5 [8389472.001]
  • [Cites] J Virol. 1993 Sep;67(9):5550-61 [8394460.001]
  • [Cites] Biochemistry. 1993 Oct 5;32(39):10436-43 [8399188.001]
  • [Cites] J Virol. 1993 Nov;67(11):6387-94 [8411340.001]
  • [Cites] J Virol. 1993 Nov;67(11):6487-98 [8411352.001]
  • [Cites] J Virol. 1994 Apr;68(4):2556-69 [8139035.001]
  • [Cites] J Virol. 1994 May;68(5):3232-42 [8151785.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 10;91(10):4594-8 [8183954.001]
  • [Cites] J Virol. 1994 Aug;68(8):5311-20 [8035531.001]
  • [Cites] J Virol. 1994 Oct;68(10):6644-54 [7521919.001]
  • [Cites] Biochemistry. 1994 Nov 8;33(44):13093-101 [7947714.001]
  • [Cites] J Mol Biol. 1994 Nov 25;244(2):198-223 [7966331.001]
  • [Cites] Virology. 1994 Nov 15;205(1):336-44 [7975229.001]
  • [Cites] Science. 1995 May 26;268(5214):1144-9 [7761829.001]
  • [Cites] Trends Biochem Sci. 1995 Jul;20(7):272-6 [7667880.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3099-104 [8610175.001]
  • [Cites] J Virol. 1996 Apr;70(4):2269-76 [8642653.001]
  • (PMID = 15858007.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA020081; United States / NIAID NIH HHS / AI / AI54167
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Liposomes; 0 / MA protein, Rous sarcoma virus; 0 / Phosphoproteins; 0 / Viral Matrix Proteins
  • [Other-IDs] NLM/ PMC1091718
  •  go-up   go-down


7. Spugnini EP, Dotsinsky I, Mudrov N, Citro G, D'Avino A, Baldi A: Biphasic pulses enhance bleomycin efficacy in a spontaneous canine genital tumor model of chemoresistance: Sticker sarcoma. J Exp Clin Cancer Res; 2008;27:58
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biphasic pulses enhance bleomycin efficacy in a spontaneous canine genital tumor model of chemoresistance: Sticker sarcoma.
  • Sticker's sarcoma (also known as transmissible venereal tumor) is a horizontally transmitted neoplasm of the dog, that is passed with coitus.
  • [MeSH-major] Anal Gland Neoplasms / drug therapy. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Dog Diseases / drug therapy. Electrochemotherapy / veterinary. Sarcoma / veterinary. Venereal Tumors, Veterinary / drug therapy

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biochem Cell Biol. 2008;40(2):159-63 [17977058.001]
  • [Cites] J Transl Med. 2007;5:48 [17910745.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Dec;26(4):483-7 [18365542.001]
  • [Cites] In Vivo. 2008 Jan-Feb;22(1):47-9 [18396781.001]
  • [Cites] In Vivo. 2008 Jan-Feb;22(1):51-3 [18396782.001]
  • [Cites] Cancer Immunol Immunother. 2008 Jul;57(7):1091-104 [18259750.001]
  • [Cites] Vet J. 2008 Nov;178(2):291-3 [17910926.001]
  • [Cites] Vet J. 2009 Jan;179(1):117-20 [17904882.001]
  • [Cites] Vet Immunol Immunopathol. 2003 May 12;92(3-4):149-62 [12730015.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1508-14 [14734728.001]
  • [Cites] Radiology. 2004 Mar;230(3):761-7 [14990840.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Dec;22(4):571-80 [15053299.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;29(3):214-8 [1733554.001]
  • [Cites] IEEE Eng Med Biol Mag. 1999 Jan-Feb;18(1):62-6 [9934602.001]
  • [Cites] J Vet Med A Physiol Pathol Clin Med. 2005 Sep;52(7):366-70 [16109105.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Jun;24(2):245-54 [16110758.001]
  • [Cites] Melanoma Res. 2006 Feb;16(1):23-7 [16432452.001]
  • [Cites] J Vasc Interv Radiol. 2006 Feb;17(2 Pt 1):351-8 [16517782.001]
  • [Cites] Cell. 2006 Aug 11;126(3):445-7 [16901777.001]
  • [Cites] Cell. 2006 Aug 11;126(3):477-87 [16901782.001]
  • [Cites] Vet Rec. 2006 Oct 28;159(18):598-600 [17071674.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Feb;59(3):375-81 [16807731.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6B):4585-9 [17201181.001]
  • [Cites] Bioelectrochemistry. 2007 May;70(2):283-6 [17150416.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Sep;26(3):343-6 [17987793.001]
  • [Cites] In Vivo. 2007 Sep-Oct;21(5):819-22 [18019417.001]
  • [Cites] In Vivo. 2007 Sep-Oct;21(5):897-9 [18019432.001]
  • [Cites] Vet Rec. 2008 Feb 9;162(6):186-8 [18263920.001]
  • (PMID = 18980687.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  • [Other-IDs] NLM/ PMC2596090
  •  go-up   go-down


8. West J, Damania B: Upregulation of the TLR3 pathway by Kaposi's sarcoma-associated herpesvirus during primary infection. J Virol; 2008 Jun;82(11):5440-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of the TLR3 pathway by Kaposi's sarcoma-associated herpesvirus during primary infection.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) is associated with several different human malignancies, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2006 Nov 15;177(10):7094-102 [17082626.001]
  • [Cites] J Immunol. 2006 Dec 1;177(11):7505-9 [17114417.001]
  • [Cites] Glia. 2007 Feb;55(3):239-52 [17091495.001]
  • [Cites] J Vasc Res. 2007;44(1):51-60 [17167270.001]
  • [Cites] FASEB J. 2006 Oct;20(12):2153-5 [16935934.001]
  • [Cites] J Neuroimmunol. 2006 Oct;179(1-2):46-52 [16884784.001]
  • [Cites] J Biol Chem. 2000 Feb 18;275(7):4670-8 [10671496.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):363-71 [10830743.001]
  • [Cites] Science. 2000 Jun 30;288(5475):2373-6 [10875924.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Jan;280(1):L18-29 [11133491.001]
  • [Cites] Nature. 2000 Dec 7;408(6813):740-5 [11130078.001]
  • [Cites] Nat Immunol. 2001 Aug;2(8):675-80 [11477402.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9237-42 [11470918.001]
  • [Cites] Nature. 2001 Oct 18;413(6857):732-8 [11607032.001]
  • [Cites] Clin Microbiol Rev. 2002 Jul;15(3):439-64 [12097251.001]
  • [Cites] Immunol Lett. 2003 Jan 22;85(2):85-95 [12527213.001]
  • [Cites] J Virol. 2003 Apr;77(8):4588-96 [12663765.001]
  • [Cites] J Virol. 2003 Jul;77(14):7978-90 [12829837.001]
  • [Cites] J Virol. 2003 Aug;77(15):8532-40 [12857922.001]
  • [Cites] Science. 2003 Aug 1;301(5633):640-3 [12855817.001]
  • [Cites] Nature. 2003 Aug 14;424(6950):743-8 [12872135.001]
  • [Cites] Trends Immunol. 2003 Oct;24(10):528-33 [14552836.001]
  • [Cites] Scand J Infect Dis. 2003;35(9):555-62 [14620134.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2179-84 [14633592.001]
  • [Cites] J Virol. 2004 Apr;78(7):3601-20 [15016882.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12542-50 [14729660.001]
  • [Cites] J Immunol. 2004 Jun 1;172(11):6545-9 [15153468.001]
  • [Cites] Cell Biochem Biophys. 2004;40(3):305-22 [15211030.001]
  • [Cites] Nat Rev Immunol. 2004 Jul;4(7):499-511 [15229469.001]
  • [Cites] Virology. 2004 Aug 1;325(2):225-40 [15246263.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Clin Infect Dis. 1992 Feb;14(2):555-67 [1313312.001]
  • [Cites] J Exp Med. 1993 Jun 1;177(6):1809-14 [8496693.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3652-6 [8170963.001]
  • [Cites] J Biol Chem. 2007 Feb 9;282(6):3423-7 [17178723.001]
  • [Cites] Clin Exp Immunol. 2007 Mar;147(3):497-503 [17302899.001]
  • [Cites] J Virol. 2007 Sep;81(18):9748-58 [17609264.001]
  • [Cites] Science. 2007 Sep 14;317(5844):1522-7 [17872438.001]
  • [Cites] FASEB J. 1994 Oct;8(13):1055-60 [7926371.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] J Immunol. 1995 Dec 15;155(12):5769-76 [7499865.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1423-31 [8608232.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] J Virol. 1997 Oct;71(10):7963-8 [9311888.001]
  • [Cites] Blood. 1997 Nov 15;90(10):4099-105 [9354680.001]
  • [Cites] J Gen Virol. 1998 Jul;79 ( Pt 7):1573-91 [9680119.001]
  • [Cites] Ann N Y Acad Sci. 1960 May 12;85:970-9 [13720072.001]
  • [Cites] Nat Struct Mol Biol. 2004 Nov;11(11):1060-7 [15502848.001]
  • [Cites] Nat Med. 2004 Dec;10(12):1366-73 [15558055.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):992-1002 [15634923.001]
  • [Cites] J Neuroimmunol. 2005 Feb;159(1-2):12-9 [15652398.001]
  • [Cites] J Immunol. 2005 Feb 1;174(3):1507-12 [15661910.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):5571-80 [15579900.001]
  • [Cites] J Virol. 2005 Mar;79(6):3350-7 [15731229.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Feb;16(1):1-14 [15733829.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5570-5 [15800047.001]
  • [Cites] J Immunol. 2005 Jul 1;175(1):376-84 [15972671.001]
  • [Cites] J Virol. 2005 Jul;79(14):9301-5 [15994824.001]
  • [Cites] J Virol. 2005 Aug;79(16):10138-46 [16051806.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2790-7 [15976177.001]
  • [Cites] J Immunol. 2005 Oct 15;175(8):5314-23 [16210637.001]
  • [Cites] Glia. 2006 Feb;53(3):248-56 [16265667.001]
  • [Cites] Immunology. 2006 Jan;117(1):11-21 [16423036.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1741-9 [16424204.001]
  • [Cites] Nat Immunol. 2006 Feb;7(2):131-7 [16424890.001]
  • [Cites] Virology. 2006 May 10;348(2):309-27 [16546233.001]
  • [Cites] J Gen Virol. 2006 Jul;87(Pt 7):1781-804 [16760382.001]
  • [Cites] J Gen Virol. 2006 Aug;87(Pt 8):2161-9 [16847112.001]
  • (PMID = 18367536.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA109232-05; United States / NCI NIH HHS / CA / R01 CA109232; United States / NIAID NIH HHS / AI / T32 AI007001; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / CA109232-03; United States / NIDCR NIH HHS / DE / R01-DE018281; United States / NCI NIH HHS / CA / CA109232-01; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01-DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NCI NIH HHS / CA / CA109232-02; United States / NIAID NIH HHS / AI / T32AI007001; United States / NCI NIH HHS / CA / R01 CA109232-05; United States / NCI NIH HHS / CA / R01 CA109232-02; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / PHS HHS / / R01-SCA096500; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NCI NIH HHS / CA / R01 CA109232-01; United States / NCI NIH HHS / CA / R01 CA109232-03; United States / NIDCR NIH HHS / DE / DE018304-03; United States / NIDCR NIH HHS / DE / R01 DE018281
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Intercellular Signaling Peptides and Proteins; 0 / Interferon Regulatory Factor-1; 0 / NF-kappa B; 0 / RNA, Small Interfering; 0 / Toll-Like Receptor 3
  • [Other-IDs] NLM/ PMC2395190
  •  go-up   go-down


9. Sánchez del Monte J, Hernández Guerrero A, Sobrino Cossio S, Lárraga Octavio A, Sánchez Benítez G, López Blanco P, Elguero Pineda E: [Clinical manifestations and endoscopic characteristics of Kaposi's sarcoma in patients with acquired immunodeficiency syndrome]. Rev Gastroenterol Mex; 2005 Oct-Dec;70(4):416-23
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical manifestations and endoscopic characteristics of Kaposi's sarcoma in patients with acquired immunodeficiency syndrome].
  • [Transliterated title] Manifestaciones clinicas y características endoscópicas del sarcoma de Kaposi en pacientes con síndrome de inmunodeficiencia adquirida.
  • BACKGROUND: Kaposi sarcoma may be the initial manifestation of immunodeficiency acquired syndrome (AIDS )in 30% of patients.
  • METHOD: 12 consecutive cases with AIDS and Kaposi sarcoma.
  • The distribution of Kaposi sarcoma was as follows: hard palate 7, soft palate 2, larynx 3, esophagus 2, stomach 10, duodenum 2, colon 5 and anal conduct 1.
  • The biopsy was positive to Kaposi sarcoma in at least one lesion of each patient.
  • CONCLUSIONS: The Kaposi sarcoma appears as a multiple lesion with diverse aspect and colors that go from purple to blue or red.
  • There is correlation between a high number of Kaposi sarcoma lesions, affected organs, immunologic status and mortality.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Gastrointestinal Neoplasms / etiology. Sarcoma, Kaposi / etiology

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058981.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


10. Chatelain D, Mokrani N, Fléjou JF: [Anal and anal margin tumors]. Ann Pathol; 2007 Dec;27(6):459-75
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal and anal margin tumors].
  • Tumors of the anal canal and anal margin are rare.
  • [MeSH-major] Anus Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Endocrine Gland Neoplasms / epidemiology. Endocrine Gland Neoplasms / pathology. France / epidemiology. Humans. Incidence. Leiomyosarcoma / pathology. Lymphoma / pathology. Melanoma / epidemiology. Melanoma / pathology. Papilloma / pathology. Sarcoma, Kaposi / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18554556.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 110
  •  go-up   go-down


11. Kim JY, Cho YM, Ro JY: Prostatic stromal sarcoma with rhabdoid features. Ann Diagn Pathol; 2010 Dec;14(6):453-6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic stromal sarcoma with rhabdoid features.
  • A 31-year-old man presented with a 4-month history of voiding difficulty and anal pain.
  • A needle biopsy was diagnosed as an unclassified spindle cell sarcoma, and 2 cycles of adriamycin-based neoadjuvant chemotherapy were given, followed by radical prostatectomy.
  • The prostatectomy specimen revealed a high-grade sarcoma with fascicles of highly cellular spindle cells and numerous mitoses with hemorrhage and necrosis.
  • The tumor showed an aggressive clinical behavior with a short-term survival (7 months after diagnosis).
  • [MeSH-major] Prostatic Neoplasms / pathology. Rhabdoid Tumor / pathology. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21074696.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Receptors, Progesterone; 0 / Vimentin
  •  go-up   go-down


12. Pepek JM, Willett CG, Wu QJ, Yoo S, Clough RW, Czito BG: Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. Int J Radiat Oncol Biol Phys; 2010 Dec 1;78(5):1413-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis.
  • PURPOSE: Intensity-modulated radiation therapy (IMRT) has the potential to reduce toxicities associated with chemoradiotherapy in the treatment of anal cancer.
  • This study reports the results of using IMRT in the treatment of anal cancer.
  • METHODS AND MATERIALS: Records of patients with anal malignancies treated with IMRT at Duke University were reviewed.
  • RESULTS: Forty-seven patients with anal malignancy (89% canal, 11% perianal skin) were treated with IMRT between August 2006 and September 2008.
  • CONCLUSIONS: IMRT-based chemoradiotherapy for anal cancer results in significant reductions in normal tissue dose and acute toxicities versus historic controls treated without IMRT, leading to reduced rates of toxicity-related treatment interruption.
  • IMRT is emerging as a standard therapy for anal cancer.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / adverse effects
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adolescent. Adult. Aged. Aged, 80 and over. Anemia / etiology. Carcinoma, Squamous Cell / radiotherapy. Diarrhea / etiology. Female. Humans. Leukopenia / etiology. Male. Melanoma / radiotherapy. Middle Aged. Neuroendocrine Tumors / radiotherapy. Radiotherapy Dosage. Rhabdomyosarcoma / radiotherapy. Sarcoma / radiotherapy. Thrombocytopenia / etiology. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20231064.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Dickson MA, Carvajal RD, Shah M, Tse AN, Dials H, Cane LM, Schwartz GK: A phase I clinical trial of FOLFIRI in combination with the pancyclin-dependentkinase (CDK) inhibitor flavopiridol. J Clin Oncol; 2009 May 20;27(15_suppl):e14511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor types: colorectal, gastric, HCC, GE junction, small bowel, pancreas, bile duct, breast, bladder, ovarian, sarcoma, melanoma, anal, urethral, thymic, head & neck, unknown primary.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963517.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


1
Advertisement
4. Lyle PL, Amato CM, Fitzpatrick JE, Robinson WA: Gastrointestinal melanoma or clear cell sarcoma? Molecular evaluation of 7 cases previously diagnosed as malignant melanoma. Am J Surg Pathol; 2008 Jun;32(6):858-66
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal melanoma or clear cell sarcoma? Molecular evaluation of 7 cases previously diagnosed as malignant melanoma.
  • Clear cell sarcoma (CCS) is a rare tumor classically associated with the tendons and aponeuroses of distal extremities of young adults.
  • In total, we examined 7 cases: Four with no prior history of MM, 2 with histories of cutaneous MM, and 1 with an anal MM.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Melanoma / diagnosis. Sarcoma, Clear Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18408594.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Yang Y, Zhang L, Wei Y, Wang H, Xiong W, Chen Z, Hes O, Zheng J: Detection of EWSR1 translocation with nuclear extraction-based fluorescence in situ hybridization for diagnosis of Ewing's sarcoma/primitive neuroectodermal tumor. Anal Quant Cytol Histol; 2007 Aug;29(4):221-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of EWSR1 translocation with nuclear extraction-based fluorescence in situ hybridization for diagnosis of Ewing's sarcoma/primitive neuroectodermal tumor.
  • OBJECTIVE: To investigate nuclear extraction-based fluorescence in situ hybridization (NE-FISH) in EWSR1 translocation of Ewing's sarcoma/primitive neuroectodermal tumor (ES/PNET) in formalin-fixed, paraffin-embedded (FFPE) tissue, compared to thin-section FISH (TS-FISH) and nested reverse-transcription polymerase chain reaction (RT-PCR).
  • A combination of NE-FISH and nested RT-PCR would improve accuracy of molecular diagnosis of ES/PNET.

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879630.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calmodulin-Binding Proteins; 0 / DNA, Neoplasm; 0 / EWSR1 protein, human; 0 / RNA-Binding Proteins
  •  go-up   go-down


16. Hayashi T, Nakamura T, Nakamura S, Kurachi K, Fukazawa A, Nakamura K, Nakajima A, Suzuki S, Konno H: Granulocytic sarcoma presenting as a thrombosed external hemorrhoid in a patient with myelodysplastic syndrome overt leukemia. Clin J Gastroenterol; 2008 Dec;1(4):145-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma presenting as a thrombosed external hemorrhoid in a patient with myelodysplastic syndrome overt leukemia.
  • A 67-year-old Japanese man complained of a painful lump in his anus.
  • A solid lump measuring 1.0 cm in diameter was detected in the anal verge.
  • Under a diagnosis of a thrombosed external hemorrhoid, thrombectomy was performed under local anesthesia.
  • Finally, the diagnosis of granulocytic sarcoma (GS) was made.
  • Though it is well known that perianal complications occur quite often in patients with leukemia, it is unusual for a diagnosis of GS of the anus to be definitely established.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 26193692.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Acute myeloid leukemia (AML) / Granulocytic sarcoma (GS) / Hemorrhoid / Myelodysplastic syndromes (MDS)
  •  go-up   go-down


17. Tan YS, Ng LG, Yip SK, Tay MH, Lim AS, Tien SL, Cheng L, Tan PH: Synovial sarcoma of the kidney: a report of 4 cases with pathologic appraisal and differential diagnostic review. Anal Quant Cytol Histol; 2010 Aug;32(4):239-45
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial sarcoma of the kidney: a report of 4 cases with pathologic appraisal and differential diagnostic review.
  • BACKGROUND: Synovial sarcoma of the kidney is rare.
  • Among malignant spindle cell tumors of the kidney, mimics of synovial sarcoma are sarcomatoid renal cell carcinoma, sarcomatoid urothelial carcinoma and other primary sarcomas, such as leiomyosarcoma and malignant fibrous histiocytoma.
  • CASES: Four cases of synovial sarcoma originated in the kidney, with this report focusing on clinicopathologic and differential diagnostic features.
  • CONCLUSION: The correct diagnosis of synovial sarcoma requires support by an immunohistochemical panel as well as adjunctive investigations like polymerase chain reaction and fluorescence in situ hybridization to determine the presence of the SYT-SSX fusion gene and translocation (X,18), respectively.

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21434526.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / SYT-SSX fusion protein
  •  go-up   go-down


18. Fuchs B, Mahlum E, Halder C, Maran A, Yaszemski M, Bode B, Bolander M, Sarkar G: High expression of tumor endothelial marker 7 is associated with metastasis and poor survival of patients with osteogenic sarcoma. Gene; 2007 Sep 15;399(2):137-43
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of tumor endothelial marker 7 is associated with metastasis and poor survival of patients with osteogenic sarcoma.
  • Our objective is to identify genes regulating metastasis of osteogenic sarcoma (OGS) since metastasis is the primary cause of mortality among patients with OGS.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6649-55 [11559528.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3750-9 [11325848.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):289-300 [12001990.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):89-96 [12027580.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):498-505 [12492492.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):55-63 [12509767.001]
  • [Cites] J Cell Biochem. 2003 Feb 1;88(2):408-17 [12520544.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):411-21 [12778131.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] Cancer Lett. 2003 Jul 30;198(1):1-20 [12893425.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6524-36 [14528277.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2447-56 [14635080.001]
  • [Cites] Curr Opin Oncol. 2004 Jan;16(1):44-9 [14685092.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25 [14685170.001]
  • [Cites] Chin Med J (Engl). 2004 Jan;117(1):94-8 [14733782.001]
  • [Cites] Nat Med. 2004 Feb;10(2):182-6 [14704791.001]
  • [Cites] Cancer. 1971 Feb;27(2):397-402 [5100401.001]
  • [Cites] N Engl J Med. 1986 Jun 19;314(25):1600-6 [3520317.001]
  • [Cites] Pediatr Clin North Am. 1997 Aug;44(4):973-89 [9286295.001]
  • [Cites] Mol Biotechnol. 1997 Oct;8(2):135-7 [9406183.001]
  • [Cites] N Engl J Med. 1999 Jul 29;341(5):342-52 [10423470.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):739-52 [10487832.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8507-11 [15574754.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • [Cites] Anal Biochem. 2000 Nov 1;286(1):91-8 [11038279.001]
  • [Cites] Gene. 2000 Nov 27;258(1-2):155-63 [11111053.001]
  • [Cites] Semin Cancer Biol. 2001 Oct;11(5):327-37 [11562175.001]
  • (PMID = 17560052.001).
  • [ISSN] 0378-1119
  • [Journal-full-title] Gene
  • [ISO-abbreviation] Gene
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR047974-01A1; United States / NIAMS NIH HHS / AR / R01 AR047974-03; United States / NIAMS NIH HHS / AR / AR47974; United States / NIAMS NIH HHS / AR / R01 AR047974-02; United States / NIAMS NIH HHS / AR / AR047974-05; United States / NIAMS NIH HHS / AR / AR047974-03; United States / NIAMS NIH HHS / AR / R01 AR047974-05; United States / NIAMS NIH HHS / AR / AR047974-04; United States / NIAMS NIH HHS / AR / AR047974-02; United States / NIAMS NIH HHS / AR / R01 AR047974; United States / NIAMS NIH HHS / AR / AR047974-01A1; United States / NIAMS NIH HHS / AR / R01 AR047974-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / PLXDC1 protein, human; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Receptors, Cell Surface
  • [Other-IDs] NLM/ NIHMS29184; NLM/ PMC2066185
  •  go-up   go-down


19. Bu W, Carroll KD, Palmeri D, Lukac DM: Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50/Rta lytic switch protein functions as a tetramer. J Virol; 2007 Jun;81(11):5788-806
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50/Rta lytic switch protein functions as a tetramer.
  • The Kaposi's sarcoma-associated herpesvirus open reading frame 50 (ORF50) protein (called Rta), is necessary and sufficient for reactivation of the virus from latency.
  • [MeSH-major] Herpesvirus 8, Human / chemistry. Immediate-Early Proteins / chemistry. Protein Structure, Quaternary. Sarcoma, Kaposi / virology. Trans-Activators / chemistry. Viral Proteins / chemistry. Virus Activation

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. L-Leucine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] J Virol. 2005 May;79(9):5640-52 [15827179.001]
  • [Cites] J Virol. 2005 Jul;79(14):8750-63 [15994769.001]
  • [Cites] Oncogene. 2005 Sep 8;24(40):6165-73 [15897867.001]
  • [Cites] Dermatology. 2001;203(1):19-23 [11549794.001]
  • [Cites] Arch Virol. 2001 Jul;146(7):1415-26 [11556717.001]
  • [Cites] J Invest Dermatol. 2001 Oct;117(4):858-63 [11676823.001]
  • [Cites] J Virol. 2001 Dec;75(24):11961-73 [11711586.001]
  • [Cites] J Virol. 2002 Mar;76(6):2634-40 [11861829.001]
  • [Cites] J Virol. 2002 Apr;76(7):3168-78 [11884541.001]
  • [Cites] J Virol. 2002 May;76(10):5000-13 [11967316.001]
  • [Cites] J Virol. 2002 Jun;76(12):6213-23 [12021355.001]
  • [Cites] J Infect Dis. 2002 Jun 15;185(12):1736-44 [12085319.001]
  • [Cites] J Virol. 2002 Aug;76(16):8252-64 [12134031.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(18):6321-35 [12192032.001]
  • [Cites] Eur J Immunol. 2002 Oct;32(10):2711-20 [12355422.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(22):8282-94 [14585985.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1632-4 [14615380.001]
  • [Cites] J Virol. 2004 Apr;78(8):4248-67 [15047839.001]
  • [Cites] AIDS. 2004 Feb 20;18(3):485-93 [15090801.001]
  • [Cites] J Virol. 2004 May;78(10):5491-9 [15113928.001]
  • [Cites] J Virol. 2004 Jul;78(13):6818-26 [15194757.001]
  • [Cites] Virology. 1999 Oct 25;263(2):436-49 [10544116.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2644-54 [15197808.001]
  • [Cites] J Virol. 2004 Aug;78(16):8615-29 [15280471.001]
  • [Cites] J Virol. 2004 Oct;78(19):10657-73 [15367633.001]
  • [Cites] Biopolymers. 1987 Sep;26(9):1587-600 [3663874.001]
  • [Cites] J Mol Biol. 1988 Jun 5;201(3):601-19 [3418712.001]
  • [Cites] Science. 1989 Jan 27;243(4890):538-42 [2911757.001]
  • [Cites] Science. 1990 Aug 24;249(4971):912-5 [2144057.001]
  • [Cites] Science. 1990 Nov 2;250(4981):646-51 [2237415.001]
  • [Cites] Science. 1990 Dec 7;250(4986):1400-3 [2147779.001]
  • [Cites] FEBS Lett. 1990 Dec 17;277(1-2):185-8 [2269352.001]
  • [Cites] J Mol Biol. 1991 Mar 20;218(2):397-412 [2010917.001]
  • [Cites] Nucleic Acids Res. 1991 May 25;19(10):2661-7 [1645863.001]
  • [Cites] Science. 1991 Oct 25;254(5031):539-44 [1948029.001]
  • [Cites] Pept Res. 1990 May-Jun;3(3):123-37 [2134057.001]
  • [Cites] Biochemistry. 1992 Jun 30;31(25):5739-46 [1610823.001]
  • [Cites] Pept Res. 1988 Sep-Oct;1(1):19-30 [2980779.001]
  • [Cites] Genes Dev. 1993 Sep;7(9):1810-23 [8370528.001]
  • [Cites] Biochem J. 1994 Jan 15;297 ( Pt 2):249-60 [8297327.001]
  • [Cites] J Mol Biol. 1994 Apr 8;237(4):500-12 [8151708.001]
  • [Cites] Cell Mol Life Sci. 2005 Dec;62(23):2771-91 [16231091.001]
  • [Cites] EMBO Rep. 2006 Jan;7(1):41-5 [16391536.001]
  • [Cites] Bioinformatics. 2006 Feb 1;22(3):356-8 [16317077.001]
  • [Cites] J Virol. 2006 Mar;80(6):2958-67 [16501105.001]
  • [Cites] J Virol. 2006 Oct;80(19):9697-709 [16973574.001]
  • [Cites] J Virol. 2006 Dec;80(24):12171-86 [17020951.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):417-22 [10662787.001]
  • [Cites] J Virol. 2000 Apr;74(8):3586-97 [10729134.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] J Clin Virol. 2000 Aug;17(2):127-36 [10942093.001]
  • [Cites] J Virol. 2000 Sep;74(18):8623-34 [10954564.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Jul 1;24(3):270-4 [10969352.001]
  • [Cites] AIDS. 2000 Sep 29;14(14):2109-16 [11061651.001]
  • [Cites] Semin Cancer Biol. 2000 Oct;10(5):367-81 [11100885.001]
  • [Cites] J Virol. 2001 Jan;75(2):891-902 [11134302.001]
  • [Cites] Cell Mol Life Sci. 1999 Nov 30;56(9-10):788-806 [11212339.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(28):44-9 [11158206.001]
  • [Cites] J Virol. 2001 Feb;75(4):1909-17 [11160690.001]
  • [Cites] J Virol. 2001 Mar;75(6):2810-7 [11222705.001]
  • [Cites] J Virol. 2001 Apr;75(7):3129-40 [11238840.001]
  • [Cites] J Virol. 2001 Apr;75(7):3175-84 [11238844.001]
  • [Cites] J Virol. 2001 May;75(10):4843-53 [11312356.001]
  • [Cites] J Virol. 2001 Jul;75(13):5891-8 [11390590.001]
  • [Cites] J Virol. 2001 Aug;75(15):6786-99 [11435557.001]
  • [Cites] J Virol. 2001 Aug;75(15):6894-900 [11435569.001]
  • [Cites] Anal Biochem. 1994 Mar;217(2):220-30 [8203750.001]
  • [Cites] Science. 1994 Jul 15;265(5170):386-91 [8023159.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Science. 1995 Feb 24;267(5201):1078-9 [7855583.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1498-502 [7878469.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Science. 1995 Apr 28;268(5210):582-3 [7725108.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] Protein Sci. 1995 Aug;4(8):1596-607 [8520486.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):158-63 [8548757.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] Lancet. 1996 Oct 26;348(9035):1133-8 [8888167.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):11718-22 [9115224.001]
  • [Cites] J Mol Biol. 1997 Oct 17;273(1):61-74 [9367746.001]
  • [Cites] J Virol. 1998 Feb;72(2):1005-12 [9444993.001]
  • [Cites] AIDS. 1998 May 7;12(7):F45-9 [9619797.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10437-42 [9724721.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 1;20(1):34-8 [9928727.001]
  • [Cites] N Engl J Med. 1999 Apr 8;340(14):1063-70 [10194235.001]
  • [Cites] J Virol. 1999 Jul;73(7):6006-14 [10364352.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] J Virol. 2004 Dec;78(24):13637-52 [15564474.001]
  • [Cites] Immunity. 2005 Jan;22(1):59-70 [15664159.001]
  • [Cites] J Virol. 2005 Feb;79(4):2420-31 [15681443.001]
  • [Cites] Virology. 2007 Mar 1;359(1):19-27 [17055026.001]
  • [Cites] J Virol. 2002 Dec;76(23):12044-54 [12414946.001]
  • [Cites] J Virol. 2002 Dec;76(24):12574-83 [12438583.001]
  • [Cites] J Virol. 2003 Jan;77(1):600-23 [12477864.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2055-67 [12612078.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] AIDS. 2003 Aug 15;17(12):1847-51 [12891072.001]
  • [Cites] J Virol. 2003 Sep;77(17):9399-411 [12915555.001]
  • [Cites] J Virol. 2003 Sep;77(17):9451-62 [12915560.001]
  • [Cites] J Virol. 2003 Sep;77(17):9590-612 [12915572.001]
  • (PMID = 17392367.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immediate-Early Proteins; 0 / ORF 50 transactivator; 0 / Rta protein, Human herpesvirus 8; 0 / Trans-Activators; 0 / Viral Proteins; 9DLQ4CIU6V / Proline; GMW67QNF9C / Leucine
  • [Other-IDs] NLM/ PMC1900300
  •  go-up   go-down


20. Carroll KD, Bu W, Palmeri D, Spadavecchia S, Lynch SJ, Marras SA, Tyagi S, Lukac DM: Kaposi's Sarcoma-associated herpesvirus lytic switch protein stimulates DNA binding of RBP-Jk/CSL to activate the Notch pathway. J Virol; 2006 Oct;80(19):9697-709
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi's Sarcoma-associated herpesvirus lytic switch protein stimulates DNA binding of RBP-Jk/CSL to activate the Notch pathway.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) lytic switch protein, Rta, is a ligand-independent inducer of the Notch signal transduction pathway, and KSHV cannot reactivate from latency in cells null for the Notch target protein RBP-Jk.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 1994 Aug 11;22(15):2938-44 [8065905.001]
  • [Cites] J Virol. 1995 Jan;69(1):253-62 [7983717.001]
  • [Cites] J Virol. 1995 Mar;69(3):1944-50 [7853539.001]
  • [Cites] Science. 1995 Apr 28;268(5210):560-3 [7725102.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] Nature. 1995 Sep 28;377(6547):355-8 [7566092.001]
  • [Cites] Genes Dev. 1995 Nov 1;9(21):2598-608 [7590238.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):952-9 [8622698.001]
  • [Cites] Development. 2004 Mar;131(5):965-73 [14973298.001]
  • [Cites] J Virol. 2004 Apr;78(8):3941-52 [15047810.001]
  • [Cites] J Virol. 2004 Apr;78(8):4248-67 [15047839.001]
  • [Cites] Immunity. 2004 May;20(5):611-22 [15142529.001]
  • [Cites] J Virol. 2004 Jul;78(13):6818-26 [15194757.001]
  • [Cites] Semin Cancer Biol. 2004 Oct;14(5):317-9 [15288256.001]
  • [Cites] EMBO J. 2004 Sep 1;23(17):3441-51 [15297877.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] J Virol. 1987 May;61(5):1310-7 [3033261.001]
  • [Cites] Gene Anal Tech. 1988 Mar-Apr;5(2):22-31 [3192155.001]
  • [Cites] Nature. 1989 Aug 3;340(6232):393-7 [2547164.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Dec;86(23):9558-62 [2556717.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(19):7390-4 [2170976.001]
  • [Cites] J Virol. 1991 May;65(5):2164-9 [1850003.001]
  • [Cites] J Virol. 1991 May;65(5):2545-54 [1850028.001]
  • [Cites] J Virol. 1991 Aug;65(8):4101-6 [1649318.001]
  • [Cites] Annu Rev Immunol. 2005;23:945-74 [15771590.001]
  • [Cites] J Virol. 2005 May;79(9):5640-52 [15827179.001]
  • [Cites] J Virol. 2005 Jul;79(14):8750-63 [15994769.001]
  • [Cites] Cancer Cell. 2005 Jul;8(1):13-23 [16023595.001]
  • [Cites] Oncogene. 2005 Sep 22;24(42):6333-44 [15940249.001]
  • [Cites] J Virol. 2005 Nov;79(22):14371-82 [16254371.001]
  • [Cites] FEBS Lett. 1996 Oct 21;395(2-3):221-4 [8898100.001]
  • [Cites] J Virol. 2000 Feb;74(4):1939-47 [10644367.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(7):2400-10 [10713164.001]
  • [Cites] J Biol Chem. 2000 Jun 2;275(22):17211-20 [10747963.001]
  • [Cites] Genes Dev. 2000 Jun 1;14(11):1343-52 [10837027.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] J Virol. 2000 Sep;74(18):8623-34 [10954564.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1906-13 [10961893.001]
  • [Cites] Nat Genet. 2000 Dec;26(4):484-9 [11101851.001]
  • [Cites] J Virol Methods. 2001 Feb;91(2):109-17 [11164492.001]
  • [Cites] J Virol. 2001 Mar;75(5):2033-40 [11160707.001]
  • [Cites] J Virol. 2001 Jul;75(13):5899-912 [11390591.001]
  • [Cites] Development. 1996 May;122(5):1373-83 [8625826.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2283-91 [8642337.001]
  • [Cites] Genes Dev. 1996 Aug 1;10(15):1930-44 [8756350.001]
  • [Cites] J Clin Invest. 1997 May 1;99(9):2082-6 [9151779.001]
  • [Cites] Mol Cell Biol. 1997 Sep;17(9):5620-8 [9271437.001]
  • [Cites] Development. 1997 Oct;124(20):4133-41 [9374409.001]
  • [Cites] Mol Cell Biol. 1998 Jan;18(1):644-54 [9418910.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2077-88 [9528780.001]
  • [Cites] Cell. 1998 May 15;93(4):649-60 [9604939.001]
  • [Cites] Nature. 1998 May 28;393(6683):382-6 [9620803.001]
  • [Cites] Genes Dev. 1998 Aug 1;12(15):2269-77 [9694793.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1507-17 [9766492.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3728-40 [9851979.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):23-8 [9874765.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] N Engl J Med. 1999 Apr 8;340(14):1063-70 [10194235.001]
  • [Cites] Hum Mol Genet. 1999 May;8(5):723-30 [10196361.001]
  • [Cites] Dev Biol. 1999 Sep 1;213(1):33-53 [10452845.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] Mol Cell. 2004 Nov 19;16(4):509-20 [15546612.001]
  • [Cites] Curr Opin Hematol. 2004 Nov;11(6):426-33 [15548998.001]
  • [Cites] Immunity. 2005 Jan;22(1):59-70 [15664159.001]
  • [Cites] J Virol. 2005 Mar;79(6):3468-78 [15731241.001]
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):551-64 [12842084.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] J Virol. 2003 Sep;77(17):9399-411 [12915555.001]
  • [Cites] J Virol. 2003 Sep;77(17):9590-612 [12915572.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2004;44:219-38 [14744245.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(13):4337-46 [11390662.001]
  • [Cites] J Virol. 2001 Aug;75(15):6786-99 [11435557.001]
  • [Cites] J Virol. 2001 Aug;75(15):6894-900 [11435569.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(18):6222-32 [11509665.001]
  • [Cites] Semin Cancer Biol. 2001 Dec;11(6):423-34 [11669604.001]
  • [Cites] Differentiation. 2001 Dec;69(2-3):135-44 [11798067.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] J Virol. 2002 Apr;76(7):3168-78 [11884541.001]
  • [Cites] J Virol. 2002 May;76(10):5000-13 [11967316.001]
  • [Cites] Nat Immunol. 2002 May;3(5):443-50 [11967543.001]
  • [Cites] Mol Cell Biol. 2002 Jun;22(11):3927-41 [11997524.001]
  • [Cites] J Virol. 2002 Jun;76(12):6185-96 [12021352.001]
  • [Cites] Genes Dev. 2002 Jun 1;16(11):1397-411 [12050117.001]
  • [Cites] Dev Cell. 2002 Jul;3(1):127-36 [12110173.001]
  • [Cites] J Virol. 2002 Aug;76(16):8252-64 [12134031.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1919-21 [12176919.001]
  • [Cites] Mol Cell Biol. 2002 Nov;22(22):7812-9 [12391150.001]
  • [Cites] J Virol. 2002 Dec;76(23):12044-54 [12414946.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(1):14-25 [12482957.001]
  • [Cites] Methods Mol Biol. 2003;212:111-28 [12491906.001]
  • [Cites] Cancer Biol Ther. 2002 Sep-Oct;1(5):466-76 [12496471.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2055-67 [12612078.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):21232-9 [12644465.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] J Virol. 1991 Nov;65(11):5880-5 [1656076.001]
  • [Cites] J Virol. 1991 Dec;65(12):6765-71 [1658373.001]
  • [Cites] J Virol. 1992 May;66(5):2846-52 [1313905.001]
  • [Cites] J Virol. 2003 Jan;77(1):600-23 [12477864.001]
  • [Cites] EMBO J. 1993 Jan;12(1):167-75 [8381349.001]
  • [Cites] Genomics. 1993 Aug;17(2):306-15 [8406481.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9237-41 [8415684.001]
  • [Cites] Mol Cell Biol. 1994 May;14(5):3310-9 [8164682.001]
  • [Cites] J Virol. 1994 Aug;68(8):5184-93 [8035517.001]
  • (PMID = 16973574.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Immediate-Early Proteins; 0 / Immunoglobulin J Recombination Signal Sequence-Binding Protein; 0 / Lectins; 0 / Receptors, Notch; 0 / Rta protein, Human herpesvirus 8; 0 / Trans-Activators; 0 / Viral Proteins; 0 / cerebellar soluble lectin
  • [Other-IDs] NLM/ PMC1617261
  •  go-up   go-down


21. Withers JB, Beemon KL: Structural features in the Rous sarcoma virus RNA stability element are necessary for sensing the correct termination codon. Retrovirology; 2010;7:65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structural features in the Rous sarcoma virus RNA stability element are necessary for sensing the correct termination codon.
  • In the case of the Rous sarcoma virus (RSV), we identified a stability element (RSE), which resides immediately downstream of the gag termination codon and facilitates NMD evasion.
  • [MeSH-major] Codon, Nonsense. Protein Biosynthesis. RNA Stability. RNA, Viral / genetics. RNA, Viral / metabolism. Rous sarcoma virus / physiology. Virus Replication

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2000 Dec 15;19(24):6860-9 [11118221.001]
  • [Cites] Microbiology. 2001 Feb;147(Pt 2):255-69 [11158343.001]
  • [Cites] Science. 2001 Mar 9;291(5510):1959-62 [11239155.001]
  • [Cites] RNA. 2001 Mar;7(3):445-56 [11333024.001]
  • [Cites] Gene. 2001 Oct 3;276(1-2):73-81 [11591473.001]
  • [Cites] Life Sci. 2001 Oct 26;69(23):2697-709 [11720075.001]
  • [Cites] Science. 2002 Oct 11;298(5592):419-22 [12228722.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):361-9 [15004559.001]
  • [Cites] J Virol. 2004 May;78(10):5139-46 [15113896.001]
  • [Cites] Ann Neurol. 2004 May;55(5):740-4 [15122717.001]
  • [Cites] Oncogene. 2004 Oct 18;23(48):7910-7 [15489909.001]
  • [Cites] J Virol. 1977 Oct;24(1):47-63 [198585.001]
  • [Cites] Virology. 1978 Mar;85(1):241-52 [77076.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Mar;75(3):1284-8 [206893.001]
  • [Cites] J Biol Chem. 1979 Aug 25;254(16):8015-22 [224042.001]
  • [Cites] J Gen Virol. 1983 Oct;64 (Pt 10):2191-202 [6311951.001]
  • [Cites] J Virol. 1988 Sep;62(9):3328-33 [2841485.001]
  • [Cites] Nucleic Acids Res. 1988 Nov 11;16(21):9893-908 [3057449.001]
  • [Cites] Mol Cell Biol. 1988 Nov;8(11):4858-67 [2850470.001]
  • [Cites] Mol Cell Biol. 1991 May;11(5):2760-8 [1850103.001]
  • [Cites] Genet Anal Tech Appl. 1991 Nov;8(7):191-205 [1663382.001]
  • [Cites] EMBO J. 1992 Oct;11(10):3747-57 [1327749.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):1835-44 [8114716.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):1986-96 [8114730.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5431-5 [7777525.001]
  • [Cites] J Virol. 1996 Jun;70(6):3834-43 [8648719.001]
  • [Cites] Biochem Cell Biol. 1995 Nov-Dec;73(11-12):1095-103 [8722026.001]
  • [Cites] Biochimie. 1996;78(11-12):945-52 [9150871.001]
  • [Cites] EMBO J. 1998 Jun 15;17(12):3484-94 [9628884.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5272-83 [9710612.001]
  • [Cites] J Mol Biol. 1998 Nov 27;284(2):205-25 [9813113.001]
  • [Cites] Mol Gen Genet. 1998 Nov;260(2-3):176-84 [9862469.001]
  • [Cites] Genome Biol. 2005;6(1):R6 [15642098.001]
  • [Cites] Biochem Soc Trans. 2006 Feb;34(Pt 1):39-42 [16246174.001]
  • [Cites] RNA. 2006 Jan;12(1):102-10 [16301601.001]
  • [Cites] Genes Dev. 2006 Feb 1;20(3):355-67 [16452507.001]
  • [Cites] Cell. 2006 Jun 16;125(6):1125-36 [16777602.001]
  • [Cites] Nucleic Acids Res. 2006;34(21):6147-57 [17088291.001]
  • [Cites] EMBO J. 2008 Mar 5;27(5):736-47 [18256688.001]
  • [Cites] PLoS Biol. 2008 Apr 29;6(4):e92 [18447580.001]
  • [Cites] PLoS Biol. 2008 Apr 29;6(4):e111 [18447585.001]
  • [Cites] J Virol. 2009 Mar;83(5):2119-29 [19091866.001]
  • [Cites] Nucleic Acids Res. 2009 May;37(9):2771-8 [19270062.001]
  • [Cites] Biochim Biophys Acta. 2009 Sep-Oct;1789(9-10):558-70 [19539793.001]
  • [Cites] RNA. 1999 Oct;5(10):1299-307 [10573121.001]
  • [Cites] Am J Hum Genet. 2000 May;66(5):1496-503 [10762540.001]
  • [Cites] J Virol. 2000 Oct;74(20):9507-14 [11000220.001]
  • (PMID = 20687936.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA048746; United States / NCI NIH HHS / CA / R01 CA048746
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / Codon, Nonsense; 0 / RNA, Viral
  • [Other-IDs] NLM/ PMC2925335
  •  go-up   go-down


22. Fujimuro M, Liu J, Zhu J, Yokosawa H, Hayward SD: Regulation of the interaction between glycogen synthase kinase 3 and the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen. J Virol; 2005 Aug;79(16):10429-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of the interaction between glycogen synthase kinase 3 and the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen.
  • The Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded latency-associated nuclear antigen (LANA) protein stabilizes beta-catenin by the novel mechanism of binding to the negative regulator, glycogen synthase kinase 3 (GSK-3), and depleting cytoplasmic GSK-3 levels.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2004 Dec;78(24):14033-8 [15564510.001]
  • [Cites] J Biol Chem. 2003 Dec 5;278(49):48872-9 [14523002.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1121-7 [11017143.001]
  • [Cites] J Gen Virol. 2000 Nov;81(Pt 11):2645-52 [11038375.001]
  • [Cites] J Virol. 2001 Apr;75(7):3250-8 [11238851.001]
  • [Cites] J Virol. 2001 Apr;75(8):3948-59 [11264383.001]
  • [Cites] Mol Cell. 2001 Jun;7(6):1321-7 [11430833.001]
  • [Cites] J Virol. 2001 Sep;75(17):7882-92 [11483733.001]
  • [Cites] J Biol Chem. 2001 Aug 17;276(33):31016-22 [11425857.001]
  • [Cites] J Biol Chem. 2001 Oct 5;276(40):37436-42 [11495916.001]
  • [Cites] Sci STKE. 2001 Sep 18;2001(100):re12 [11579232.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Oct;2(10):769-76 [11584304.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):39037-45 [11487578.001]
  • [Cites] J Biol Chem. 2002 Jan 18;277(3):2176-85 [11707456.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1182-7 [11818547.001]
  • [Cites] Virology. 2001 Dec 20;291(2):241-59 [11878894.001]
  • [Cites] EMBO J. 2002 Apr 2;21(7):1733-42 [11927557.001]
  • [Cites] J Biol Chem. 2002 May 3;277(18):16147-52 [11861647.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1066-76 [12000790.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7951-5 [12048243.001]
  • [Cites] J Neurochem. 2002 Jun;81(5):1073-83 [12065620.001]
  • [Cites] J Biol Chem. 2002 Jun 28;277(26):23330-5 [11967263.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):27401-11 [12015325.001]
  • [Cites] J Virol. 2004 Jan;78(1):294-301 [14671111.001]
  • [Cites] Blood. 2004 Jan 1;103(1):222-8 [12969971.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15572-6 [14663138.001]
  • [Cites] J Biol Chem. 2004 Feb 13;279(7):5263-7 [14630927.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(5):2012-24 [14966281.001]
  • [Cites] J Virol. 2005 Feb;79(4):2637-42 [15681465.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3862-74 [15525642.001]
  • [Cites] J Virol. 2005 Mar;79(6):3468-78 [15731241.001]
  • [Cites] J Virol. 2000 Oct;74(20):9637-45 [11000236.001]
  • [Cites] Virology. 1999 Nov 25;264(2):254-64 [10562490.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]
  • [Cites] J Virol. 2000 Sep;74(18):8532-40 [10954554.001]
  • [Cites] J Virol. 2002 Nov;76(22):11596-604 [12388720.001]
  • [Cites] J Virol. 2002 Nov;76(22):11677-87 [12388727.001]
  • [Cites] J Biol Chem. 2002 Nov 15;277(46):43844-8 [12223487.001]
  • [Cites] J Virol. 2002 Dec;76(24):12917-24 [12438617.001]
  • [Cites] J Virol. 2003 Feb;77(4):2779-83 [12552022.001]
  • [Cites] EMBO J. 2003 Feb 3;22(3):494-501 [12554650.001]
  • [Cites] Nat Med. 2003 Mar;9(3):300-6 [12592400.001]
  • [Cites] J Virol. 2003 May;77(10):5975-84 [12719589.001]
  • [Cites] J Gen Virol. 2003 Jun;84(Pt 6):1451-62 [12771414.001]
  • [Cites] J Virol. 2003 Jul;77(14):8019-30 [12829841.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33067-77 [12796505.001]
  • [Cites] Genes Dev. 2003 Nov 15;17(22):2753-64 [14600025.001]
  • [Cites] Virology. 2004 Feb 20;319(2):225-36 [14980483.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2882-7 [14981260.001]
  • [Cites] Trends Genet. 2004 Apr;20(4):177-81 [15041171.001]
  • [Cites] Trends Biochem Sci. 2004 Feb;29(2):95-102 [15102436.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5251-60 [15289331.001]
  • [Cites] Mol Cell. 2004 Aug 27;15(4):511-21 [15327768.001]
  • [Cites] J Virol. 2004 Sep;78(18):10074-85 [15331740.001]
  • [Cites] J Virol. 2004 Oct;78(19):10348-59 [15367601.001]
  • [Cites] Aging Cell. 2004 Oct;3(5):309-17 [15379854.001]
  • [Cites] J Virol. 2004 Nov;78(21):11648-55 [15479806.001]
  • [Cites] Biochem Soc Trans. 2004 Nov;32(Pt 5):803-8 [15494020.001]
  • [Cites] Anal Biochem. 1987 Nov 1;166(2):368-79 [2449095.001]
  • [Cites] Science. 1996 May 17;272(5264):1023-6 [8638126.001]
  • [Cites] Genes Dev. 1998 Nov 15;12(22):3499-511 [9832503.001]
  • [Cites] J Biol Chem. 1999 Apr 16;274(16):10681-4 [10196136.001]
  • [Cites] Science. 1999 Apr 23;284(5414):641-4 [10213686.001]
  • [Cites] Genes Dev. 1999 Jul 15;13(14):1768-73 [10421629.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):7147-57 [10490650.001]
  • (PMID = 16051835.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA085151; United States / NCI NIH HHS / CA / R01 CA85151
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Nuclear Proteins; 0 / latency-associated nuclear antigen; EC 2.7.11.26 / Glycogen Synthase Kinase 3
  • [Other-IDs] NLM/ PMC1182668
  •  go-up   go-down


23. Greer DA, Ivey S: Distinct N-glycan glycosylation of P-glycoprotein isolated from the human uterine sarcoma cell line MES-SA/Dx5. Biochim Biophys Acta; 2007 Sep;1770(9):1275-82
Hazardous Substances Data Bank. DIGOXIGENIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct N-glycan glycosylation of P-glycoprotein isolated from the human uterine sarcoma cell line MES-SA/Dx5.
  • The uterine sarcoma human cell line MES-SA/Dx5 overexpresses the MDR1 gene product, P-glycoprotein (Pgp).

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1987 Feb 5;262(4):1596-601 [3805045.001]
  • [Cites] Cell. 1986 Nov 7;47(3):381-9 [2876781.001]
  • [Cites] J Biol Chem. 1988 Jan 15;263(2):728-34 [3335522.001]
  • [Cites] J Biol Chem. 1987 Sep 5;262(25):12018-29 [3624245.001]
  • [Cites] Biochemistry. 1988 Oct 4;27(20):7607-13 [2905169.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(1):152-6 [1688652.001]
  • [Cites] Biochemistry. 1990 Mar 6;29(9):2295-303 [1970935.001]
  • [Cites] J Biol Chem. 1991 Jan 5;266(1):83-8 [1985926.001]
  • [Cites] Biochim Biophys Acta. 1991 Mar 4;1073(2):309-15 [1672608.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2302-6 [1347948.001]
  • [Cites] Protein Expr Purif. 1991 Aug;2(4):256-65 [1687982.001]
  • [Cites] J Biol Chem. 1993 Apr 5;268(10):7474-81 [8096511.001]
  • [Cites] Annu Rev Biochem. 1993;62:385-427 [8102521.001]
  • [Cites] Comp Biochem Physiol B. 1993 Nov;106(3):551-6 [8281752.001]
  • [Cites] Methods Enzymol. 1994;230:44-57 [8139511.001]
  • [Cites] Biochemistry. 1994 May 10;33(18):5607-13 [8180185.001]
  • [Cites] Biochem Soc Trans. 1995 Feb;23(1):1-25 [7758655.001]
  • [Cites] J Bioenerg Biomembr. 1995 Feb;27(1):43-52 [7629051.001]
  • [Cites] J Biol Chem. 1995 Sep 29;270(39):22957-61 [7559432.001]
  • [Cites] Am J Med. 1995 Dec 29;99(6A):31S-34S [8585532.001]
  • [Cites] J Biol Chem. 1996 May 24;271(21):12322-6 [8647833.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5969-74 [8650203.001]
  • [Cites] Cancer Res. 1996 Aug 1;56(15):3490-4 [8758935.001]
  • [Cites] Neuron. 1996 Feb;16(2):431-40 [8789958.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jan 13;230(2):398-401 [9016791.001]
  • [Cites] Cancer Lett. 1997 May 19;115(2):221-7 [9149128.001]
  • [Cites] Clin Sci (Lond). 1997 Oct;93(4):287-93 [9404219.001]
  • [Cites] Methods Enzymol. 1998;292:492-504 [9711577.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4C):3107-11 [9713518.001]
  • [Cites] Eur J Biochem. 1998 Aug 15;256(1):170-8 [9746361.001]
  • [Cites] J Biol Chem. 2005 Jan 28;280(4):2857-62 [15485807.001]
  • [Cites] J Biol Chem. 2005 Jan 28;280(4):2522-8 [15542593.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1A):383-9 [15816562.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 May 1;204(3):216-37 [15845415.001]
  • [Cites] Pharmacogenomics. 2005 Mar;6(2):115-38 [15882131.001]
  • [Cites] Gynecol Oncol. 2005 Jul;98(1):31-8 [15921732.001]
  • [Cites] Eur J Pharm Sci. 2006 Apr;27(5):392-400 [16352426.001]
  • [Cites] Curr Opin Struct Biol. 2006 Oct;16(5):584-91 [16938453.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1799-810 [16844681.001]
  • [Cites] Curr Opin Mol Ther. 2006 Dec;8(6):514-20 [17243487.001]
  • [Cites] Pharmacogenomics J. 2007 Jun;7(3):154-79 [16969364.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3661-8 [10589784.001]
  • [Cites] J Membr Biol. 2000 Feb 1;173(3):203-14 [10667916.001]
  • [Cites] Eur J Biochem. 2000 Sep;267(17):5298-305 [10951188.001]
  • [Cites] Rapid Commun Mass Spectrom. 2001;15(6):428-32 [11291121.001]
  • [Cites] Int J Biol Macromol. 2001 Jun 12;28(5):365-71 [11325423.001]
  • [Cites] J Virol. 2001 Oct;75(19):9517-25 [11533214.001]
  • [Cites] Biochim Biophys Acta. 2002 Feb 10;1559(1):21-31 [11825585.001]
  • [Cites] Parasitol Res. 2002 Sep;88(9):816-21 [12172813.001]
  • [Cites] Genome Biol. 2002;3(12):REVIEWS1034 [12537579.001]
  • [Cites] Biochim Biophys Acta. 2003 Feb 17;1610(1):63-76 [12586381.001]
  • [Cites] Anal Biochem. 2003 Aug 1;319(1):122-30 [12842115.001]
  • [Cites] Biochim Biophys Acta. 2003 Nov 20;1639(3):213-24 [14636953.001]
  • [Cites] Biol Pharm Bull. 2004 Jul;27(7):939-48 [15256718.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38395-401 [15247215.001]
  • [Cites] Biochemistry. 1971 Jun 22;10(13):2606-17 [4326772.001]
  • [Cites] Adv Carbohydr Chem Biochem. 1978;35:127-340 [356549.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] J Biol Chem. 1983 Apr 25;258(8):5117-23 [6300116.001]
  • [Cites] Arch Biochem Biophys. 1984 Jun;231(2):524-33 [6203486.001]
  • [Cites] Cancer Res. 1985 Sep;45(9):4091-6 [4028002.001]
  • [Cites] J Biol Chem. 1988 Apr 5;263(10):4576-85 [3350806.001]
  • (PMID = 17692467.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA068992-03; United States / NCI NIH HHS / CA / CA68992-03; United States / NCI NIH HHS / CA / R03 CA068992-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Oligosaccharides, Branched-Chain; 0 / P-Glycoprotein; NQ1SX9LNAU / Digoxigenin
  • [Other-IDs] NLM/ NIHMS29676; NLM/ PMC2034348
  •  go-up   go-down


24. Meşină C, Vasile I, Vîlcea ID, Paşalega M, Pârvănescu H, Calotă F, Georgescu CV, Ghiluşi M, Dumitrescu T, Mirea C, Mogoanţă S, Moraru E: [Soft tissue sarcoma--problems of diagnosis and treatment]. Chirurgia (Bucur); 2010 Mar-Apr;105(2):257-66
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soft tissue sarcoma--problems of diagnosis and treatment].
  • We present 3 cases of soft tissue sarcomas (the tumors were located to the right axilary region, perianal and dorsale face of the left leg) hospitalized in 2nd Surgical Clinic of Emergency Hospital of Craiova and we discuss the difficulties of diagnosis and treatment.
  • In conclusion surgical treatment is mainstay of treatment for soft-tissue sarcomas and is usefull the prompt diagnosis for decrease the risk of local recurrence and metastatic disease.
  • [MeSH-major] Sarcoma / diagnosis. Sarcoma / surgery
  • [MeSH-minor] Aged. Anal Canal / pathology. Anal Canal / surgery. Axilla / pathology. Axilla / surgery. Female. Humans. Leg / pathology. Leg / surgery. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20540243.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


25. Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, Abaan OD, Chou TH, Dakshanamurthy S, Brown ML, Uren A, Toretsky JA: A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med; 2009 Jul;15(7):750-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma.
  • Ewing's sarcoma family tumors (ESFTs) contain a characteristic t(11;22) translocation leading to expression of the oncogenic fusion protein EWS-FLI1.

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Protein Sci. 2000 Sep;9(9):1753-73 [11045621.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10149-54 [18626011.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22317-22 [11301318.001]
  • [Cites] Anal Biochem. 2002 Sep 15;308(2):364-72 [12419351.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):15105-15 [12560328.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):685-94 [12951587.001]
  • [Cites] Semin Cancer Biol. 2003 Aug;13(4):275-81 [14563122.001]
  • [Cites] Biochemistry. 2003 Dec 2;42(47):13787-99 [14636045.001]
  • [Cites] Blood. 2004 Jan 1;103(1):229-35 [12946992.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17134-41 [14769796.001]
  • [Cites] Eur J Biochem. 2004 Sep;271(18):3741-51 [15355351.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4135-9 [15483023.001]
  • [Cites] Biochemistry. 2004 Oct 26;43(42):13579-89 [15491164.001]
  • [Cites] Nature. 1992 Sep 10;359(6391):162-5 [1522903.001]
  • [Cites] J Cell Sci. 1993 Jun;105 ( Pt 2):481-8 [8408279.001]
  • [Cites] N Engl J Med. 1994 Aug 4;331(5):294-9 [8022439.001]
  • [Cites] J Clin Invest. 1997 Jan 15;99(2):239-47 [9005992.001]
  • [Cites] Cell. 1997 Sep 19;90(6):1107-12 [9323138.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4947-52 [9389713.001]
  • [Cites] Nat Genet. 1998 Jul;19(3):254-6 [9662397.001]
  • [Cites] Oncogene. 1998 Aug 6;17(5):603-10 [9704926.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13709-13 [9811865.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):580-4 [9859993.001]
  • [Cites] Cancer Cell. 2005 May;7(5):457-68 [15894266.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6199-206 [16024621.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8984-92 [16204072.001]
  • [Cites] J Comput Chem. 2005 Dec;26(16):1668-88 [16200636.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5574-81 [16740692.001]
  • [Cites] Nat Struct Mol Biol. 2006 Jun;13(6):509-16 [16680162.001]
  • [Cites] Mol Cell Proteomics. 2006 Jul;5(7):1212-23 [16571897.001]
  • [Cites] Nucleic Acids Res. 2006;34(14):3938-46 [16914450.001]
  • [Cites] Trends Biotechnol. 2006 Oct;24(10):435-42 [16876893.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):479-84 [17202261.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):233-45 [17361217.001]
  • [Cites] J Proteome Res. 2007 May;6(5):1882-98 [17391014.001]
  • [Cites] Cancer Cell. 2007 May;11(5):421-9 [17482132.001]
  • [Cites] Mol Cell. 2007 May 25;26(4):523-37 [17531811.001]
  • [Cites] Nat Rev Drug Discov. 2007 Nov;6(11):881-90 [17971784.001]
  • [Cites] Leuk Res. 2008 Apr;32(4):633-42 [17875318.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6004-9 [18413612.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1634-42 [11038348.001]
  • (PMID = 19584866.001).
  • [ISSN] 1546-170X
  • [Journal-full-title] Nature medicine
  • [ISO-abbreviation] Nat. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA138212-01; United States / NCI NIH HHS / CA / R01CA138212; United States / NCI NIH HHS / CA / R01CA133662; United States / NCI NIH HHS / CA / R01 CA088004-08; United States / NCI NIH HHS / CA / R01 CA133662; United States / NCI NIH HHS / CA / CA138212-01; United States / NCI NIH HHS / CA / P01 CA47179; United States / NCI NIH HHS / CA / CA133662-01A2; United States / NCI NIH HHS / CA / R01 CA138212; United States / NCI NIH HHS / CA / P30 CA051008; United States / NCI NIH HHS / CA / R01 CA088004; United States / NCI NIH HHS / CA / R01 CA133662-01A2; United States / NCI NIH HHS / CA / CA088004-08; United States / NCI NIH HHS / CA / P01 CA047179
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / EWS-FLI fusion protein; 0 / Indoles; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Protein c-fli-1; 0 / RNA-Binding Protein EWS; 0 / Transcription Factors; 0 / YK 4-279; EC 3.4.22.- / Caspase 3; EC 3.6.1.- / DHX9 protein, human; EC 3.6.4.13 / DEAD-box RNA Helicases
  • [Other-IDs] NLM/ NIHMS116382; NLM/ PMC2777681
  •  go-up   go-down


26. Delos SE, Godby JA, White JM: Receptor-induced conformational changes in the SU subunit of the avian sarcoma/leukosis virus A envelope protein: implications for fusion activation. J Virol; 2005 Mar;79(6):3488-99
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Receptor-induced conformational changes in the SU subunit of the avian sarcoma/leukosis virus A envelope protein: implications for fusion activation.
  • The avian sarcoma/leukosis virus (ASLV) is activated for fusion by a two-step mechanism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1998 Jan 2;273(1):404-9 [9417096.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2580-5 [9482929.001]
  • [Cites] J Biol Chem. 1998 Mar 13;273(11):6057-65 [9497322.001]
  • [Cites] Nature. 1998 Jun 18;393(6686):648-59 [9641677.001]
  • [Cites] J Virol. 1999 Apr;73(4):3054-61 [10074155.001]
  • [Cites] J Virol. 1999 Jun;73(6):4567-74 [10233915.001]
  • [Cites] J Virol. 2002 Oct;76(19):9920-33 [12208969.001]
  • [Cites] J Virol. 2002 Dec;76(24):12405-13 [12438566.001]
  • [Cites] J Virol. 2003 Jan;77(1):560-70 [12477860.001]
  • [Cites] Science. 2002 Dec 20;298(5602):2353-8 [12459547.001]
  • [Cites] J Virol. 2003 Mar;77(5):3058-66 [12584331.001]
  • [Cites] J Virol. 2003 Jul;77(13):7517-26 [12805452.001]
  • [Cites] Biochim Biophys Acta. 2003 Jul 11;1614(1):3-13 [12873761.001]
  • [Cites] Biochim Biophys Acta. 2003 Jul 11;1614(1):36-50 [12873764.001]
  • [Cites] J Virol. 2003 Oct;77(19):10504-14 [12970435.001]
  • [Cites] J Biol Chem. 2003 Oct 24;278(43):42149-60 [12923196.001]
  • [Cites] Protein Expr Purif. 2004 Apr;34(2):284-95 [15003263.001]
  • [Cites] J Virol. 2004 Apr;78(7):3753-62 [15016895.001]
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):16629-37 [14749324.001]
  • [Cites] Nat Struct Mol Biol. 2004 May;11(5):429-34 [15064754.001]
  • [Cites] Biotechnol Bioeng. 2004 Jun 20;86(6):650-60 [15137076.001]
  • [Cites] Proteins. 2004 Jun 1;55(4):874-84 [15146486.001]
  • [Cites] J Virol. 2004 Aug;78(15):8201-9 [15254191.001]
  • [Cites] Virology. 2004 Aug 15;326(1):171-81 [15262505.001]
  • [Cites] Nature. 1981 Jan 29;289(5796):366-73 [7464906.001]
  • [Cites] J Virol. 1988 Jan;62(1):75-83 [2824857.001]
  • [Cites] J Gen Virol. 1988 Nov;69 ( Pt 11):2785-95 [3183628.001]
  • [Cites] J Virol. 1988 Dec;62(12):4703-11 [2460639.001]
  • [Cites] J Biol Chem. 1990 Jun 25;265(18):10373-82 [2355006.001]
  • [Cites] Science. 1990 Nov 23;250(4984):1139-42 [2251501.001]
  • [Cites] J Virol. 1991 May;65(5):2682-5 [2016774.001]
  • [Cites] J Exp Med. 1991 Aug 1;174(2):407-15 [1713252.001]
  • [Cites] Cell. 1992 Feb 21;68(4):635-45 [1739972.001]
  • [Cites] J Virol. 1992 Aug;66(8):4940-50 [1629960.001]
  • [Cites] Biochemistry. 1993 Oct 12;32(40):10658-65 [8399211.001]
  • [Cites] Biochemistry. 1993 Oct 12;32(40):10839-47 [8399234.001]
  • [Cites] Eur Biophys J. 1994;23(2):105-13 [8050396.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Jan 5;206(1):355-61 [7818541.001]
  • [Cites] Nature. 1995 Jul 6;376(6535):92-4 [7596443.001]
  • [Cites] J Virol. 1995 Nov;69(11):7244-7 [7474146.001]
  • [Cites] J Virol. 1995 Dec;69(12):7410-5 [7494245.001]
  • [Cites] Nat Struct Biol. 1996 May;3(5):465-9 [8612078.001]
  • [Cites] Anal Biochem. 1996 Mar 15;235(2):175-84 [8833325.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12766-71 [10535997.001]
  • [Cites] J Cell Sci. 2000 Jan;113 ( Pt 1):37-44 [10591623.001]
  • [Cites] FEBS Lett. 1999 Dec 17;463(3):255-9 [10606732.001]
  • [Cites] J Virol. 2000 Jan;74(2):627-43 [10623724.001]
  • [Cites] J Biol Chem. 2000 Feb 4;275(5):3264-9 [10652313.001]
  • [Cites] Science. 2000 Mar 10;287(5459):1828-30 [10710311.001]
  • [Cites] J Virol. 2000 Jul;74(14):6469-75 [10864659.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21017-24 [10747921.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9026-31 [10922058.001]
  • [Cites] Annu Rev Biochem. 2000;69:531-69 [10966468.001]
  • [Cites] J Virol. 2001 Apr;75(8):3685-95 [11264358.001]
  • [Cites] J Virol. 2001 Oct;75(19):9096-105 [11533173.001]
  • [Cites] J Biol Chem. 2001 Nov 16;276(46):42667-76 [11544255.001]
  • [Cites] FEBS Lett. 2001 Dec 7;509(2):161-8 [11768384.001]
  • [Cites] Cell. 1999 Jun 11;97(6):671-4 [10380917.001]
  • [Cites] Biochemistry. 1999 Jul 20;38(29):9405-16 [10413516.001]
  • [Cites] Annu Rev Nutr. 1999;19:141-72 [10448520.001]
  • [Cites] J Virol. 2004 Dec;78(24):13430-9 [15564453.001]
  • [Cites] J Virol. 2002 Mar;76(6):2848-56 [11861852.001]
  • [Cites] Virology. 2002 Mar 15;294(2):354-63 [12009877.001]
  • [Cites] Trends Endocrinol Metab. 2002 Mar;13(2):66-74 [11854021.001]
  • [Cites] J Virol. 1996 Nov;70(11):7510-6 [8892869.001]
  • [Cites] J Virol. 1997 Mar;71(3):2383-9 [9032375.001]
  • [Cites] J Virol. 1997 May;71(5):3458-65 [9094617.001]
  • [Cites] Nature. 1997 Aug 14;388(6643):691-3 [9262405.001]
  • [Cites] J Virol. 1997 Dec;71(12):9722-31 [9371638.001]
  • [Cites] J Cell Biol. 1997 Dec 15;139(6):1455-64 [9396751.001]
  • (PMID = 15731243.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI022470; United States / NIAID NIH HHS / AI / AI22470
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Avian Proteins; 0 / Protein Subunits; 0 / Receptors, Virus; 0 / Recombinant Proteins; 0 / Tva receptor; 0 / Viral Envelope Proteins; 0 / glycoprotein 85, avian leukosis virus
  • [Other-IDs] NLM/ PMC1075726
  •  go-up   go-down


27. Garrigues HJ, Rubinchikova YE, Dipersio CM, Rose TM: Integrin alphaVbeta3 Binds to the RGD motif of glycoprotein B of Kaposi's sarcoma-associated herpesvirus and functions as an RGD-dependent entry receptor. J Virol; 2008 Feb;82(3):1570-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrin alphaVbeta3 Binds to the RGD motif of glycoprotein B of Kaposi's sarcoma-associated herpesvirus and functions as an RGD-dependent entry receptor.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) envelope-associated glycoprotein B (gB) is involved in the initial steps of binding to host cells during KSHV infection. gB contains an RGD motif reported to bind the integrin alpha(3)beta(1) during virus entry.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1997 May 1;57(9):1682-9 [9135008.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):19794-800 [9242639.001]
  • [Cites] Int J Biochem Cell Biol. 1997 May;29(5):721-5 [9251239.001]
  • [Cites] J Virol. 1997 Dec;71(12):9764-9 [9371642.001]
  • [Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]
  • [Cites] Annu Rev Cell Biol. 1988;4:487-525 [3058164.001]
  • [Cites] J Biol Chem. 1988 Dec 15;263(35):18726-31 [2461930.001]
  • [Cites] J Biol Chem. 1990 Feb 5;265(4):2168-72 [1688848.001]
  • [Cites] Cell. 1991 May 17;65(4):599-610 [2032285.001]
  • [Cites] J Invest Dermatol. 1992 May;98(5):764-70 [1569325.001]
  • [Cites] J Virol. 1999 Apr;73(4):3040-53 [10074154.001]
  • [Cites] Biochem Soc Symp. 1999;65:79-99 [10320934.001]
  • [Cites] J Biol Chem. 1999 Aug 20;274(34):24080-6 [10446179.001]
  • [Cites] J Nucl Med. 1999 Jun;40(6):1061-71 [10452325.001]
  • [Cites] J Virol. 2005 Jan;79(2):1191-206 [15613346.001]
  • [Cites] Exp Cell Res. 2005 Mar 10;304(1):317-27 [15707596.001]
  • [Cites] J Virol. 2005 Aug;79(16):10308-29 [16051824.001]
  • [Cites] J Virol. 2006 Feb;80(3):1167-80 [16414994.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1741-9 [16424204.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1921-4 [16574866.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):20932-9 [16731529.001]
  • [Cites] J Virol. 2006 Oct;80(20):10073-82 [17005685.001]
  • [Cites] Virology. 2006 Oct 10;354(1):103-15 [16879850.001]
  • [Cites] J Cell Biol. 1993 Jan;120(2):523-35 [8421064.001]
  • [Cites] J Biol Chem. 1993 Apr 25;268(12):8651-7 [8473308.001]
  • [Cites] Cell. 1993 Apr 23;73(2):309-19 [8477447.001]
  • [Cites] J Biol Chem. 1998 Jun 19;273(25):15854-9 [9624186.001]
  • [Cites] Biotechnology (N Y). 1995 Mar;13(3):265-70 [9634769.001]
  • [Cites] J Gen Virol. 1998 Jul;79 ( Pt 7):1573-91 [9680119.001]
  • [Cites] Biochemistry. 1998 Aug 4;37(31):10945-55 [9692987.001]
  • [Cites] J Cell Biol. 1998 Sep 7;142(5):1357-69 [9732295.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):21785-8 [10801897.001]
  • [Cites] J Cell Sci. 2000 Aug;113 ( Pt 16):2909-21 [10910775.001]
  • [Cites] Microsc Res Tech. 2000 Nov 1;51(3):280-301 [11054877.001]
  • [Cites] Virology. 2001 Apr 10;282(2):245-55 [11289807.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1251-69 [11423257.001]
  • [Cites] J Virol. 2001 Aug;75(16):7517-27 [11462024.001]
  • [Cites] Bioconjug Chem. 2002 Jan-Feb;13(1):128-35 [11792188.001]
  • [Cites] Chembiochem. 2000 Aug 18;1(2):107-14 [11828404.001]
  • [Cites] Cell. 2002 Feb 8;108(3):407-19 [11853674.001]
  • [Cites] Cell. 2002 Sep 20;110(6):673-87 [12297042.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6146-51 [12414640.001]
  • [Cites] BMC Biochem. 2001;2:10 [11696247.001]
  • [Cites] J Virol. 2003 Jan;77(2):1524-39 [12502866.001]
  • [Cites] J Virol. 2003 Mar;77(5):3131-47 [12584338.001]
  • [Cites] J Virol. 2003 Jun;77(11):6474-81 [12743304.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21878-85 [12676956.001]
  • [Cites] J Virol. 2003 Oct;77(19):10179-85 [12970403.001]
  • [Cites] J Biochem. 2003 Oct;134(4):497-504 [14607975.001]
  • [Cites] J Virol. 2004 Apr;78(8):4207-23 [15047836.001]
  • [Cites] Biochim Biophys Acta. 2004 Jul 5;1692(2-3):103-19 [15246682.001]
  • [Cites] J Cell Biol. 1987 Oct;105(4):1873-84 [2822727.001]
  • [Cites] J Biol Chem. 1987 Dec 25;262(36):17294-8 [3693352.001]
  • [Cites] J Biol Chem. 1994 Jan 14;269(2):960-7 [7507113.001]
  • [Cites] Science. 1994 Apr 22;264(5158):569-71 [7512751.001]
  • [Cites] Mol Biol Cell. 1994 Feb;5(2):203-15 [8019006.001]
  • [Cites] J Biol Chem. 1994 Aug 12;269(32):20233-8 [8051114.001]
  • [Cites] J Pathol. 1994 May;173(1):23-31 [7523640.001]
  • [Cites] Infect Agents Dis. 1994 Feb;3(1):9-28 [7952927.001]
  • [Cites] Anal Biochem. 1994 Aug 1;220(2):360-6 [7978279.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] J Biochem. 1994 Oct;116(4):862-9 [7533763.001]
  • [Cites] Cell Immunol. 1995 Feb;160(2):165-72 [7536632.001]
  • [Cites] J Cell Sci. 1995 Jun;108 ( Pt 6):2511-23 [7673365.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] Histopathology. 1996 Oct;29(4):337-46 [8910041.001]
  • [Cites] J Biol Chem. 1996 Nov 29;271(48):30587-94 [8940031.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • (PMID = 18045938.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / K02 AI049275; United States / NCI NIH HHS / CA / R01 CA091760; United States / NCI NIH HHS / CA / CA91760; United States / NIAID NIH HHS / AI / K02-AI49275
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrin alphaVbeta3; 0 / Receptors, Virus; 0 / Viral Envelope Proteins; 0 / glycoprotein B, human herpesvirus 8
  • [Other-IDs] NLM/ PMC2224453
  •  go-up   go-down


28. Spadavecchia S, Gonzalez-Lopez O, Carroll KD, Palmeri D, Lukac DM: Convergence of Kaposi's sarcoma-associated herpesvirus reactivation with Epstein-Barr virus latency and cellular growth mediated by the notch signaling pathway in coinfected cells. J Virol; 2010 Oct;84(20):10488-500
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Convergence of Kaposi's sarcoma-associated herpesvirus reactivation with Epstein-Barr virus latency and cellular growth mediated by the notch signaling pathway in coinfected cells.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiologic agent of primary effusion lymphoma (PEL).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1997 Nov 3;16(21):6478-85 [9351829.001]
  • [Cites] Blood. 1998 Feb 1;91(3):747-55 [9446632.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2835-44 [9566902.001]
  • [Cites] Oncogene. 1998 Apr 2;16(13):1731-42 [9582021.001]
  • [Cites] J Gen Virol. 1998 Jun;79 ( Pt 6):1445-52 [9634087.001]
  • [Cites] Dev Biol. 1999 Sep 1;213(1):33-53 [10452845.001]
  • [Cites] Virology. 1999 Sep 15;262(1):18-30 [10489337.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] Science. 1999 Oct 8;286(5438):300-3 [10514374.001]
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] J Virol. 2005 Nov;79(22):14371-82 [16254371.001]
  • [Cites] Blood. 2006 Jan 1;107(1):277-84 [16150942.001]
  • [Cites] J Virol. 2006 Oct;80(19):9697-709 [16973574.001]
  • [Cites] Physiol Rev. 2007 Jan;87(1):99-163 [17237344.001]
  • [Cites] J Virol. 2007 Jun;81(11):6068-78 [17376914.001]
  • [Cites] J Virol. 2007 Jun;81(11):5788-806 [17392367.001]
  • [Cites] Anal Biochem. 2007 Jul 15;366(2):197-206 [17512890.001]
  • [Cites] J Virol. 2007 Aug;81(16):8451-67 [17537858.001]
  • [Cites] J Virol. 2007 Dec;81(24):13299-314 [17913801.001]
  • [Cites] PLoS One. 2008;3(2):e1569 [18253508.001]
  • [Cites] J Virol. 2008 Nov;82(21):10709-23 [18715905.001]
  • [Cites] J Virol. 2009 May;83(10):5014-27 [19264782.001]
  • [Cites] Dev Cell. 2009 May;16(5):633-47 [19460341.001]
  • [Cites] J Virol. 1999 Dec;73(12):10525-30 [10559372.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):401-9 [10830748.001]
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] J Virol. 2001 Mar;75(5):2033-40 [11160707.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1195-203 [11031256.001]
  • [Cites] J Virol. 2001 Apr;75(8):3537-46 [11264343.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1507-17 [9766492.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] J Virol. 1999 Apr;73(4):2770-80 [10074124.001]
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):16085-96 [10347160.001]
  • [Cites] J Virol. 2001 Jul;75(13):5899-912 [11390591.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3694-704 [12446712.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] Blood. 2004 Jan 1;103(1):313-6 [12969959.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):141-6 [14691250.001]
  • [Cites] J Virol. 2004 Apr;78(8):3941-52 [15047810.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2681-93 [14767477.001]
  • [Cites] J Exp Med. 1984 May 1;159(5):1554-9 [6325575.001]
  • [Cites] J Exp Med. 1990 Jul 1;172(1):61-8 [2162905.001]
  • [Cites] J Virol. 1992 Nov;66(11):6496-501 [1404600.001]
  • [Cites] J Biol Chem. 1992 Dec 5;267(34):24157-60 [1332946.001]
  • [Cites] J Exp Med. 1993 Mar 1;177(3):763-74 [8382256.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] EMBO J. 1995 Jan 3;14(1):88-96 [7828599.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):549-60 [7845680.001]
  • [Cites] Cell. 1995 Feb 10;80(3):389-99 [7859281.001]
  • [Cites] J Virol. 1995 May;69(5):2968-76 [7707523.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Nature. 1995 Sep 28;377(6547):355-8 [7566092.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] EMBO J. 1996 Jan 15;15(2):375-82 [8617212.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] Lancet. 1996 Oct 26;348(9035):1133-8 [8888167.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] Cytometry. 1996 Dec 1;25(4):333-40 [8946140.001]
  • [Cites] Oncogene. 1996 Nov 21;13(10):2243-54 [8950992.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] EMBO J. 1996 Dec 16;15(24):7070-8 [9003782.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1186-91 [9242551.001]
  • [Cites] Development. 1997 Oct;124(20):4133-41 [9374409.001]
  • (PMID = 20686042.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI078138; United States / NIAID NIH HHS / AI / AI 078138
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / DNA Primers; 0 / EBNA-2 protein, Human herpesvirus 4; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Immediate-Early Proteins; 0 / Immunoglobulin J Recombination Signal Sequence-Binding Protein; 0 / Receptors, Notch; 0 / Rta protein, Human herpesvirus 8; 0 / Trans-Activators; 0 / Viral Matrix Proteins; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2950570
  •  go-up   go-down


29. Kalt I, Borodianskiy-Shteinberg T, Schachor A, Sarid R: GLTSCR2/PICT-1, a putative tumor suppressor gene product, induces the nucleolar targeting of the Kaposi's sarcoma-associated herpesvirus KS-Bcl-2 protein. J Virol; 2010 Mar;84(6):2935-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GLTSCR2/PICT-1, a putative tumor suppressor gene product, induces the nucleolar targeting of the Kaposi's sarcoma-associated herpesvirus KS-Bcl-2 protein.
  • KS-Bcl-2, encoded by Kaposi's sarcoma-associated herpesvirus (KSHV), is a structural and functional homologue of the Bcl-2 family of apoptosis regulators.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2001 May;75(10):4843-53 [11312356.001]
  • [Cites] J Pathol. 2008 Oct;216(2):218-24 [18729076.001]
  • [Cites] J Virol. 2002 Mar;76(5):2551-6 [11836434.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3428-33 [11904405.001]
  • [Cites] Genes Dev. 2002 Oct 1;16(19):2465-78 [12368257.001]
  • [Cites] Mol Biol Cell. 2002 Nov;13(11):4100-9 [12429849.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] Trends Cell Biol. 2003 Sep;13(9):478-83 [12946627.001]
  • [Cites] Brain Res. 2004 Mar 19;1001(1-2):133-42 [14972662.001]
  • [Cites] J Biol Chem. 2004 Oct 29;279(44):45300-3 [15355975.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):690-4 [9012846.001]
  • [Cites] Nat Med. 1997 Mar;3(3):293-8 [9055856.001]
  • [Cites] J Biol Chem. 1997 May 23;272(21):13829-34 [9153240.001]
  • [Cites] J Virol. 1999 May;73(5):3810-7 [10196275.001]
  • [Cites] Genomics. 2000 Feb 15;64(1):44-50 [10708517.001]
  • [Cites] J Virol. 2000 Jun;74(11):5024-31 [10799576.001]
  • [Cites] Mol Cell. 2000 Jul;6(1):31-40 [10949025.001]
  • [Cites] Nat Cell Biol. 2000 Nov;2(11):819-25 [11056537.001]
  • [Cites] Genes Dev. 1999 Aug 1;13(15):1899-911 [10444588.001]
  • [Cites] Anal Biochem. 2005 Jan 1;336(1):138-40 [15582570.001]
  • [Cites] Nature. 2005 Jan 6;433(7021):77-83 [15635413.001]
  • [Cites] Biochem J. 2005 May 1;387(Pt 3):659-67 [15554878.001]
  • [Cites] Cell Cycle. 2005 Apr;4(4):590-6 [15876860.001]
  • [Cites] Crit Rev Clin Lab Sci. 2005;42(2):101-53 [15941082.001]
  • [Cites] Cell. 2005 Sep 23;122(6):927-39 [16179260.001]
  • [Cites] Arch Virol. 2005 Nov;150(11):2387-95 [15883654.001]
  • [Cites] Nat Cell Biol. 2006 Jul;8(7):688-99 [16799551.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1318-24 [16741528.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1339-50 [16763614.001]
  • [Cites] Mol Biol Cell. 2006 Nov;17(11):4888-95 [16971513.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jul;8(7):574-85 [17519961.001]
  • [Cites] Oncogene. 2007 Aug 30;26(40):5851-65 [17369848.001]
  • [Cites] Cell Death Differ. 2007 Nov;14(11):1872-9 [17657248.001]
  • [Cites] Virology. 2008 Feb 5;371(1):14-31 [17963810.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):580-8 [18084238.001]
  • [Cites] Mol Cell. 2008 Jun 20;30(6):678-88 [18570871.001]
  • [Cites] Curr Biol. 2008 Jul 8;18(13):933-42 [18571408.001]
  • [Cites] FEBS J. 2008 Aug;275(16):4164-78 [18631361.001]
  • [Cites] J Virol. 2002 Mar;76(5):2469-79 [11836425.001]
  • (PMID = 20042497.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GLTSCR2 protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Recombinant Fusion Proteins; 0 / Tumor Suppressor Proteins; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2826064
  •  go-up   go-down


30. Aboumarzouk OM, Coleman R, Goepel JR, Shorthouse AJ: PNET/Ewing's sarcoma of the rectum: a case report and review of the literature. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PNET/Ewing's sarcoma of the rectum: a case report and review of the literature.
  • Serial CT scanning and endoscopy revealed no recurrence after 7 years of follow-up, when she presented with a malignant anal fissure.
  • Imaging and subsequently abdominoperineal resection revealed no evidence of metastases from either the anal cancer or the PNET tumour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2006 Jul;37(7):845-53 [16784984.001]
  • [Cites] MedGenMed. 2006;8(3):6 [17406148.001]
  • [Cites] Clin Imaging. 1993 Apr-Jun;17(2):149-52 [8348407.001]
  • [Cites] Cancer. 1973 Oct;32(4):890-7 [4751919.001]
  • [Cites] Gynecol Oncol. 2007 Aug;106(2):427-32 [17572479.001]
  • [Cites] Acta Oncol. 2006;45(4):484-6 [16760186.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):910-2 [15681537.001]
  • [Cites] Pediatr Pathol Mol Med. 2003 Sep-Oct;22(5):391-8 [14692190.001]
  • [Cites] Tumori. 2002 Jul-Aug;88(4):345-6 [12400989.001]
  • [Cites] Cancer. 1975 Jul;36(1):240-51 [1203852.001]
  • [Cites] Arch Pathol Lab Med. 2001 Oct;125(10):1358-60 [11570916.001]
  • [Cites] Radiology. 1969 Jun;92(7):1501-9 [5799839.001]
  • [Cites] Cancer. 1991 Aug 1;68(3):648-54 [2065287.001]
  • [Cites] Ann Thorac Surg. 2004 Aug;78(2):715-7 [15276562.001]
  • (PMID = 21691396.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029497
  •  go-up   go-down


31. Yamaguchi U, Hasegawa T, Morimoto Y, Tateishi U, Endo M, Nakatani F, Kawai A, Chuman H, Beppu Y, Endo M, Kurotaki H, Furuta K: A practical approach to the clinical diagnosis of Ewing's sarcoma/primitive neuroectodermal tumour and other small round cell tumours sharing EWS rearrangement using new fluorescence in situ hybridisation probes for EWSR1 on formalin fixed, paraffin wax embedded tissue. J Clin Pathol; 2005 Oct;58(10):1051-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A practical approach to the clinical diagnosis of Ewing's sarcoma/primitive neuroectodermal tumour and other small round cell tumours sharing EWS rearrangement using new fluorescence in situ hybridisation probes for EWSR1 on formalin fixed, paraffin wax embedded tissue.
  • BACKGROUND: Over 90% of Ewing's sarcoma/primitive neuroectodermal tumour (ES/PNET) cases have the t(11;22) chromosomal rearrangement, which is also found in other small round cell tumours, including desmoplastic small round cell tumour (DSRCT) and clear cell sarcoma (CCS).
  • Although this rearrangement can be analysed by fluorescence in situ hybridisation (FISH) using routinely formalin fixed, paraffin wax embedded (FFPE) tissues when fresh or frozen tissues are not available, a sensitive and convenient detection method is needed for routine clinical diagnosis.
  • AIMS: To investigate the usefulness of newly developed probes for detecting EWS rearrangement resulting from chromosomal translocations using FISH and FFPE tissue in the clinical diagnosis of ES/PNET, DSRCT, and CCS.
  • CONCLUSIONS: Interphase FISH using this newly developed probe is sensitive and specific for detecting the EWS gene on FFPE tissues and is of value in the routine clinical diagnosis of ES/PNET, DSRCT, and CCS.
  • [MeSH-major] Bone Neoplasms / diagnosis. Calmodulin-Binding Proteins / genetics. Neuroectodermal Tumors, Primitive, Peripheral / diagnosis. RNA-Binding Proteins / genetics. Sarcoma, Ewing / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 22 / genetics. DNA Probes. Female. Formaldehyde. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Proteins / genetics. Paraffin Embedding. Reverse Transcriptase Polymerase Chain Reaction / methods. Sarcoma, Clear Cell / diagnosis. Sarcoma, Clear Cell / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Diagn. 2002 Feb;4(1):44-52 [11826187.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2869-72 [8187070.001]
  • [Cites] Cancer Genet Cytogenet. 1984 May;12(1):1-19 [6713356.001]
  • [Cites] Cancer Genet Cytogenet. 1984 May;12(1):21-5 [6713357.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Am J Clin Pathol. 1990 Jan;93(1):26-31 [2294702.001]
  • [Cites] Cancer Genet Cytogenet. 1994 May;74(1):13-8 [8194041.001]
  • [Cites] J Clin Invest. 1994 Aug;94(2):489-96 [8040301.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):502-8 [7951320.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1028-32 [7862627.001]
  • [Cites] Virchows Arch. 1995;426(5):519-22 [7633662.001]
  • [Cites] J Pathol. 1995 Jun;176(2):137-42 [7636623.001]
  • [Cites] Am J Pathol. 1995 Dec;147(6):1584-91 [7495283.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):406-12 [8604806.001]
  • [Cites] Am J Surg Pathol. 1997 Mar;21(3):354-9 [9060607.001]
  • [Cites] J Pathol. 1997 Jan;181(1):62-6 [9072004.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):461-8 [9130994.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3028-36 [9738572.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Jan 1;108(1):19-25 [9973919.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):324-30 [10088552.001]
  • [Cites] Histopathology. 2004 Dec;45(6):651-4 [15569062.001]
  • [Cites] Am J Surg Pathol. 2004 Dec;28(12):1579-86 [15577676.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5747-54 [11607824.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1886-93 [1848471.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):499-513 [1709557.001]
  • [Cites] Genes Chromosomes Cancer. 1991 Sep;3(5):400-2 [1797088.001]
  • [Cites] Genes Chromosomes Cancer. 1992 Sep;5(2):184 [1381956.001]
  • [Cites] Genes Chromosomes Cancer. 1992 Jul;5(1):30-4 [1384659.001]
  • [Cites] Am J Pathol. 1992 Dec;141(6):1265-9 [1466394.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Dec;64(2):189-91 [1486572.001]
  • [Cites] Br J Cancer. 1993 Jan;67(1):128-33 [8381297.001]
  • [Cites] Am J Pathol. 1993 Jul;143(1):15-9 [8391214.001]
  • [Cites] Zentralbl Pathol. 1993 Jun;139(2):141-51 [8396418.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Aug;69(1):17-21 [8374894.001]
  • [Cites] Hum Pathol. 1993 Aug;24(8):850-65 [8375856.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2837-40 [8187063.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):160-5 [15354743.001]
  • (PMID = 16189150.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calmodulin-Binding Proteins; 0 / DNA Probes; 0 / EWSR1 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins; 1HG84L3525 / Formaldehyde
  • [Other-IDs] NLM/ PMC1770737
  •  go-up   go-down


32. Li X, Uchimura T, Kawanabe S, Imasaka T: Use of a fluorescence lifetime imaging microscope in an apoptosis assay of Ewing's sarcoma cells with a vital fluorescent probe. Anal Biochem; 2007 Aug 15;367(2):219-24
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a fluorescence lifetime imaging microscope in an apoptosis assay of Ewing's sarcoma cells with a vital fluorescent probe.
  • [MeSH-major] Apoptosis. Microscopy, Fluorescence / methods. Sarcoma, Ewing / pathology

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17543878.001).
  • [ISSN] 0003-2697
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / Organic Chemicals; 0 / SYTO 13; 80168379AG / Doxorubicin
  •  go-up   go-down


33. Spoerner M, Hozsa C, Poetzl JA, Reiss K, Ganser P, Geyer M, Kalbitzer HR: Conformational states of human rat sarcoma (Ras) protein complexed with its natural ligand GTP and their role for effector interaction and GTP hydrolysis. J Biol Chem; 2010 Dec 17;285(51):39768-78
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conformational states of human rat sarcoma (Ras) protein complexed with its natural ligand GTP and their role for effector interaction and GTP hydrolysis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2010 Jul 16;285(29):22696-705 [20479006.001]
  • [Cites] Nat Struct Biol. 1997 Sep;4(9):694-9 [9302994.001]
  • [Cites] J Biol Chem. 1999 May 7;274(19):13556-62 [10224125.001]
  • [Cites] FEBS Lett. 1999 May 21;451(2):175-80 [10371160.001]
  • [Cites] Biochemistry. 1999 Aug 31;38(35):11250-60 [10471274.001]
  • [Cites] FEBS Lett. 2004 Dec 17;578(3):305-10 [15589837.001]
  • [Cites] Biochemistry. 2005 Feb 15;44(6):2225-36 [15697248.001]
  • [Cites] J Biol Chem. 2005 Jul 8;280(27):25697-705 [15878843.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 26;334(2):709-13 [16036132.001]
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):31267-75 [15994326.001]
  • [Cites] FEBS J. 2007 Mar;274(6):1419-33 [17302736.001]
  • [Cites] Chembiochem. 2007 May 7;8(7):781-7 [17385754.001]
  • [Cites] Structure. 2007 Dec;15(12):1618-29 [18073111.001]
  • [Cites] J Biol Chem. 2008 May 16;283(20):14153-64 [18348980.001]
  • [Cites] Anal Bioanal Chem. 2009 Jun;394(4):989-96 [19039578.001]
  • [Cites] Biochemistry. 2009 Mar 17;48(10):2192-206 [19166349.001]
  • [Cites] J Am Chem Soc. 2009 Nov 25;131(46):16714-9 [19856908.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):4931-6 [20194776.001]
  • [Cites] Angew Chem Int Ed Engl. 2010 May 17;49(22):3830-3 [20401883.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):4944-9 [11320243.001]
  • [Cites] Structure. 2001 Nov;9(11):1029-41 [11709167.001]
  • [Cites] J Mol Biol. 2002 Nov 8;323(5):899-907 [12417202.001]
  • [Cites] J Mol Biol. 2004 Sep 17;342(3):1033-40 [15342254.001]
  • [Cites] Biochem Biophys Res Commun. 1986 Mar 13;135(2):549-55 [3485974.001]
  • [Cites] EMBO J. 1986 Jun;5(6):1351-8 [3015600.001]
  • [Cites] EMBO J. 1990 Aug;9(8):2351-9 [2196171.001]
  • [Cites] Biochemistry. 1990 Jun 26;29(25):6058-65 [2200519.001]
  • [Cites] J Biol Chem. 1993 Jan 15;268(2):923-9 [8419371.001]
  • [Cites] J Biol Chem. 1995 Feb 17;270(7):2901-5 [7852367.001]
  • [Cites] Cell. 1995 Feb 24;80(4):533-41 [7867061.001]
  • [Cites] Nat Struct Biol. 1995 Jan;2(1):36-44 [7719852.001]
  • [Cites] J Biol Chem. 1996 Mar 22;271(12):6794-800 [8636102.001]
  • [Cites] Nat Struct Biol. 1996 Aug;3(8):723-9 [8756332.001]
  • [Cites] Biochemistry. 1996 Aug 13;35(32):10308-20 [8756686.001]
  • [Cites] Biochemistry. 1996 Nov 12;35(45):14225-31 [8916907.001]
  • [Cites] Science. 1997 Jul 18;277(5324):333-8 [9219684.001]
  • [Cites] Structure. 1999 Nov 15;7(11):1311-24 [10574788.001]
  • (PMID = 20937837.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 86-01-1 / Guanosine Triphosphate; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  • [Other-IDs] NLM/ PMC3000958
  •  go-up   go-down


34. Ambinder RF, Bhatia K, Martinez-Maza O, Mitsuyasu R: Cancer biomarkers in HIV patients. Curr Opin HIV AIDS; 2010 Nov;5(6):531-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECENT FINDINGS: CD4 lymphocyte count is associated with primary central nervous system lymphoma (PCNSL), systemic non-Hodgkin's lymphoma (NHL) (except perhaps for Burkitt lymphoma), Kaposi's sarcoma, cervical cancer, and anal cancer.
  • HIV load is associated with Burkitt lymphoma and systemic NHL (but not PCNSL), with Kaposi's sarcoma and with anal cancer.
  • EBV and Kaposi's sarcoma-associated herpesvirus (KSHV) have not yet emerged as especially promising markers of risk for either lymphoma or Kaposi's sarcoma.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2000 Jan 28;14(2):133-40 [10708283.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):979-84 [10566552.001]
  • [Cites] Clin Immunol. 2003 Nov;109(2):119-29 [14597210.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1396-7; author reply 1397-8 [15494920.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1838-42 [10068655.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3561-4 [10446961.001]
  • [Cites] Clin Immunol. 1999 Sep;92(3):293-9 [10479534.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):760-4 [15721423.001]
  • [Cites] Tumour Biol. 2006;27(4):187-94 [16651853.001]
  • [Cites] J Clin Virol. 2006 Aug;36(4):258-63 [16762591.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Int J Infect Dis. 2007 Mar;11(2):172-8 [16931088.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] PLoS Med. 2007 Mar 27;4(3):e96 [17388662.001]
  • [Cites] J Clin Virol. 2008 Aug;42(4):433-6 [18455472.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):427-9 [19322036.001]
  • [Cites] PLoS One. 2009;4(4):e5360 [19390683.001]
  • [Cites] J Clin Oncol. 2009 May 20;27(15):2496-502 [19349542.001]
  • [Cites] Haematologica. 2009 Jun;94(6):875-80 [19336735.001]
  • [Cites] J Infect Dis. 2009 Jul 1;200(1):79-87 [19476437.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5737-42 [19336755.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2354; author reply 2354-5 [19745076.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2730-2 [19638620.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Dec;52(5):611-22 [19770804.001]
  • [Cites] Lancet Oncol. 2009 Dec;10(12):1152-9 [19818686.001]
  • [Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):170-9 [19654554.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Feb;16(2):287-91 [19835968.001]
  • [Cites] J Clin Oncol. 2010 Feb 10;28(5):773-9 [20048176.001]
  • [Cites] Leuk Lymphoma. 2010 Mar;51(3):497-506 [20038229.001]
  • [Cites] J Clin Oncol. 2010 Mar 20;28(9):1514-9 [20177022.001]
  • [Cites] AIDS. 2010 Apr 24;24(7):1025-33 [20299965.001]
  • [Cites] Cancer Causes Control. 2010 May;21(5):759-69 [20087644.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 May 1;54(1):78-84 [20418723.001]
  • [Cites] Sex Transm Dis. 2010 May;37(5):311-5 [20065890.001]
  • [Cites] J Natl Cancer Inst. 2010 Jun 2;102(11):784-92 [20442214.001]
  • [Cites] BMC Cancer. 2010;10:278 [20537184.001]
  • [Cites] Clin Infect Dis. 2010 Aug 1;51(3):342-9 [20572760.001]
  • [Cites] PLoS One. 2010;5(7):e11448 [20625427.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2730-4 [11023505.001]
  • (PMID = 20978397.001).
  • [ISSN] 1746-6318
  • [Journal-full-title] Current opinion in HIV and AIDS
  • [ISO-abbreviation] Curr Opin HIV AIDS
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA121947-05; United States / NCI NIH HHS / CA / CA096888-05S2; United States / NCI NIH HHS / CA / UO1 CA 121947; United States / NCI NIH HHS / CA / P50 CA096888-05S2; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / P50 CA096888
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS274983; NLM/ PMC3055562
  •  go-up   go-down


35. Cuffy M, Abir F, Longo WE: Management of less common tumors of the colon, rectum, and anus. Clin Colorectal Cancer; 2006 Jan;5(5):327-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of less common tumors of the colon, rectum, and anus.
  • The majority of colorectal and anal malignancies are adenocarcinomas and squamous cell cancers, respectively.
  • Despite the predominance of these neoplasms in these locations, rare histiotypes of the colon, rectum, and anus do occur.
  • These histotypes include but are not limited to lymphoma, melanoma, diffuse cavernous hemangioma, and sarcomas, such as leiomyosarcoma or Kaposi's sarcoma.
  • These tumors often present challenges to clinicians with respect to diagnosis, staging, management, and pathology because of their unfamiliarity.
  • A Medline search using "colon," "rectum,""anus," "lymphoma," "melanoma," "diffuse cavernous hemangioma," "squamous cell carcinoma," "carcinoid," "sarcoma," "leiomyosarcoma," "Kaposi's sarcoma," "Paget's disease," "Bowen's disease," and "basal cell carcinoma" as key words was performed as well as a cross-referencing of the bibliography cited in each work.
  • Rare tumors of the colon, rectum, and anus present diagnostic and management dilemmas for clinicians.
  • For uncommon anal lesions, such as Bowen's disease, Paget's disease, and basal cell carcinoma, wide local excision (WLE) with negative margins is the standard of care.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Colonic Neoplasms / therapy. Hemangioma, Cavernous / therapy. Lymphoma / therapy. Neuroendocrine Tumors / therapy. Rectal Neoplasms / therapy. Sarcoma / therapy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512991.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 164
  •  go-up   go-down


36. Katona TM, Shienbaum AJ, Wyatt LL, Brown GA, Cheng L: Malignant fibrous histiocytoma of the glans penis: a case report. Anal Quant Cytol Histol; 2006 Feb;28(1):39-42
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Malignant fibrous histiocytoma has been regarded as the most common sarcoma of older adults.
  • However, recent opinion regards pleomorphic malignant fibrous histiocytoma as an undifferentiated high grade pleomorphic sarcoma not otherwise classifiable utilizing current techniques available in surgical pathology.
  • Biopsy revealed a markedly pleomorphic sarcoma.
  • CONCLUSION: Malignant fibrous histiocytoma remains a diagnosis of exclusion.
  • Therapeutically important entities in the differential diagnosis that must be ruled out include other poorly differentiated sarcomas, sarcomatoid squamous cell carcinoma and desmoplastic melanoma.

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566278.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Potthoff A, Brockmeyer NH: [HIV-associated tumors]. Hautarzt; 2006 Nov;57(11):988, 990-3
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the beginning of the HIV epidemic, Kaposi sarcoma was a common stigma in AIDS patients and one of the leading causes of death.
  • While Kaposi sarcoma is seen less frequently since the introduction of antiretroviral therapy, lymphoma and other malignancies are an increasing therapeutic challenge.
  • The incidence of HPV-related anal carcinoma and its precursor lesions is rising so dramatically that screening programs as they are already established for cervical carcinoma should be implemented.
  • [MeSH-major] HIV Infections / complications. Neoplasms / etiology. Sarcoma, Kaposi / etiology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. Adult. Antiretroviral Therapy, Highly Active. Anus Neoplasms / etiology. Carcinoma, Hepatocellular / etiology. Female. HIV Seropositivity / complications. Humans. Liver Neoplasms / etiology. Lung Neoplasms / drug therapy. Lung Neoplasms / etiology. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / etiology. Male. Middle Aged. Papillomavirus Infections / complications. Risk Factors. Skin Neoplasms / etiology. Smoking / adverse effects. Uterine Cervical Neoplasms / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17036250.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


38. Bower M, Palmieri C, Dhillon T: AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis; 2006 Feb;19(1):14-9
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Three cancers in people with HIV denote an AIDS diagnosis: Kaposi's sarcoma, high-grade B-cell non-Hodgkin's lymphoma and invasive cervical cancer.
  • RECENT FINDINGS: The incidence of both Kaposi's sarcoma and non-Hodgkin's lymphoma has declined in the era of highly active antiretroviral therapy and the outcome of both tumours has improved.
  • Moreover, highly active antiretroviral therapy alone produces a response in a majority of antiretroviral-naïve patients with Kaposi's sarcoma.
  • In contrast, highly active antiretroviral therapy has had little impact on the incidence of human papilloma virus-associated tumours (cervical and anal cancer) in people with HIV, although it may improve survival by reducing opportunistic infection deaths.
  • SUMMARY: For those with access to highly active antiretroviral therapy, the good news from the AIDS-defining cancers - particularly Kaposi's sarcoma and non-Hodgkin's lymphoma - may be balanced by the increasing numbers of non AIDS-defining cancers.
  • [MeSH-minor] Female. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / epidemiology. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / epidemiology. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16374212.001).
  • [ISSN] 0951-7375
  • [Journal-full-title] Current opinion in infectious diseases
  • [ISO-abbreviation] Curr. Opin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


39. Malone VS, Dobin SM, Jones KA, Donner LR: CD99-positive large cell neuroendocrine carcinoma with rearranged EWSR1 gene in an infant: a case of prognostically favorable tumor. Virchows Arch; 2010 Sep;457(3):389-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor arose at the anal verge of a 1-year-old girl.
  • The diagnosis of this CD99-positive tumor was supported by expression of epithelial (keratins, EMA, and Ep-CAM) and neuroendocrine (chromogranin A, synaptophysin, and neuron-specific enolase) markers and absence of immunoreactivity for Fli-1.
  • Because the tumor was initially misclassified as an extraskeletal Ewing's sarcoma, the patient was treated according to the Ewing's sarcoma treatment protocol.
  • She remains free of tumor 8 years after initial diagnosis.
  • [MeSH-major] Antigens, CD / biosynthesis. Anus Neoplasms / pathology. Calmodulin-Binding Proteins / genetics. Carcinoma, Large Cell / pathology. Carcinoma, Neuroendocrine / pathology. Cell Adhesion Molecules / biosynthesis. RNA-Binding Proteins / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. Bone Neoplasms / pathology. Diagnostic Errors. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infant. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Sarcoma, Ewing / pathology

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20617339.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Calmodulin-Binding Proteins; 0 / Cell Adhesion Molecules; 0 / EWSR1 protein, human; 0 / RNA-Binding Proteins
  •  go-up   go-down


40. van Leeuwen MT, Vajdic CM, Middleton MG, McDonald AM, Law M, Kaldor JM, Grulich AE: Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. AIDS; 2009 Oct 23;23(16):2183-90
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Incidence of Kaposi sarcoma and non-Hodgkin lymphoma declined significantly (Ptrend < 0.001).
  • Incidence of anal cancer was unchanged (Ptrend = 0.451) and remained raised more than 30-fold.
  • CONCLUSION: Incidence of Kaposi sarcoma and non-Hodgkin lymphoma has continued to decline among people with HIV in Australia, though it remains very substantially elevated.
  • Incidence of anal cancer has remained stable, and it is now the third most common cancer in HIV-infected Australians.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Melanoma Res. 2009 Apr;19(2):63-8 [19194340.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Haematologica. 2009 Jun;94(6):875-80 [19336735.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5737-42 [19336755.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2297-303 [19622722.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] AIDS. 2001 Mar 30;15(5):629-33 [11317001.001]
  • [Cites] Am J Epidemiol. 2002 Jan 15;155(2):153-8 [11790679.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5230-5 [12234989.001]
  • [Cites] Sex Health. 2008 Jun;5(2):141-54 [18588779.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):800-4 [18665172.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] Circulation. 2009 Feb 17;119(6):770-2 [19221228.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2627-36 [15197806.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492 [9705682.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] AIDS Patient Care STDS. 2005 Oct;19(10):655-71 [16232050.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):463-8 [16894294.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):401-4 [17337646.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • (PMID = 19734774.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI069907; United States / NIAID NIH HHS / AI / U01 AI069907-03; United States / NIAID NIH HHS / AI / U01AI069907
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS199813; NLM/ PMC2873230
  •  go-up   go-down


41. Vidarsdóttir H, Möller PH, Tryggvason G, Kjartansson S, Jónasson JG: [Gastrointestinal Stromal Tumour (GIST). Case report]. Laeknabladid; 2005 Feb;91(2):177-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 1987 a 73 year old man was diagnosed with a malignant sarcoma of the anus.
  • Fourteen years later the original diagnoses of the specimen was reviewed and the diagnosis was changed to GIST (gastrointestinal stromal tumour).
  • This diagnosis was confirmed with appropriate immunohistochemical staining on the tumour tissue.
  • This is the first case of GIST in the anus diagnosed in Iceland.
  • [MeSH-major] Anus Neoplasms / diagnosis. Gastrointestinal Stromal Tumors / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Iceland. Immunohistochemistry. Leiomyosarcoma / diagnosis. Male

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155313.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


42. Ho-Yen C, Chang F, van der Walt J, Lucas S: Gastrointestinal malignancies in HIV-infected or immunosuppressed patients: pathologic features and review of the literature. Adv Anat Pathol; 2007 Nov;14(6):431-43
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is the second most common site for Kaposi sarcoma after skin, and the commonest visceral site, for Kaposi sarcoma in AIDS patients.
  • Several other malignancies that occur in the GI tract are also closely related to HIV-infected or immunosuppressed individuals; these include posttransplant lymphoproliferative disorder, Epstein-Barr virus-associated smooth muscle tumors, anal precancerous lesions, and squamous cell carcinoma.
  • In this paper, the clinicopathologic features of GI malignancies associated with AIDS patients are reviewed and the differential diagnosis with other mimic lesions is discussed.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / pathology. Gastrointestinal Neoplasms / pathology. Immunocompromised Host. Immunosuppression. Lymphoma, AIDS-Related / pathology. Sarcoma, Kaposi / pathology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18049132.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 103
  •  go-up   go-down


43. Bonnet F, Morlat P: [Cancer and HIV infection: any association?]. Rev Med Interne; 2006 Mar;27(3):227-35
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among AIDS-cancers, the incidences of Kaposi sarcoma and of cerebral lymphoma decreased in a same way than AIDS infections but the incidences of systemic non-Hodgkin lymphoma and of cervical cancer decreased less than the others and remain higher than in the general population.
  • These malignancies include Hodgkin disease, lung, anal, head and neck cancers, hemopathies, and conjunctival cancers.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16337065.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 86
  •  go-up   go-down


44. Monaco S, Sparano V, Gioia M, Sbardella D, Di Pierro D, Marini S, Coletta M: Enzymatic processing of collagen IV by MMP-2 (gelatinase A) affects neutrophil migration and it is modulated by extracatalytic domains. Protein Sci; 2006 Dec;15(12):2805-15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have compared quantitatively its action on the soluble forms of collagen IV extracted with or without pepsin (from human placenta and from Engelbreth-Holm-Swarm [EHS] murine sarcoma, respectively).
  • The catalytic efficiency of MMP-2 is dramatically reduced in the case of the EHS murine sarcoma with respect to the human placenta, probably due to the much tighter packing of the network which renders very slow the speed of the rate-limiting step.
  • [MeSH-minor] Animals. Catalysis. Cell Membrane / metabolism. Cell Movement. Female. Humans. Mice. Mutant Proteins / chemistry. Mutant Proteins / metabolism. Placenta / enzymology. Placenta / metabolism. Protein Denaturation. Protein Structure, Tertiary / physiology. Sarcoma, Experimental / enzymology. Sarcoma, Experimental / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2001 Sep 3;154(5):1069-79 [11535623.001]
  • [Cites] FEBS Lett. 2001 Aug 17;503(2-3):158-62 [11513874.001]
  • [Cites] J Med Invest. 2001 Aug;48(3-4):133-41 [11694952.001]
  • [Cites] J Biol Chem. 2002 Jun 28;277(26):23123-30 [11953425.001]
  • [Cites] J Biomed Mater Res. 2002 Sep 5;61(3):474-81 [12115473.001]
  • [Cites] Matrix Biol. 2002 Aug;21(5):399-414 [12225805.001]
  • [Cites] Mol Biotechnol. 2002 Sep;22(1):51-86 [12353914.001]
  • [Cites] J Cell Sci. 2002 Nov 15;115(Pt 22):4201-14 [12376553.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):422-33 [12778132.001]
  • [Cites] Genome Biol. 2003;4(6):216 [12801404.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2543-56 [12815141.001]
  • [Cites] Reprod Domest Anim. 2003 Dec;38(6):464-9 [14629669.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 30;314(1):11-6 [14715239.001]
  • [Cites] EMBO J. 2004 Aug 4;23(15):3020-30 [15257288.001]
  • [Cites] Am J Respir Cell Mol Biol. 1996 Mar;14(3):288-95 [8845180.001]
  • [Cites] J Biol Chem. 1996 Nov 29;271(48):30964-70 [8940084.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 Jun;20(6):1303-9 [10340950.001]
  • [Cites] Am J Kidney Dis. 2005 Feb;45(2):397-406 [15685519.001]
  • [Cites] Am J Pathol. 2005 Mar;166(3):901-11 [15743801.001]
  • [Cites] Biochem J. 2005 Nov 15;392(Pt 1):127-34 [16008524.001]
  • [Cites] J Biol Chem. 2006 Mar 3;281(9):6058-69 [16373348.001]
  • [Cites] Matrix Biol. 2004 Jun;23(3):171-81 [15296945.001]
  • [Cites] J Biol Chem. 2004 Oct 8;279(41):43336-44 [15292230.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] FEBS Lett. 1981 Mar 9;125(1):123-8 [6262125.001]
  • [Cites] Eur J Biochem. 1981 Nov;120(2):203-11 [6274634.001]
  • [Cites] FEBS Lett. 1987 Nov 30;224(2):297-305 [2826228.001]
  • [Cites] FEBS Lett. 1987 Dec 10;225(1-2):188-94 [3691802.001]
  • [Cites] Eur J Biochem. 1988 Dec 15;178(2):357-66 [2850175.001]
  • [Cites] J Clin Invest. 1989 Aug;84(2):678-85 [2760206.001]
  • [Cites] J Biol Chem. 1990 Dec 15;265(35):21929-34 [2174891.001]
  • [Cites] FEBS Lett. 1992 Jan 27;296(3):263-6 [1537400.001]
  • [Cites] Annu Rev Cell Biol. 1993;9:541-73 [8280471.001]
  • [Cites] Matrix Biol. 1995 Feb;14(6):439-45 [7795882.001]
  • [Cites] Biochem J. 1995 Jul 1;309 ( Pt 1):299-306 [7619071.001]
  • [Cites] Circ Res. 1996 Jan;78(1):38-43 [8603503.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):8051-61 [10713126.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):3884-9 [10760260.001]
  • [Cites] J Biol Chem. 2000 Jun 23;275(25):18657-63 [10749856.001]
  • [Cites] Biophys J. 2000 Oct;79(4):2138-49 [11023917.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:463-516 [11687497.001]
  • (PMID = 17088321.001).
  • [ISSN] 0961-8368
  • [Journal-full-title] Protein science : a publication of the Protein Society
  • [ISO-abbreviation] Protein Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Collagen Type IV; 0 / Mutant Proteins; EC 3.4.24.24 / Matrix Metalloproteinase 2
  • [Other-IDs] NLM/ PMC2242443
  •  go-up   go-down


45. Marigny K, Aubin F, Burgot G, Le Gall E, Gandemer V: Particular cutaneous side effects with etoposide-containing courses: is VP16 or etoposide phosphate responsible? Cancer Chemother Pharmacol; 2005 Mar;55(3):244-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Five types of etoposide-containing protocols were chosen: NB 97 and NB 99 (neuroblastoma), FRALLE 93 (acute lymphoid leukaemia), LAME 91 (acute myeloid leukaemia), OS 94 (osteosarcoma), Ewing 97 and Euro-Ewing 99 (Ewing sarcoma).
  • (1) palmar-plantar eruptions and nail inflammations, and (2) irritation of the anal area and anal fissures.
  • Those side effects were observed with three of the studied protocols: NB 97, OS 94 and Ewing sarcoma treatments.
  • CONCLUSIONS: No striking differences in toxicity appeared between the two etoposide formulations, but this retrospective study seemed to confirm the appearance of particular cutaneous and anal side effects especially with two associations:.
  • [MeSH-minor] Adolescent. Anal Canal / drug effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Child. Child, Preschool. Fingers. Humans. Infant. Infant, Newborn. Retrospective Studies. Toes

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15526203.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Organophosphorus Compounds; 528XYJ8L1N / etoposide phosphate; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


46. Seaberg EC, Wiley D, Martínez-Maza O, Chmiel JS, Kingsley L, Tang Y, Margolick JB, Jacobson LP, Multicenter AIDS Cohort Study (MACS): Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer; 2010 Dec 1;116(23):5507-16
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The incidence of Kaposi sarcoma (KS) and non-Hodgkin lymphoma (NHL) among human immunodeficiency virus (HIV)-infected individuals declined after the introduction of highly active antiretroviral therapy (HAART) in the mid-1990s, but the cancer risk associated with HIV infection during the HAART era remains to be clarified.
  • Compared with SEER, MACS HIV-infected men had significantly (P<.05) elevated rates of KS (standardized incidence ratio [SIR], 139.10), NHL (SIR, 36.80), Hodgkin lymphoma (HL)(SIR, 7.30), and anal cancer (SIR, 25.71).
  • Within MACS, HIV infection was found to be independently associated with each of these cancers across the entire follow-up period, and KS (incidence rate ratio [IRR], 54.93), NHL (IRR, 11.18), and anal cancer (IRR, 18.50) were each found to be significantly elevated among HIV-infected men during the HAART era.
  • Among these men, the incidence of KS and NHL declined (IRR, 0.13 and 0.23, respectively), the incidence of anal cancer increased (IRR, 5.84), and the incidence of HL remained statistically unchanged (IRR, 0.75) from the pre-HAART to the HAART era.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):446-51 [17762569.001]
  • [Cites] Ann Epidemiol. 2008 Mar;18(3):230-4 [18083545.001]
  • [Cites] AIDS. 2008 Feb 19;22(4):489-96 [18301061.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] Lancet. 2008 Jul 26;372(9635):293-9 [18657708.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):1-2 [19339933.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5737-42 [19336755.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):56-63 [15654781.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] AIDS. 2005 Nov 18;19(17):2009-18 [16260908.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1383-8 [16549832.001]
  • [Cites] Cancer. 2000 Aug 15;89(4):901-12 [10951356.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] J Clin Epidemiol. 2001 Dec;54 Suppl 1:S29-34 [11750207.001]
  • [Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Am J Public Health. 2006 Jun;96(6):1020-7 [16670218.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):469-78 [16894295.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1725-30 [9848347.001]
  • [CommentIn] Cancer. 2010 Dec 1;116(23):5344-7 [20960526.001]
  • (PMID = 20672354.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIAID NIH HHS / AI / U01-AI-35043; United States / NIAID NIH HHS / AI / U01-AI-35042; United States / NCRR NIH HHS / RR / M01 RR000052-46; United States / NIAID NIH HHS / AI / U01 AI035041-17; United States / NCRR NIH HHS / RR / 5-M01-RR-00052; United States / NIAID NIH HHS / AI / U01 AI035039-17; United States / NIAID NIH HHS / AI / AI035039-17; United States / NIAID NIH HHS / AI / U01 AI035042-17; United States / NIAID NIH HHS / AI / U01-AI-35041; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NIAID NIH HHS / AI / AI035042-17; United States / NIAID NIH HHS / AI / AI035043-17; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NIAID NIH HHS / AI / AI035040-17; United States / NIAID NIH HHS / AI / U01 AI035043-17; United States / NCRR NIH HHS / RR / M01 RR000052; United States / NIAID NIH HHS / AI / U01-AI-35040; United States / NIAID NIH HHS / AI / U01 AI035040-17; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / U01-AI-35039; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NIAID NIH HHS / AI / U01 AI035039
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS218249; NLM/ PMC2991510
  • [Investigator] Margolick JB; Jacobson LP; Phair JP; Wolinsky SM; Detels R; Rinaldo CR
  •  go-up   go-down


47. Simard EP, Pfeiffer RM, Engels EA: Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med; 2010 Aug 9;170(15):1337-45
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Risk was elevated for the 2 major AIDS-defining cancers: Kaposi sarcoma (SIRs, 5321 and 1347 in years 3-5 and 6-10, respectively) and non-Hodgkin lymphoma (SIRs, 32 and 15).
  • Risk was elevated for all non-AIDS-defining cancers combined (SIRs, 1.7 and 1.6 in years 3-5 and 6-10, respectively) and for the following specific non-AIDS-defining cancers: Hodgkin lymphoma and cancers of the oral cavity and/or pharynx, tongue, anus, liver, larynx, lung and/or bronchus, and penis.
  • Anal cancer incidence increased between 1990-1995 and 1996-2006 (RR, 2.9; 95% confidence interval [CI], 2.1-4.0), as did that of Hodgkin lymphoma (RR, 2.0; 95% CI, 1.3-2.9).
  • CONCLUSION: Among people who survived for several years or more after an AIDS diagnosis, we observed high risks of AIDS-defining cancers and increasing incidence of anal cancer and Hodgkin lymphoma.
  • [MeSH-minor] Adolescent. Adult. Anus Neoplasms / epidemiology. Anus Neoplasms / virology. Bronchial Neoplasms / epidemiology. Bronchial Neoplasms / virology. Female. Humans. Incidence. Laryngeal Neoplasms / epidemiology. Laryngeal Neoplasms / virology. Liver Neoplasms / epidemiology. Liver Neoplasms / virology. Lung Neoplasms / epidemiology. Lung Neoplasms / virology. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / virology. Male. Middle Aged. Mouth Neoplasms / epidemiology. Mouth Neoplasms / virology. Penile Neoplasms / epidemiology. Penile Neoplasms / virology. Risk Assessment. Risk Factors. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / virology. Time Factors. United States / epidemiology. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1227-35 [11423255.001]
  • [Cites] Ann Intern Med. 2009 Feb 17;150(4):283-4; author reply 284-5 [19221387.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]
  • [Cites] MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207; quiz CE1-4 [19357635.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5737-42 [19336755.001]
  • [Cites] Stat Med. 2000 Feb 15;19(3):335-51 [10649300.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Oct 1;25(2):115-23 [11103041.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] AIDS. 2004 Jul 2;18(10):1393-401 [15199315.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Am J Public Health. 1995 Nov;85(11):1552-5 [7485671.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492 [9705682.001]
  • [Cites] Lancet. 1998 Jun 6;351(9117):1682-6 [9734884.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] JAMA. 1999 Jun 23-30;281(24):2305-15 [10386555.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S34-41 [10430217.001]
  • [Cites] Clin Infect Dis. 2005 Feb 1;40(3):490-1 [15668878.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] AIDS Educ Prev. 2005 Dec;17(6 Suppl B):39-48 [16401181.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1383-8 [16549832.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34 [16878047.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):642-8 [16868538.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Ann Epidemiol. 2008 Mar;18(3):230-4 [18083545.001]
  • [Cites] HIV Med. 2008 Apr;9(4):196-202 [18366443.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [CommentIn] Arch Intern Med. 2010 Aug 9;170(15):1345-6 [20696959.001]
  • (PMID = 20696958.001).
  • [ISSN] 1538-3679
  • [Journal-full-title] Archives of internal medicine
  • [ISO-abbreviation] Arch. Intern. Med.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010150-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS212628; NLM/ PMC2921231
  •  go-up   go-down


48. Collins JJ, Bodner K, Aylward LL, Wilken M, Bodnar CM: Mortality rates among trichlorophenol workers with exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Am J Epidemiol; 2009 Aug 15;170(4):501-6
Hazardous Substances Data Bank. Pentachlorophenol .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, for 4 deaths of soft tissue sarcoma (SMR = 4.1, 95% CI: 1.1, 10.5), the mortality rates increased with exposure.
  • The small number of deaths and the uncertainty in both diagnosis and nosology coding make interpretation of this finding tenuous.
  • With the exception of soft tissue sarcoma, the authors found little evidence of increased disease risk from exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin.
  • [MeSH-minor] Adult. Case-Control Studies. Cause of Death. Follow-Up Studies. Humans. Michigan / epidemiology. Neoplasms / mortality. Pentachlorophenol / adverse effects. Pentachlorophenol / analysis. Proportional Hazards Models. Risk. Sarcoma / mortality. Soft Tissue Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ind Health. 2003 Jul;41(3):175-80 [12916747.001]
  • [Cites] Occup Environ Med. 2003 Sep;60(9):672-5 [12937189.001]
  • [Cites] Regul Toxicol Pharmacol. 2003 Dec;38(3):378-88 [14623487.001]
  • [Cites] Environ Health Perspect. 2004 Sep;112(13):1265-8 [15345337.001]
  • [Cites] J Occup Med. 1980 Jan;22(1):11-4 [6444441.001]
  • [Cites] J Occup Med. 1980 Aug;22(8):530-2 [6447199.001]
  • [Cites] J Occup Med. 1987 May;29(5):422-9 [2439670.001]
  • [Cites] J Occup Med. 1989 Sep;31(9):771-4 [2529357.001]
  • [Cites] N Engl J Med. 1991 Jan 24;324(4):212-8 [1985242.001]
  • [Cites] Ann N Y Acad Sci. 1990;609:87-97; discussion 97-9 [2264660.001]
  • [Cites] Epidemiology. 1992 Jan;3(1):65-9 [1554813.001]
  • [Cites] Epidemiology. 1993 Jan;4(1):14-9 [8420575.001]
  • [Cites] Epidemiology. 1993 Jan;4(1):7-13 [8420584.001]
  • [Cites] Am J Ind Med. 1993 Feb;23(2):289-300 [8427257.001]
  • [Cites] Am J Epidemiol. 1995 Dec 1;142(11):1165-75 [7485063.001]
  • [Cites] J Toxicol Environ Health. 1996 Mar;47(4):363-78 [8600289.001]
  • [Cites] Cancer Causes Control. 1996 May;7(3):312-21 [8734824.001]
  • [Cites] Occup Environ Med. 1996 Sep;53(9):606-12 [8882118.001]
  • [Cites] Am J Epidemiol. 1997 Jun 15;145(12):1061-75 [9199536.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;69:1-631 [9379504.001]
  • [Cites] J Occup Environ Med. 1998 Apr;40(4):351-62 [9571527.001]
  • [Cites] Am J Epidemiol. 1998 May 1;147(9):891-901 [9583720.001]
  • [Cites] Environ Health Perspect. 1998 Apr;106 Suppl 2:655-62 [9599713.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):779-86 [10328108.001]
  • [Cites] Mil Med. 2005 May;170(5):406-13 [15974208.001]
  • [Cites] Risk Anal. 2006 Aug;26(4):1059-71 [16948697.001]
  • [Cites] J Expo Sci Environ Epidemiol. 2007 Sep;17(6):541-8 [17426737.001]
  • [Cites] J Occup Environ Med. 2008 Mar;50(3):330-40 [18332783.001]
  • [Cites] Am J Epidemiol. 2008 Apr 1;167(7):847-58 [18192277.001]
  • [CommentIn] Am J Epidemiol. 2010 Jan 1;171(1):129-30; author reply 130-1 [19995829.001]
  • (PMID = 19561065.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chlorophenols; 0 / Dioxins; 04PL7F455E / 2,3,7,8-tetrabromodibenzo-4-dioxin; D9BSU0SE4T / Pentachlorophenol
  • [Other-IDs] NLM/ PMC2717168
  •  go-up   go-down


49. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S, Swiss HIV Cohort: Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst; 2005 Mar 16;97(6):425-32
MedlinePlus Health Information. consumer health - Smoking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Highly elevated SIRs were confirmed in persons infected with HIV for Kaposi sarcoma (KS) (SIR = 192, 95% confidence interval [CI] = 170 to 217) and non-Hodgkin lymphoma (SIR = 76.4, 95% CI = 66.5 to 87.4).
  • Statistically significantly elevated SIRs were also observed for anal cancer (SIR = 33.4, 95% CI = 10.5 to 78.6); Hodgkin lymphoma (SIR = 17.3, 95% CI = 10.2 to 27.4); cancers of the cervix (SIR = 8.0, 95% CI = 2.9 to 17.4); liver (SIR = 7.0, 95% CI = 2.2 to 16.5); lip, mouth, and pharynx (SIR = 4.1, 95% CI = 2.1 to 7.4); trachea, lung, and bronchus (SIR = 3.2, 95% CI = 1.7 to 5.4); and skin, nonmelanomatous (SIR = 3.2, 95% CI = 2.2 to 4.5).
  • [MeSH-minor] Adult. Aged. Cohort Studies. Confounding Factors (Epidemiology). Female. Humans. Incidence. Lymphocyte Count. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / virology. Male. Medical Record Linkage. Middle Aged. Odds Ratio. Papillomaviridae. Prospective Studies. Registries. Research Design. Risk Assessment. Risk Factors. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / virology. Switzerland / epidemiology. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2005 Mar 16;97(6):407-9 [15769998.001]
  • (PMID = 15770006.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


50. Rennel E, Waine E, Guan H, Schüler Y, Leenders W, Woolard J, Sugiono M, Gillatt D, Kleinerman E, Bates D, Harper S: The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer; 2008 Apr 8;98(7):1250-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we show that overexpression of VEGF165b by tumour cells inhibits the growth of prostate carcinoma, Ewing's sarcoma and renal cell carcinoma in xenografted mouse tumour models.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Nephrol. 2007 Mar;18(3):719-29 [17267748.001]
  • [Cites] Cell Mol Life Sci. 2006 Sep;63(17):2067-77 [16909199.001]
  • [Cites] Br J Cancer. 2007 Jul 16;97(2):223-30 [17595666.001]
  • [Cites] Oncogene. 2007 Aug 23;26(39):5808-15 [17353901.001]
  • [Cites] Biomed Pharmacother. 2008 Mar;62(3):158-63 [17851027.001]
  • [Cites] Int J Cancer. 2000 Jun 15;86(6):768-76 [10842189.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4123-31 [12124351.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):10-4 [12516033.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Mol Endocrinol. 1991 Dec;5(12):1806-14 [1791831.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4575-80 [7553632.001]
  • [Cites] J Urol. 1997 Jun;157(6):2323-8 [9146664.001]
  • [Cites] J Urol. 1997 Jun;157(6):2329-33 [9146665.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7647-54 [15520162.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7822-35 [15520188.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2805-16 [15625332.001]
  • [Cites] Oncogene. 2005 Jan 27;24(5):889-901 [15580293.001]
  • [Cites] Diabetologia. 2005 Nov;48(11):2422-7 [16193288.001]
  • [Cites] Urology. 2006 Aug;68(2):244-8 [16904427.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):133-42 [17027147.001]
  • (PMID = 18349828.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / A5047; United Kingdom / British Heart Foundation / / BS/06/005/20340; United Kingdom / British Heart Foundation / / BB2000003; United Kingdom / British Heart Foundation / / BS06/005
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2359649; NLM/ UKMS3369
  •  go-up   go-down


51. Ramasamy P, Md Nor A, Kamil NA, Harun N, Yusof MM, Md Hassan MZ: Perineal myxoid liposarcomas: a case report and literature review. Malays J Med Sci; 2010 Oct;17(4):62-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We introduce an unusual case of a myxoid liposarcoma presenting as a large perineal swelling occupying the para-rectal and para-anal spaces in a 49-year-old male patient.
  • The diagnosis, management, and prognosis of myxoid liposarcoma are discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22135563.001).
  • [ISSN] 2180-4303
  • [Journal-full-title] The Malaysian journal of medical sciences : MJMS
  • [ISO-abbreviation] Malays J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Malaysia
  • [Other-IDs] NLM/ PMC3216183
  • [Keywords] NOTNLM ; myxoid liposarcoma / oncology / perineum / soft tissue sarcoma / surgery / tomography
  •  go-up   go-down


52. Jin Z, Wallace L, Harper SQ, Yang J: PP2A:B56{epsilon}, a substrate of caspase-3, regulates p53-dependent and p53-independent apoptosis during development. J Biol Chem; 2010 Nov 5;285(45):34493-502
Xenbase. Xenbase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A recent study has demonstrated that single nucleotide polymorphism in B56ε (PPP2R5E), a B56 family regulatory subunit of PP2A, is associated with human soft tissue sarcoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Metastasis Rev. 2008 Jun;27(2):137-46 [18214640.001]
  • [Cites] Genome Dyn. 2006;1:131-48 [18724058.001]
  • [Cites] J Biol Chem. 2008 Dec 19;283(51):35474-85 [18957415.001]
  • [Cites] Biochim Biophys Acta. 2009 Jan;1795(1):1-15 [18588945.001]
  • [Cites] Oncogene. 2009 Feb 5;28(5):721-33 [19029949.001]
  • [Cites] Cell Adh Migr. 2007 Jul-Sep;1(3):140-1 [19262135.001]
  • [Cites] J Biol Chem. 2009 Mar 13;284(11):7190-200 [19129191.001]
  • [Cites] Mol Cell. 2009 Mar 13;33(5):537-45 [19285938.001]
  • [Cites] Nature. 2009 Apr 30;458(7242):1127-30 [19407794.001]
  • [Cites] Biochim Biophys Acta. 2009 May;1787(5):414-20 [19007744.001]
  • [Cites] Anal Chem. 2009 Jun 1;81(11):4493-501 [19413330.001]
  • [Cites] Dev Cell. 2009 Sep;17(3):303-5 [19758553.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6301-8 [19773383.001]
  • [Cites] Development. 2003 Dec;130(23):5569-78 [14522869.001]
  • [Cites] Annu Rev Biochem. 2004;73:87-106 [15189137.001]
  • [Cites] Dev Biol. 1987 Feb;119(2):560-78 [3803718.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Mar;85(6):1768-71 [3126494.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(19):7555-9 [1699228.001]
  • [Cites] Oncogene. 1993 Aug;8(8):2159-66 [8336941.001]
  • [Cites] Cytogenet Cell Genet. 1995;69(3-4):190-2 [7698009.001]
  • [Cites] Genes Dev. 1995 May 15;9(10):1164-76 [7758942.001]
  • [Cites] Oncogene. 1995 Jun 15;10(12):2361-6 [7784084.001]
  • [Cites] J Biol Chem. 1995 Nov 3;270(44):26123-8 [7592815.001]
  • [Cites] J Biol Chem. 1996 May 10;271(19):11059-62 [8626647.001]
  • [Cites] Mol Cell Biol. 1996 Nov;16(11):6593-602 [8887688.001]
  • [Cites] J Biol Chem. 1997 May 23;272(21):13459-62 [9153186.001]
  • [Cites] Trends Biochem Sci. 1997 Jul;22(7):245-51 [9255065.001]
  • [Cites] Development. 1997 Aug;124(16):3185-95 [9272959.001]
  • [Cites] Dev Biol. 1997 Sep 15;189(2):335-46 [9299125.001]
  • [Cites] Mech Dev. 1997 Dec;69(1-2):183-95 [9486540.001]
  • [Cites] Science. 1998 Oct 9;282(5387):284-7 [9765152.001]
  • [Cites] Exp Cell Res. 1998 Oct 10;244(1):302-9 [9770373.001]
  • [Cites] Dev Biol. 1998 Nov 1;203(1):36-48 [9806771.001]
  • [Cites] Cell Death Differ. 1998 Sep;5(9):774-84 [10200537.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8183-92 [16166293.001]
  • [Cites] Oncogene. 2005 Nov 21;24(52):7746-55 [16299534.001]
  • [Cites] J Biol Chem. 2006 Apr 28;281(17):11515-22 [16495229.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):23003-12 [16717086.001]
  • [Cites] Bioessays. 2006 Aug;28(8):775-9 [16927389.001]
  • [Cites] Cell. 2006 Oct 20;127(2):341-53 [17055435.001]
  • [Cites] Curr Opin Cell Biol. 2006 Dec;18(6):623-31 [17030123.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1239-51 [17174897.001]
  • [Cites] J Biol Chem. 2007 Jan 5;282(1):573-80 [17085438.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):53-7 [17086192.001]
  • [Cites] EMBO J. 2007 Jan 24;26(2):402-11 [17245430.001]
  • [Cites] Mol Cell Proteomics. 2007 Feb;6(2):319-32 [17121811.001]
  • [Cites] Dev Biol. 2007 Feb 15;302(2):477-93 [17074314.001]
  • [Cites] Cell. 2007 Jun 1;129(5):969-82 [17540176.001]
  • [Cites] Cell. 2007 Jul 13;130(1):21-4 [17632053.001]
  • [Cites] PLoS Biol. 2007 Aug;5(8):e202 [17608567.001]
  • [Cites] Cell Cycle. 2007 Oct 1;6(19):2377-85 [17700073.001]
  • [Cites] Mol Cell Biol. 2008 Jan;28(1):448-56 [17967874.001]
  • [Cites] Cell Cycle. 2008 Jan 1;7(1):3-6 [18196968.001]
  • [Cites] Cell. 2009 Oct 30;139(3):468-84 [19879837.001]
  • [Cites] Cell Death Differ. 2010 Jan;17(1):158-69 [19680261.001]
  • [Cites] Science. 2010 Jan 8;327(5962):172-7 [19965387.001]
  • [Cites] J Exp Med. 1999 Dec 20;190(12):1879-90 [10601362.001]
  • [Cites] Biochem J. 2001 Feb 1;353(Pt 3):417-39 [11171037.001]
  • [Cites] Oncogene. 2001 Jan 4;20(1):10-5 [11244497.001]
  • [Cites] J Comp Neurol. 2001 Apr 23;433(1):4-22 [11283945.001]
  • [Cites] Oncogene. 2001 Apr 5;20(15):1892-9 [11313937.001]
  • [Cites] J Biol Chem. 2001 Jun 8;276(23):20633-40 [11279218.001]
  • [Cites] Adv Cancer Res. 2001;82:55-84 [11447765.001]
  • [Cites] Int J Cancer. 2001 Sep15;93(6):798-804 [11519040.001]
  • [Cites] J Virol. 2001 Oct;75(19):9142-55 [11533178.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4221-6 [11904383.001]
  • [Cites] Mol Cell. 2002 Apr;9(4):761-71 [11983168.001]
  • [Cites] Mol Cell Biol. 2002 Jun;22(11):3674-84 [11997504.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):27449-67 [11956189.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1310-7 [12149212.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):594-604 [12154352.001]
  • [Cites] Genes Cells. 2002 Aug;7(8):869-80 [12167164.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11025-30 [12177420.001]
  • [Cites] Science. 2002 Dec 6;298(5600):1912-34 [12471243.001]
  • [Cites] Curr Opin Cell Biol. 2002 Dec;14(6):721-6 [12473345.001]
  • [Cites] Cell. 2003 May 2;113(3):301-14 [12732139.001]
  • [Cites] Biochem Pharmacol. 2003 Oct 15;66(8):1453-8 [14555221.001]
  • (PMID = 20807766.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM093217; United States / NCRR NIH HHS / RR / UL1 RR025755; United States / NIGMS NIH HHS / GM / 1R01GM093217-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 0 / Xenopus Proteins; EC 3.1.3.16 / Protein Phosphatase 2; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ PMC2966064
  •  go-up   go-down


53. Aldo S, Salmaso L, El Barmi H, Pesarin F: Conditional tests in a competing risks model. Lifetime Data Anal; 2008 Jun;14(2):154-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animals. Computer Simulation. Lymphoma, T-Cell / mortality. Male. Mice. Sarcoma / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17943442.001).
  • [ISSN] 1380-7870
  • [Journal-full-title] Lifetime data analysis
  • [ISO-abbreviation] Lifetime Data Anal
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Hagen T: Characterization of the interaction between latency-associated nuclear antigen and glycogen synthase kinase 3beta. J Virol; 2009 Jun;83(12):6312-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The latency-associated nuclear antigen (LANA) of Karposi's sarcoma-associated herpesvirus has been reported to interact with glycogen synthase kinase 3beta (GSK-3beta) and regulate its activity, leading to inhibition of GSK-3-dependent beta-catenin degradation.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2007 Oct;81(19):10413-23 [17634230.001]
  • [Cites] J Virol. 2007 Oct;81(19):10451-9 [17634226.001]
  • [Cites] FEBS Lett. 2001 Nov 2;507(3):288-94 [11696357.001]
  • [Cites] Cell. 2002 Mar 22;108(6):837-47 [11955436.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1066-76 [12000790.001]
  • [Cites] Nat Med. 2003 Mar;9(3):300-6 [12592400.001]
  • [Cites] J Virol. 2003 Jul;77(14):8019-30 [12829841.001]
  • [Cites] EMBO J. 1997 Feb 3;16(3):441-50 [9034327.001]
  • [Cites] Cell. 1998 Jun 12;93(6):1031-41 [9635432.001]
  • [Cites] Anal Biochem. 1998 Nov 1;264(1):124-7 [9784196.001]
  • [Cites] FEBS Lett. 1999 Sep 17;458(2):247-51 [10481074.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30419-23 [10521419.001]
  • [Cites] J Virol. 2005 Aug;79(16):10429-41 [16051835.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):9971-6 [16476742.001]
  • [Cites] J Virol. 2006 Aug;80(16):7965-75 [16873253.001]
  • [Cites] PLoS Pathog. 2006 Oct;2(10):e116 [17069461.001]
  • [Cites] Curr Top Microbiol Immunol. 2007;312:101-36 [17089795.001]
  • [Cites] J Biol Chem. 2007 Jun 8;282(23):17032-40 [17439941.001]
  • [Cites] Virology. 2007 Aug 1;364(2):317-29 [17434559.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):4979-86 [17310999.001]
  • [Cites] J Cell Biol. 2000 Feb 21;148(4):691-702 [10684251.001]
  • (PMID = 19321622.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Nuclear Proteins; 0 / beta Catenin; 0 / latency-associated nuclear antigen; EC 2.7.11.1 / glycogen synthase kinase 3 beta; EC 2.7.11.26 / Glycogen Synthase Kinase 3
  • [Other-IDs] NLM/ PMC2687375
  •  go-up   go-down


55. Balgley BM, Guo T, Zhao K, Fang X, Tavassoli FA, Lee CS: Evaluation of archival time on shotgun proteomics of formalin-fixed and paraffin-embedded tissues. J Proteome Res; 2009 Feb;8(2):917-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Optimized protein extraction and digestion procedures for handling FFPE tissues are coupled with the capillary isotachophoresis-based proteome technology to evaluate the effects of length of storage period on archival tissue proteome analysis across 10 archived uterine mesenchymal tumor tissue blocks, including 9 uterine leiomyomas dating from 1990 to 2002 and a single case of alveolar soft part sarcoma (ASPS) from 1980.
  • Despite using tissue blocks stored for as many as 28 years, high confidence and comparative proteome analysis between the leiomyomas and the sarcoma is achieved.
  • Though sharing over 1800 common proteins in a core set, a total of 80 proteins unique to the sarcoma are identified distinguishing the ASPS from the leiomyomas.

  • Biospecimen Research Database. Biospecimen Research Database .
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Chem. 2000 May 1;72(9):2154-9 [10815979.001]
  • [Cites] Nat Biotechnol. 2007 Jan;25(1):117-24 [17187058.001]
  • [Cites] J Pathol. 2001 Sep;195(1):66-71 [11568892.001]
  • [Cites] Genome Res. 2002 Aug;12(8):1231-45 [12176931.001]
  • [Cites] Anal Chem. 2003 Jul 1;75(13):3145-52 [12964763.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):172-4 [14983929.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]
  • [Cites] J Proteome Res. 2004 Sep-Oct;3(5):958-64 [15473683.001]
  • [Cites] J Histochem Cytochem. 1979 Aug;27(8):1189-91 [383824.001]
  • [Cites] J Histochem Cytochem. 1980 Aug;28(8):777-87 [7003004.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • [Cites] J Histochem Cytochem. 1992 Jun;40(6):787-92 [1588025.001]
  • [Cites] J Histochem Cytochem. 1997 Mar;45(3):327-43 [9071315.001]
  • [Cites] J Histochem Cytochem. 1998 Mar;46(3):397-403 [9487122.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Anal Chem. 1998 Dec 1;70(23):4945-50 [9852780.001]
  • [Cites] Nat Methods. 2005 Sep;2(9):667-75 [16118637.001]
  • [Cites] Mol Cell Proteomics. 2005 Sep;4(9):1265-72 [15958392.001]
  • [Cites] J Histochem Cytochem. 2005 Nov;53(11):1421-32 [16046672.001]
  • [Cites] Biotechniques. 2005 Jun;Suppl:32-5 [16528915.001]
  • [Cites] J Histochem Cytochem. 2006 Jun;54(6):739-43 [16399996.001]
  • [Cites] J Proteome Res. 2006 Nov;5(11):2909-18 [17081042.001]
  • [Cites] Oncogene. 2007 Jan 4;26(1):65-76 [16799640.001]
  • [Cites] Nat Methods. 2007 Mar;4(3):207-14 [17327847.001]
  • [Cites] J Proteome Res. 2007 Mar;6(3):1038-47 [17266348.001]
  • [Cites] Environ Mol Mutagen. 2007 Apr-May;48(3-4):299-306 [16395694.001]
  • [Cites] J Histochem Cytochem. 2007 Jul;55(7):763-72 [17409379.001]
  • [Cites] Lab Invest. 2007 Aug;87(8):836-46 [17530029.001]
  • [Cites] Anal Chem. 2007 Aug 1;79(15):5785-92 [17614365.001]
  • [Cites] Mol Cell Proteomics. 2007 Aug;6(8):1291-8 [17513294.001]
  • [Cites] Mol Cell Proteomics. 2007 Sep;6(9):1599-608 [17533222.001]
  • [Cites] J Proteome Res. 2008 Mar;7(3):1098-108 [18257518.001]
  • [Cites] Electrophoresis. 2008 May;29(10):2215-23 [18425750.001]
  • [Cites] Mol Biosyst. 2008 Jul;4(7):712-20 [18563244.001]
  • [Cites] Electrophoresis. 2008 Jul;29(14):3047-54 [18655040.001]
  • [Cites] J Histochem Cytochem. 2001 Aug;49(8):931-7 [11457921.001]
  • (PMID = 19128014.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM073723; United States / NCI NIH HHS / CA / R42 CA122715; United States / NIGMS NIH HHS / GM / R01 GM073723-04; United States / NCI NIH HHS / CA / R41 CA122715; United States / NCI NIH HHS / CA / CA122715; United States / NIGMS NIH HHS / GM / GM073723; United States / NIGMS NIH HHS / GM / GM073723-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Peptides; 1HG84L3525 / Formaldehyde
  • [Other-IDs] NLM/ NIHMS91394; NLM/ PMC2664629
  •  go-up   go-down


56. Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D, Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort: Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol; 2009 Dec;10(12):1152-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We investigated the incidence of both AIDS-defining cancers (Kaposi's sarcoma, non-Hodgkin lymphoma, and cervical cancer) and non-AIDS-defining cancers (Hodgkin's lymphoma, lung cancer, liver cancer, and anal cancer) in 52 278 patients followed up in the French Hospital Database on HIV cohort during 1998-2006 (median follow-up 4.9 years, IQR 2.1-7.9; 255 353 person-years).
  • FINDINGS: Current CD4 cell count was the most predictive risk factor for all malignancies apart from anal cancer.
  • Compared with patients with CD4 count greater than 500 cells per microL, rate ratios (RR) ranged from 1.9 (95% CI 1.3-2.7) for CD4 counts 350-499 cells per microL to 25.2 (17.1-37.0) for counts less than 50 cells per microL for Kaposi's sarcoma (p<0.0001), from 1.3 (0.9-2.0) to 14.8 (9.7-22.6) for non-Hodgkin lymphoma (p<0.0001), from 1.2 (0.7-2.2) to 5.4 (2.4-12.1) for Hodgkin's lymphoma (p<0.0001), from 2.2 (1.3-3.6) to 8.5 (4.3-16.7) for lung cancer (p<0.0001), and from 2.0 (0.9-4.5) to 7.6 (2.7-20.8) for liver cancer (p<0.0001).
  • The risk of Kaposi's sarcoma and non-Hodgkin lymphoma increased for current plasma HIV RNA greater than 100 000 copies per mL compared with patients with controlled viral load (RR 3.1, 95% CI 2.3-4.2, p<0.0001; and 2.9, 2.1-3.9, p<0.0001, respectively), whereas cART was independently associated with a decreased incidence (0.3, 0.2-0.4, p<0.0001; and 0.8, 0.6-1.0, p=0.07, respectively).
  • The risk of anal cancer increased with the time during which the CD4 count was less than 200 cells per microL (1.3 per year, 1.2-1.5; p=0.0001), and viral load was greater than 100 000 copies per mL (1.2 per year, 1.1-1.4, p=0.005).
  • INTERPRETATION: cART would be most beneficial if it restores or maintains CD4 count above 500 cells per microL, thereby indicating an earlier diagnosis of HIV infection and an earlier treatment initiation.


57. Casper C, Carrell D, Miller KG, Judson FD, Meier AS, Pauk JS, Morrow RA, Corey L, Wald A, Celum C: HIV serodiscordant sex partners and the prevalence of human herpesvirus 8 infection among HIV negative men who have sex with men: baseline data from the EXPLORE Study. Sex Transm Infect; 2006 Jun;82(3):229-35
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a multivariate model, reporting more than the median number of lifetime sex partners (OR 2.2, p = 0.03) or lifetime sex partners of unknown HIV status (OR 1.7, p = 0.03), and the performance of oro-anal sex ("rimming") on partners whose HIV status is unknown (OR 2.7, p = 0.04) were independently associated with HHV-8 infection.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2002 Mar 13;287(10):1295-300 [11886321.001]
  • [Cites] Sex Transm Dis. 2001 Mar;28(3):176-83 [11289201.001]
  • [Cites] J Clin Microbiol. 2002 Oct;40(10):3822-5 [12354890.001]
  • [Cites] Am J Public Health. 2003 Jun;93(6):926-32 [12773357.001]
  • [Cites] AIDS. 2003 Aug 15;17(12):1717-30 [12891058.001]
  • [Cites] J Virol. 2004 Apr;78(8):4074-84 [15047824.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):233-8 [15076237.001]
  • [Cites] Lancet. 1992 Mar 14;339(8794):632-5 [1347337.001]
  • [Cites] Am J Epidemiol. 1993 Aug 15;138(4):256-65 [8356966.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] J Leukoc Biol. 2001 Apr;69(4):639-44 [11310851.001]
  • [Cites] Rev Med Virol. 2002 Jan-Feb;12(1):47-63 [11787083.001]
  • [Cites] J Infect Dis. 2002 Apr 1;185(7):990-3 [11920325.001]
  • [Cites] Clin Infect Dis. 1996 Aug;23(2):406-7 [8842293.001]
  • [Cites] Lancet. 1996 Oct 26;348(9035):1133-8 [8888167.001]
  • [Cites] J Infect Dis. 1997 Jul;176(1):94-102 [9207354.001]
  • [Cites] J Virol. 1997 Sep;71(9):7083-7 [9261440.001]
  • [Cites] J Infect Dis. 1998 Jan;177(1):213-6 [9419191.001]
  • [Cites] Int J Cancer. 1998 Aug 12;77(4):543-8 [9679756.001]
  • [Cites] J Infect Dis. 1998 Dec;178(6):1610-5 [9815212.001]
  • [Cites] Adv Cancer Res. 1999;76:121-60 [10218100.001]
  • [Cites] Am J Epidemiol. 2000 Feb 1;151(3):213-24 [10670545.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1369-77 [11070101.001]
  • [Cites] Epidemiol Infect. 2000 Dec;125(3):671-5 [11218216.001]
  • [Cites] J Infect Dis. 1999 Oct;180(4):1010-7 [10479125.001]
  • (PMID = 16731675.001).
  • [ISSN] 1368-4973
  • [Journal-full-title] Sexually transmitted infections
  • [ISO-abbreviation] Sex Transm Infect
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U19 AI031448; United States / NIAID NIH HHS / AI / U19 AI31448; United States / NIAID NIH HHS / AI / P01 AI030731; United States / NIAID NIH HHS / AI / K23 AI054162; United States / NIAID NIH HHS / AI / P01 AI30731
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2564745
  •  go-up   go-down


58. Lim ST, Levine AM: Non-AIDS-defining cancers and HIV infection. Curr HIV/AIDS Rep; 2005 Aug;2(3):146-53
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Apart from Kaposi's sarcoma, non-Hodgkin's lymphoma, and cervical cancer, which are considered as AIDS-defining, several additional cancers, referred to as non-AIDS-defining cancers, are also statistically increased in HIV-infected persons.
  • These include Hodgkin's disease, anal carcinoma, lung cancer, nonmelanomatous skin cancer, and testicular germ cell tumors, among others.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16091262.001).
  • [ISSN] 1548-3568
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 64
  •  go-up   go-down


59. Nadal SR, Manzione CR, Horta SH: Comparison of perianal diseases in HIV-positive patients during periods before and after protease inhibitors use: what changed in the 21st century. Dis Colon Rectum; 2008 Oct;51(10):1491-4
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In Group 1, the most common diseases were condylomas (24.7 percent), ulcers (21.8 percent), and anal fistulas (19.7 percent).
  • Tumors occurred in 2.5 percent, with Kaposi's sarcoma in 51.1 percent, and squamous-cell carcinoma in 27.6 percent.
  • The tumor incidence was 1.8 percent, with squamous-cell carcinoma in 59.4 percent and Kaposi's sarcoma in 23.2 percent.
  • Changes in incidence were statistically significant for the increase in condylomas and fissures, and for the decrease in ulcers, fistulas, and Kaposi's sarcoma among Group 2 patients.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670819.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protease Inhibitors
  •  go-up   go-down


60. Gatta G, Ciccolallo L, Kunkler I, Capocaccia R, Berrino F, Coleman MP, De Angelis R, Faivre J, Lutz JM, Martinez C, Möller T, Sankila R, EUROCARE Working Group: Survival from rare cancer in adults: a population-based study. Lancet Oncol; 2006 Feb;7(2):132-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FINDINGS: Overall 5-year relative survival was good (ie, >65%) for placental choriocarcinoma (85.4% [95% CI 81.4-89.5]), thyroid medullary carcinoma (72.4% [69.2-75.5]), ovarian germ-cell cancer (73.0% [70.0-76.0]), lung carcinoid (70.1% [67.3-72.9]), and cervical adenocarcinoma (65.5% [64.3-66.6]); intermediate (ie, 35-65%) for testicular cancer at age 65 years or older (64.0% [59.3-68.7]), sarcoma of extremities (60.0% [58.9-61.2]), digestive-system endocrine cancers (55.6% [54.9-56.3]), anal squamous-cell carcinoma (53.1% [51.5-54.8]), and uterine sarcoma (43.5% [42.0-44.9]); low for carcinoma of adrenal-gland cortex (32.7% [28.3-37.2]) and bladder squamous-cell carcinoma (20.4% [18.8-22.0]); and poor for angiosarcoma of liver (6.4% [1.8-11.0]) and mesothelioma (4.7% [4.3-5.2]).
  • Survival significantly improved over time for ovarian germ-cell cancer, sarcomas of extremities, digestive-system endocrine tumours, anal squamous-cell carcinoma, and angiosarcoma of liver.

  • MedlinePlus Health Information. consumer health - Rare Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16455477.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


66. Wagner DG, Yao JL, di Sant'Agnese PA, Cheng L, Lopez-Beltran A, Montironi R, Huang J: Soft tissue tumors of the prostate: a review. Anal Quant Cytol Histol; 2007 Dec;29(6):341-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnostic immunohistochemistry is an important adjunct to histopathology for proper diagnosis and tumor subclassification.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18225389.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 90
  •  go-up   go-down


67. Clifford GM, Franceschi S: Cancer risk in HIV-infected persons: influence of CD4(+) count. Future Oncol; 2009 Jun;5(5):669-78
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whereas Kaposi sarcoma and non-Hodgkin lymphoma were recognised as AIDS-defining illnesses early in the HIV epidemic, the influence of declining CD4(+) count on other infection-related cancers has taken longer to establish, undoubtedly because the association is weaker and the dose-response relationship is less steep.
  • However, following improved survival made possible by combined antiretroviral therapy, declining CD4(+) count starts showing an impact on the natural history of various carcinogenic infections and on the risk for an increasingly wide range of cancers, including Hodgkin lymphoma, cervical, anal and liver cancers.

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19519206.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 91
  •  go-up   go-down


68. Cáceres W, Cruz-Amy M, Díaz-Meléndez V: AIDS-related malignancies: revisited. P R Health Sci J; 2010 Mar;29(1):70-5
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi sarcoma (KS), non-Hodgkin's lymphomas (NHL), and cervical cancer are classified by the Centers for Disease Control and Prevention (CDC) as AIDS-defining malignancies.
  • However, since the availability of highly active combination antiretroviral therapy (cART), especially protease inhibitors, there has been a steady increase in non- AIDS defining malignancies, such as Hodgkin's lymphoma (HL), lung cancer, hepatocellular cancer, anal cancer and others and a decline in AIDS-defining neoplasias.


69. Dhir AA, Sawant SP: Malignancies in HIV: the Indian scenario. Curr Opin Oncol; 2008 Sep;20(5):517-21
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma is rare in India.
  • Amongst the non-AIDS defining cancers anal cancer, testicular cancer, Hodgkin's disease, colon cancer and certain head and neck cancer sites in men and vaginal cancers among women were found to occur more frequently.

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106653.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


70. Barbaro G, Barbarini G: HIV infection and cancer in the era of highly active antiretroviral therapy (Review). Oncol Rep; 2007 May;17(5):1121-6
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of cancers affecting HIV-infected subjects are those established as acquired immunodeficiency syndrome (AIDS)-defining: Kaposi's sarcoma (KS), non-Hodgkin's lymphoma (NHL), and invasive cervical cancer (ICC).
  • However, other types of cancer, such as Hodgkin's disease (HD), anal cancer, lung cancer and testicular germ cell tumors appear to be more common among HIV-infected subjects compared to the general population.
  • While a significant decrease in the incidence of KS has been observed, HAART has not had a significant impact on NHL incidence, particularly systemic NHL, or on ICC, HD, anal cancers and other non-AIDS-defining cancers.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17390054.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 44
  •  go-up   go-down


71. Yoo HJ, Yun BR, Kwon JH, Ahn HS, Seol MA, Lee MJ, Yu GR, Yu HC, Hong B, Choi K, Kim DG: Genetic and expression alterations in association with the sarcomatous change of cholangiocarcinoma cells. Exp Mol Med; 2009 Feb 28;41(2):102-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Cholangiocarcinoma / genetics. Gene Expression Profiling. Sarcoma / genetics


72. van de Luijtgaarden AC, Veth RP, Slootweg PJ, Wijers-Koster PM, Schultze Kool LJ, Bovee JV, van der Graaf WT: Metastatic potential of an aneurysmal bone cyst. Virchows Arch; 2009 Nov;455(5):455-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple cases of malignant transformation of ABC into (osteo)sarcoma have been described, as well as a number of cases of telangiectatic osteosarcoma which had been misdiagnosed as ABC.
  • Diagnosis was confirmed by the presence of a break in the USP6 gene, which is pathognomonic for ABC, in a pulmonary metastasis of our patient.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2000 Jun;28(2):233-4 [10825009.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):311-5 [16755186.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):e1; author reply e2 [16382110.001]
  • [Cites] Oncogene. 2005 May 12;24(21):3419-26 [15735689.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Nov;26(3):265-6 [10502326.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1206-10 [11106078.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jul;48(7):583-602 [19396867.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Oct 15;178(2):155-9 [17954273.001]
  • [Cites] Pediatr Dev Pathol. 2007 Jan-Feb;10(1):46-9 [17378626.001]
  • [Cites] Pediatr Dev Pathol. 2006 Jan-Feb;9(1):38-43 [16808643.001]
  • [Cites] Pediatr Dev Pathol. 2001 Jul-Aug;4(4):418-9 [11441369.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Sep;129(2):177-80 [11566352.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):636-9 [11764383.001]
  • [Cites] Anal Cell Pathol. 2001;23(2):89-95 [11904464.001]
  • [Cites] Life Sci. 2003 Aug 1;73(11):1427-36 [12850503.001]
  • [Cites] J Formos Med Assoc. 2003 Sep;102(9):631-6 [14625608.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1920-3 [15026324.001]
  • [Cites] Mod Pathol. 2004 May;17(5):518-25 [15044915.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1773-80 [15509545.001]
  • [Cites] Pediatr Radiol. 1986;16(2):140-3 [3456553.001]
  • [Cites] Skeletal Radiol. 1987;16(3):196-200 [3473690.001]
  • [Cites] Cancer. 1988 Jun 15;61(12):2532-40 [3163257.001]
  • [Cites] Ital J Orthop Traumatol. 1987 Dec;13(4):425-36 [3503870.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Jan;58(1):2-13 [1728946.001]
  • [Cites] Cancer. 1992 Jun 15;69(12):2921-31 [1591685.001]
  • [Cites] Surg Today. 1994;24(5):476-80 [8054822.001]
  • [Cites] Cytometry. 1995 Mar 1;19(3):256-62 [7736870.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Oct 1;84(1):27-31 [7497439.001]
  • [Cites] Pathologe. 1996 Jan;17(1):44-9 [8685095.001]
  • [Cites] Clin Orthop Relat Res. 1997 Feb;(335):253-61 [9020226.001]
  • (PMID = 19838726.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins; 2S9ZZM9Q9V / Bevacizumab; EC 3.1.2.15 / USP6 protein, human; EC 3.1.2.15 / Ubiquitin Thiolesterase
  •  go-up   go-down


73. Tan AY, Manley JL: The TET family of proteins: functions and roles in disease. J Mol Cell Biol; 2009 Dec;1(2):82-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Translocated in liposarcoma, Ewing's sarcoma and TATA-binding protein-associated factor 15 constitute an interesting and important family of proteins known as the TET proteins.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1999 Oct;23(2):222-7 [10508522.001]
  • [Cites] Oncogene. 1999 Sep 30;18(40):5592-7 [10523836.001]
  • [Cites] Nature. 2004 Nov 11;432(7014):235-40 [15531877.001]
  • [Cites] Nucleic Acids Res. 2005;33(4):1323-31 [15743974.001]
  • [Cites] Curr Biol. 2005 Mar 29;15(6):587-93 [15797031.001]
  • [Cites] Semin Cancer Biol. 2005 Jun;15(3):189-96 [15826833.001]
  • [Cites] Semin Cancer Biol. 2005 Jun;15(3):197-205 [15826834.001]
  • [Cites] Neurosci Lett. 2005 May 13;379(3):152-7 [15843054.001]
  • [Cites] Curr Opin Cell Biol. 2005 Jun;17(3):251-6 [15901493.001]
  • [Cites] Stem Cells. 2005 Jun-Jul;23(6):738-51 [15917470.001]
  • [Cites] Proteins. 2005 Oct 1;61(1):164-75 [16044463.001]
  • [Cites] Nature. 2005 Oct 20;437(7062):1173-8 [16189514.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2513-27 [16213703.001]
  • [Cites] Gene. 2005 Dec 19;363:1-14 [16202544.001]
  • [Cites] J Cell Sci. 2005 Dec 15;118(Pt 24):5755-65 [16317045.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1381-9 [16206264.001]
  • [Cites] Cancer Cell. 2006 May;9(5):405-16 [16697960.001]
  • [Cites] Oncologist. 2006 May;11(5):503-19 [16720851.001]
  • [Cites] Proteomics. 2006 Nov;6(22):5962-72 [17106916.001]
  • [Cites] Oncogene. 1999 Dec 9;18(52):7599-601 [10602520.001]
  • [Cites] Oncogene. 2009 Mar 5;28(9):1280-4 [19151750.001]
  • [Cites] Biochemistry. 2009 Apr 7;48(13):2849-57 [19290668.001]
  • [Cites] Exp Cell Res. 2009 Apr 15;315(7):1273-86 [19124016.001]
  • [Cites] PLoS One. 2009;4(4):e5415 [19404404.001]
  • [Cites] EMBO Rep. 2009 May;10(5):494-500 [19282884.001]
  • [Cites] Cancer Sci. 2009 Feb;100(2):200-8 [19076980.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Apr 8;329(2):653-60 [15737635.001]
  • [Cites] Science. 1990 Aug 3;249(4968):505-10 [2200121.001]
  • [Cites] Nature. 1992 Sep 10;359(6391):162-5 [1522903.001]
  • [Cites] EMBO J. 1993 Feb;12(2):489-99 [8440239.001]
  • [Cites] Nature. 1993 Jun 17;363(6430):640-4 [8510758.001]
  • [Cites] Trends Biochem Sci. 1993 Jun;18(6):226-30 [7688487.001]
  • [Cites] Nat Genet. 1993 Jun;4(2):175-80 [7503811.001]
  • [Cites] EMBO J. 1993 Dec;12(12):4481-7 [8223458.001]
  • [Cites] Genes Dev. 1994 Feb 15;8(4):453-64 [8125258.001]
  • [Cites] Mol Cell Biol. 1994 May;14(5):3230-41 [8164678.001]
  • [Cites] Science. 1994 Jul 29;265(5172):615-21 [8036511.001]
  • [Cites] Oncogene. 1994 Oct;9(10):3087-97 [8084618.001]
  • [Cites] Genes Dev. 1994 Nov 1;8(21):2513-26 [7958914.001]
  • [Cites] Eur J Biochem. 2001 Jun;268(12):3483-9 [11422378.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5747-54 [11607824.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):41977-84 [11553628.001]
  • [Cites] Oncogene. 2001 Oct 11;20(46):6653-9 [11709699.001]
  • [Cites] Nature. 2001 Dec 20-27;414(6866):929-33 [11780068.001]
  • [Cites] Genes Dev. 2002 Mar 15;16(6):673-5 [11963920.001]
  • [Cites] Cancer Cell. 2002 May;1(4):393-401 [12086853.001]
  • [Cites] Genome Res. 2002 Aug;12(8):1231-45 [12176931.001]
  • [Cites] Nature. 2002 Sep 12;419(6903):182-5 [12226669.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5408-12 [12359745.001]
  • [Cites] Nat Struct Biol. 2002 Nov;9(11):790-1 [12402032.001]
  • [Cites] Cell. 2002 Nov 1;111(3):407-17 [12419250.001]
  • [Cites] Cancer Biol Ther. 2002 Jul-Aug;1(4):428-32 [12432261.001]
  • [Cites] Oncogene. 2002 Nov 28;21(54):8302-9 [12447693.001]
  • [Cites] Ann Hum Genet. 2002 Nov;66(Pt 5-6):331-42 [12485467.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):482-92 [12509448.001]
  • [Cites] Gene. 2003 Jan 16;303:11-34 [12559563.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):5427-32 [12459554.001]
  • [Cites] Exp Cell Res. 2003 Feb 15;283(2):184-95 [12581738.001]
  • [Cites] Exp Cell Res. 2003 Aug 15;288(2):374-81 [12915128.001]
  • [Cites] Anal Chem. 2003 Jul 1;75(13):3107-14 [12964758.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8338-44 [14678994.001]
  • [Cites] Cell Signal. 2004 Apr;16(4):515-20 [14709340.001]
  • [Cites] FEBS Lett. 2004 Apr 23;564(1-2):188-98 [15094065.001]
  • [Cites] EMBO J. 2004 Apr 21;23(8):1782-91 [15057275.001]
  • [Cites] J Orthop Res. 2004 Jul;22(4):910-7 [15183454.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(16):7275-83 [15282325.001]
  • [Cites] Neuron. 2004 Aug 19;43(4):513-25 [15312650.001]
  • [Cites] RNA. 2004 Oct;10(10):1489-98 [15383674.001]
  • [Cites] J Biol Chem. 2004 Oct 22;279(43):44834-40 [15299008.001]
  • [Cites] Biochemistry. 2004 Oct 26;43(42):13579-89 [15491164.001]
  • [Cites] Cell. 1977 May;11(1):127-38 [872217.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1248-55 [9552022.001]
  • [Cites] J Biol Chem. 1998 Jul 17;273(29):18086-91 [9660765.001]
  • [Cites] EMBO J. 1998 Aug 3;17(15):4442-55 [9687511.001]
  • [Cites] Oncogene. 1998 Aug 6;17(5):603-10 [9704926.001]
  • [Cites] Genes Dev. 1998 Oct 1;12(19):2992-6 [9765201.001]
  • [Cites] J Biol Chem. 1998 Oct 23;273(43):27761-4 [9774382.001]
  • [Cites] Oncogene. 1999 Jan 21;18(3):721-9 [9989822.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1428-32 [10197607.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5025-30 [10220412.001]
  • [Cites] Genes Dev. 1999 May 1;13(9):1102-15 [10323862.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4515-21 [10442642.001]
  • [Cites] Semin Cancer Biol. 1999 Aug;9(4):303-18 [10448117.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):30-3 [10449603.001]
  • [Cites] Nucleic Acids Res. 1995 Mar 11;23(5):835-43 [7708500.001]
  • [Cites] Mol Cell Biol. 1995 May;15(5):2800-8 [7739561.001]
  • [Cites] Mol Cell Biol. 1995 Aug;15(8):4562-71 [7623847.001]
  • [Cites] RNA. 1995 Sep;1(7):724-33 [7585257.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1245-51 [8648380.001]
  • [Cites] Science. 1996 Oct 25;274(5287):605-10 [8849451.001]
  • [Cites] EMBO J. 1996 Sep 16;15(18):5022-31 [8890175.001]
  • [Cites] Genomics. 1996 Nov 15;38(1):51-7 [8954779.001]
  • [Cites] Oncogene. 1996 Dec 19;13(12):2649-58 [9000139.001]
  • [Cites] J Clin Invest. 1997 Jan 15;99(2):239-47 [9005992.001]
  • [Cites] Oncogene. 1997 Jan 30;14(4):451-61 [9053842.001]
  • [Cites] Oncogene. 1997 Mar 20;14(11):1259-68 [9178886.001]
  • [Cites] EMBO J. 1997 Jul 16;16(14):4421-32 [9250686.001]
  • [Cites] J Cell Sci. 1997 Aug;110 ( Pt 15):1741-50 [9264461.001]
  • [Cites] Oncogene. 1997 Sep;15(11):1357-62 [9315104.001]
  • [Cites] J Biol Chem. 1997 Oct 24;272(43):27369-77 [9341188.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):495-7 [9398859.001]
  • [Cites] Mol Endocrinol. 1998 Jan;12(1):4-18 [9440806.001]
  • [Cites] Mol Cell Biol. 1998 Mar;18(3):1489-97 [9488465.001]
  • [Cites] J Biol Chem. 1998 Feb 27;273(9):4838-42 [9478924.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5064-7 [10537274.001]
  • [Cites] J Biol Chem. 1999 Nov 26;274(48):34337-42 [10567410.001]
  • [Cites] Oncogene. 1999 Dec 9;18(52):7594-8 [10602519.001]
  • [Cites] Oncogene. 1999 Dec 23;18(56):8000-10 [10637511.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):175-9 [10655065.001]
  • [Cites] EMBO J. 2000 Feb 1;19(3):453-62 [10654943.001]
  • [Cites] Mol Cell Biol. 2000 May;20(10):3345-54 [10779324.001]
  • [Cites] Oncogene. 2000 May 11;19(20):2413-22 [10828883.001]
  • [Cites] Genes Dev. 2000 Jun 15;14(12):1415-29 [10859161.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):6159-69 [10913197.001]
  • [Cites] J Biol Chem. 2000 Jul 28;275(30):23053-8 [10767297.001]
  • [Cites] J Biol Chem. 2000 Dec 1;275(48):37612-8 [10982800.001]
  • [Cites] Oncogene. 2000 Nov 23;19(50):5821-5 [11126370.001]
  • [Cites] Lab Invest. 2000 Dec;80(12):1833-44 [11140696.001]
  • [Cites] Oncogene. 2000 Dec 7;19(52):6015-22 [11146553.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6807-16 [11098054.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2690-5 [11289149.001]
  • [Cites] Oncogene. 2001 Mar 22;20(12):1519-24 [11313895.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3586-90 [11325824.001]
  • [Cites] J Biol Chem. 2001 Jun 1;276(22):18681-7 [11278906.001]
  • [Cites] Oncogene. 2001 May 28;20(24):3014-20 [11420716.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):479-84 [17202261.001]
  • [Cites] Cell Res. 2007 Apr;17(4):286-8 [17426699.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1314-23 [17415412.001]
  • [Cites] Cancer Lett. 2007 Aug 28;254(1):1-10 [17250957.001]
  • [Cites] J Mol Med (Berl). 2007 Sep;85(9):1015-29 [17453169.001]
  • [Cites] J Pathol. 2007 Sep;213(1):4-20 [17691072.001]
  • [Cites] PLoS One. 2007;2(10):e979 [17912356.001]
  • [Cites] Carcinogenesis. 2007 Oct;28(10):2069-73 [17468515.001]
  • [Cites] J Orthop Res. 2008 Jun;26(6):886-93 [18271016.001]
  • [Cites] FEBS Lett. 2008 Jun 18;582(14):1971-6 [18435923.001]
  • [Cites] Nature. 2008 Jul 3;454(7200):126-30 [18509338.001]
  • [Cites] PLoS One. 2008;3(7):e2569 [18596980.001]
  • [Cites] BMC Cell Biol. 2008;9:37 [18620564.001]
  • [Cites] Pathology. 2008 Oct;40(6):547-52 [18752119.001]
  • [Cites] Proteins. 2008 Sep;72(4):1125-37 [18320585.001]
  • [Cites] J Androl. 2008 Sep-Oct;29(5):572-9 [18567644.001]
  • [Cites] Biochem J. 2008 Oct 15;415(2):297-307 [18620545.001]
  • [Cites] Oncogene. 2008 Oct 9;27(46):6034-43 [18591936.001]
  • [Cites] Rev Recent Clin Trials. 2009 Jan;4(1):12-26 [19149759.001]
  • [Cites] BMC Cancer. 2009;9:17 [19144156.001]
  • [Cites] Biochem J. 2009 Mar 15;418(3):625-34 [19076070.001]
  • [Cites] Science. 2009 Feb 27;323(5918):1205-8 [19251627.001]
  • [Cites] Science. 2009 Feb 27;323(5918):1208-11 [19251628.001]
  • (PMID = 19783543.001).
  • [ISSN] 1759-4685
  • [Journal-full-title] Journal of molecular cell biology
  • [ISO-abbreviation] J Mol Cell Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transcription Factors
  • [Number-of-references] 120
  • [Other-IDs] NLM/ PMC2905059
  •  go-up   go-down


74. Biggar RJ, Chaturvedi AK, Bhatia K, Mbulaiteye SM: Cancer risk in persons with HIV/AIDS in India: a review and future directions for research. Infect Agent Cancer; 2009;4:4
HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, Kaposi sarcoma is rare, in association with an apparently low prevalence of Kaposi sarcoma-associated herpesvirus.
  • Cervical, anal, vulva/vaginal and penile cancers all appear to be increased in PHA, based on limited data.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmic Epidemiol. 2008 Jul-Aug;15(4):264-71 [18780260.001]
  • [Cites] Br J Cancer. 1999 Nov;81(5):893-7 [10555764.001]
  • [Cites] Science. 2008 Feb 22;319(5866):1096-100 [18202256.001]
  • [Cites] Cancer Causes Control. 2008 Mar;19(2):147-53 [17992576.001]
  • [Cites] Eur J Cancer. 2007 Sep;43(14):2117-23 [17764927.001]
  • [Cites] Dis Markers. 2007;23(4):213-27 [17627057.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1266-9 [17548695.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Lancet Infect Dis. 2006 Aug;6(8):508-21 [16870529.001]
  • [Cites] J Indian Med Assoc. 2006 Jan;104(1):19-22, 24 [16850862.001]
  • [Cites] Indian J Pathol Microbiol. 2005 Jan;48(1):7-12 [16758774.001]
  • [Cites] Indian J Pathol Microbiol. 2005 Apr;48(2):151-60 [16758653.001]
  • [Cites] Adv Dent Res. 2006;19(1):99-105 [16672559.001]
  • [Cites] Adv Dent Res. 2006;19(1):63-8 [16672552.001]
  • [Cites] J Med Virol. 2005 Aug;76(4):470-5 [15977244.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):199-204 [15690139.001]
  • [Cites] BMC Infect Dis. 2004 Nov 22;4:52 [15555069.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1998 Jun;29(2):373-6 [9886131.001]
  • [Cites] Br J Ophthalmol. 1996 Jun;80(6):503-8 [8759259.001]
  • [Cites] J Assoc Physicians India. 1993 Apr;41(4):241-2 [8270582.001]
  • [Cites] AIDS Res Hum Retroviruses. 1993 Jun;9(6):573-7 [8347400.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):26-36 [8478145.001]
  • [Cites] Indian J Pathol Microbiol. 2001 Jan;44(1):1-4 [12561985.001]
  • [Cites] J Infect Dis. 2004 Oct 15;190(8):1382-6 [15378429.001]
  • [Cites] Am J Med Sci. 2004 Jul;328(1):57-63 [15254442.001]
  • [Cites] Indian J Pathol Microbiol. 2002 Jul;45(3):293-8 [12785169.001]
  • [Cites] J Infect Dis. 2003 Jun 1;187(11):1780-5 [12751036.001]
  • [Cites] Neurol India. 2002 Dec;50(4):424-9 [12577089.001]
  • [Cites] Dermatol Online J. 2002 Oct;8(2):19 [12546774.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):536-41 [12473843.001]
  • [Cites] Surg Neurol. 2002 Feb;57(2):113-6 [11904205.001]
  • [Cites] Lancet. 2002 Feb 9;359(9305):497-8 [11853800.001]
  • [Cites] Acta Cytol. 2002 Jan-Feb;46(1):35-9 [11843556.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 Feb 1;29(2):181-3 [11832689.001]
  • [Cites] HIV Med. 2001 Oct;2(4):266-71 [11737408.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] J Infect Dis. 2000 May;181(5):1562-8 [10823754.001]
  • [Cites] Am J Ophthalmol. 2000 Jan;129(1):9-15 [10653406.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2590-3 [18224690.001]
  • (PMID = 19327166.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2667414
  •  go-up   go-down


75. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D: AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol; 2008 Oct 10;26(29):4834-42
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the advent of cART has resulted in reductions in the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma, non-AIDS-defining malignancies present an increased risk for HIV-infected patients, characterized by some common clinical features, generally with a more aggressive behavior and a more advanced disease at diagnosis, which is responsible for poorer patient outcomes.
  • Specific therapeutic recommendations are lacking for these new nonopportunistic malignancies, such as Hodgkin's lymphoma, anal cancer, lung cancer, hepatocarcinoma, and many others.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18591544.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


76. Bonnet F, Chêne G: Evolving epidemiology of malignancies in HIV. Curr Opin Oncol; 2008 Sep;20(5):534-40
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the introduction of combination antiretroviral therapy, the incidence of Kaposi's sarcoma and cerebral lymphoma (among AIDS-defining cancers) decreased in parallel with AIDS-defining infections, whereas the incidence of systemic non-Hodgkin's lymphoma and cervical cancer decreased less than others and remains higher in HIV-infected patients than in the general population.
  • These malignancies include Hodgkin's disease, lung, anal, head and neck cancers, hemopathies, and conjunctival cancers.

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106656.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 75
  •  go-up   go-down


77. Mathew SS, Bryant PW, Burch AD: Accumulation of oxidized proteins in Herpesvirus infected cells. Free Radic Biol Med; 2010 Aug 1;49(3):383-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we show that oxidized proteins accumulate during infections with two distantly related herpesviruses, HSV-1 and Rhesus Rhadinovirus (RRV), a close relative of the Kaposi's sarcoma-associated herpesvirus (KSHV).

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Free Radic Biol Med. 1999 Dec;27(11-12):1151-63 [10641706.001]
  • [Cites] Exp Eye Res. 2000 Feb;70(2):215-20 [10655147.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):5746-9 [10811907.001]
  • [Cites] Methods Mol Biol. 2000;99:15-24 [10909073.001]
  • [Cites] Drug Metab Rev. 2000 Aug-Nov;32(3-4):307-26 [11139131.001]
  • [Cites] Biochimie. 2001 Mar-Apr;83(3-4):301-10 [11295490.001]
  • [Cites] Free Radic Biol Med. 2001 May 15;30(10):1171-6 [11369508.001]
  • [Cites] EMBO J. 2001 Sep 17;20(18):5280-9 [11566891.001]
  • [Cites] IUBMB Life. 2001 Dec;52(6):303-7 [11895079.001]
  • [Cites] Free Radic Biol Med. 2002 May 1;32(9):790-6 [11978480.001]
  • [Cites] Biochem Pharmacol. 2002 Sep;64(5-6):1019-26 [12213601.001]
  • [Cites] Ann N Y Acad Sci. 2002 Nov;973:488-504 [12485918.001]
  • [Cites] Trends Mol Med. 2003 Apr;9(4):169-76 [12727143.001]
  • [Cites] Virology. 2003 Jul 20;312(1):122-34 [12890626.001]
  • [Cites] Circulation. 2004 Feb 3;109(4):500-5 [14732750.001]
  • [Cites] J Virol. 2004 Jul;78(13):7175-85 [15194794.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Dec;36(12):2519-30 [15325589.001]
  • [Cites] J Virol. 1978 Sep;27(3):490-504 [212578.001]
  • [Cites] Free Radic Res Commun. 1986;1(6):361-7 [3505892.001]
  • [Cites] Methods Enzymol. 1990;186:464-78 [1978225.001]
  • [Cites] Methods Enzymol. 1994;233:346-57 [8015469.001]
  • [Cites] J Biol Chem. 1995 Feb 3;270(5):2344-51 [7836468.001]
  • [Cites] Ann Med. 1994 Dec;26(6):435-41 [7695870.001]
  • [Cites] J Neurochem. 1995 Nov;65(5):2146-56 [7595501.001]
  • [Cites] Antiviral Res. 1995 Jun;27(3):237-53 [8540746.001]
  • [Cites] J Biol Chem. 1996 Jun 28;271(26):15504-9 [8663134.001]
  • [Cites] Free Radic Biol Med. 1996;21(5):641-9 [8891667.001]
  • [Cites] FASEB J. 1997 Jun;11(7):526-34 [9212076.001]
  • [Cites] J Proteome Res. 2008 Sep;7(9):3868-78 [18652502.001]
  • [Cites] J Virol. 2009 Sep;83(18):9304-12 [19587060.001]
  • [Cites] PLoS Pathog. 2009 Oct;5(10):e1000619 [19816571.001]
  • [Cites] J Biol Chem. 1997 Aug 15;272(33):20313-6 [9252331.001]
  • [Cites] Anal Biochem. 1999 Jan 1;266(1):48-57 [9887212.001]
  • [Cites] Arch Biochem Biophys. 1999 Feb 15;362(2):211-6 [9989929.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6223-8 [10339569.001]
  • [Cites] Free Radic Biol Med. 2004 Dec 15;37(12):2072-81 [15544925.001]
  • [Cites] Antioxid Redox Signal. 2005 Mar-Apr;7(3-4):414-22 [15706088.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11648-55 [15659387.001]
  • [Cites] EMBO J. 2005 Apr 6;24(7):1311-7 [15775985.001]
  • [Cites] J Virol. 2005 Aug;79(16):10740-9 [16051866.001]
  • [Cites] Free Radic Biol Med. 2005 Nov 1;39(9):1208-15 [16214036.001]
  • [Cites] Proteomics. 2006 Feb;6(4):1250-60 [16408314.001]
  • [Cites] J Virol. 2006 Apr;80(7):3567-81 [16537625.001]
  • [Cites] J Cell Mol Med. 2006 Apr-Jun;10(2):389-406 [16796807.001]
  • [Cites] Exp Cell Res. 2007 Jan 1;313(1):195-209 [17123510.001]
  • [Cites] J Neurovirol. 2007 Oct;13(5):416-25 [17994426.001]
  • [Cites] PLoS One. 2008;3(1):e1491 [18231578.001]
  • [Cites] J Virol. 2008 Apr;82(7):3381-90 [18234803.001]
  • [Cites] Mol Cell Biochem. 2008 Jun;313(1-2):179-86 [18414998.001]
  • [Cites] J Virol. 2008 Jul;82(13):6324-36 [18434395.001]
  • (PMID = 20441790.001).
  • [ISSN] 1873-4596
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / K22 AI062991; United States / NIAID NIH HHS / AI / K22AI062991
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HSP27 Heat-Shock Proteins; 0 / Molecular Chaperones; 0 / Proteins; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Other-IDs] NLM/ NIHMS233650; NLM/ PMC3206308
  •  go-up   go-down


78. Chen W, Jarzyna PA, van Tilborg GA, Nguyen VA, Cormode DP, Klink A, Griffioen AW, Randolph GJ, Fisher EA, Mulder WJ, Fayad ZA: RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J; 2010 Jun;24(6):1689-99
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe.
  • High density lipoprotein (HDL), an endogenous nanoparticle, transports fat throughout the body and is capable of transferring cholesterol from atheroma in the vessel wall to the liver.
  • In the present study, we utilized HDL as a multimodal nanoparticle platform for tumor targeting and imaging via nonspecific accumulation and specific binding to angiogenically activated blood vessels.
  • We reconstituted HDL (rHDL) with amphiphilic gadolinium chelates and fluorescent dyes.
  • To target angiogenic endothelial cells, rHDL was functionalized with alphavbeta3-integrin-specific RGD peptides (rHDL-RGD).
  • Nonspecific RAD peptides were conjugated to rHDL nanoparticles as a control (rHDL-RAD).
  • It was observed in vitro that all 3 nanoparticles were phagocytosed by macrophages, while alphavbeta3-integrin-specific rHDL-RGD nanoparticles were preferentially taken up by endothelial cells.
  • The uptake of nanoparticles in mouse tumors was evaluated in vivo using near infrared (NIR) and MR imaging.
  • All nanoparticles accumulated in tumors but with very different accumulation/binding kinetics as observed by NIR imaging.
  • Moreover, confocal microscopy revealed rHDL-RGD to be associated with tumor endothelial cells, while rHDL and rHDL-RAD nanoparticles were mainly found in the interstitial space.
  • This study demonstrates the ability to reroute HDL from its natural targets to tumor blood vessels and its potential for multimodal imaging of tumor-associated processes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Magn Reson Med. 2009 May;61(5):1022-32 [19235908.001]
  • [Cites] Pathobiology. 2001;69(4):225-9 [12007282.001]
  • [Cites] Mol Imaging. 2002 Oct;1(4):365-77 [12940233.001]
  • [Cites] Technol Cancer Res Treat. 2003 Dec;2(6):553-62 [14640766.001]
  • [Cites] Nat Biotechnol. 2004 Jan;22(1):93-7 [14661026.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Atherosclerosis. 1994 Feb;105(2):145-57 [8003090.001]
  • [Cites] J Lipid Res. 1999 Sep;40(9):1647-54 [10484611.001]
  • [Cites] J Am Chem Soc. 2004 Dec 22;126(50):16316-7 [15600321.001]
  • [Cites] J Am Coll Cardiol. 2005 Sep 20;46(6):937-54 [16168274.001]
  • [Cites] Mol Imaging. 2005 Jul-Sep;4(3):143-64 [16194447.001]
  • [Cites] J Am Coll Cardiol. 2005 Oct 4;46(7):1209-18 [16198833.001]
  • [Cites] FASEB J. 2005 Dec;19(14):2008-10 [16204353.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17757-62 [16306263.001]
  • [Cites] Nano Lett. 2006 Jan;6(1):1-6 [16402777.001]
  • [Cites] Magn Reson Med. 2006 Mar;55(3):491-7 [16450336.001]
  • [Cites] Nat Clin Pract Cardiovasc Med. 2006 Mar;3(3):144-53 [16505860.001]
  • [Cites] Nano Lett. 2006 Oct;6(10):2220-4 [17034087.001]
  • [Cites] J Lipid Res. 2006 Nov;47(11):2408-21 [16926440.001]
  • [Cites] Am J Cardiol. 2006 Dec 1;98(11):1542-9 [17126667.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1951-7 [17278104.001]
  • [Cites] NMR Biomed. 2007 Apr;20(2):77-89 [16952123.001]
  • [Cites] Bioconjug Chem. 2007 Mar-Apr;18(2):379-88 [17298029.001]
  • [Cites] J Am Chem Soc. 2007 May 9;129(18):5798-9 [17428054.001]
  • [Cites] Curr Opin Lipidol. 2007 Aug;18(4):443-50 [17620862.001]
  • [Cites] Expert Opin Drug Deliv. 2007 Nov;4(6):665-75 [17970668.001]
  • [Cites] Int J Nanomedicine. 2007;2(4):767-74 [18203443.001]
  • [Cites] Nutr Metab Cardiovasc Dis. 2008 May;18(4):329-35 [18378129.001]
  • [Cites] Curr Opin Cardiol. 2008 Jul;23(4):370-8 [18520722.001]
  • [Cites] FASEB J. 2008 Aug;22(8):2758-67 [18362202.001]
  • [Cites] Small. 2008 Sep;4(9):1437-44 [18712752.001]
  • [Cites] Nano Lett. 2008 Nov;8(11):3715-23 [18939808.001]
  • [Cites] Neoplasia. 2008 Dec;10(12):1459-69 [19048124.001]
  • [Cites] Clin Sci (Lond). 2009 Jan;116(2):87-98 [19076062.001]
  • [Cites] Bioconjug Chem. 2008 Dec;19(12):2471-9 [19035793.001]
  • [Cites] Contrast Media Mol Imaging. 2008 Nov-Dec;3(6):233-42 [19072768.001]
  • [Cites] Angiogenesis. 2009;12(1):17-24 [19067197.001]
  • [Cites] Magn Reson Med. 2009 May;61(5):1049-58 [19215042.001]
  • [Cites] Bioconjug Chem. 2002 Jan-Feb;13(1):128-35 [11792188.001]
  • (PMID = 20075195.001).
  • [ISSN] 1530-6860
  • [Journal-full-title] FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • [ISO-abbreviation] FASEB J.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5R24 CA-095823-04; United States / PHS HHS / / R01 H-71021; United States / NIBIB NIH HHS / EB / EB-009638; United States / PHS HHS / / R01 H-78667; United States / NIBIB NIH HHS / EB / R01 EB009638; United States / NCI NIH HHS / CA / R24 CA095823; United States / NCRR NIH HHS / RR / 1 S10 RR-09145-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrin alphaVbeta3; 0 / Lipoproteins, HDL; 0 / Molecular Probes; 0 / Oligopeptides; 99896-85-2 / arginyl-glycyl-aspartic acid
  • [Other-IDs] NLM/ PMC2874482
  •  go-up   go-down


79. Rajwanshi A, Srinivas R, Upasana G: Malignant small round cell tumors. J Cytol; 2009 Jan;26(1):1-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They generally include Ewing's sarcoma, peripheral neuroectodermal tumor, rhabdomyosarcoma, synovial sarcoma, non-Hodgkin's lymphoma, retinoblastoma, neuroblastoma, hepatoblastoma, and nephroblastoma or Wilms' tumor.
  • Other differential diagnoses of small round cell tumors include small cell osteogenic sarcoma, undifferentiated hepatoblastoma, granulocytic sarcoma, and intraabdominal desmoplastic small round cell tumor.
  • Differential diagnosis of small round cell tumors is particularly difficult due to their undifferentiated or primitive character.
  • Tumors that show good differentiation are generally easy to diagnose, but when a tumor is poorly differentiated, identification of the diagnostic, morphological features is difficult and therefore, no definitive diagnosis may be possible.
  • As seen in several study reports, fine needle aspiration cytology (FNAC) has become an important modality of diagnosis for these tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1992 Feb 15;69(4):1067-73 [1370916.001]
  • [Cites] Cancer Res. 1992 Sep 1;52(17):4701-5 [1380888.001]
  • [Cites] Diagn Cytopathol. 1992;8(5):465-74 [1396025.001]
  • [Cites] Diagn Cytopathol. 2003 Dec;29(6):341-3 [14648792.001]
  • [Cites] Diagn Cytopathol. 2004 Jan;30(1):19-23 [14696140.001]
  • [Cites] Neuroscience. 1992 Aug;49(3):497-528 [1501763.001]
  • [Cites] Diagn Cytopathol. 2004 Sep;31(3):147-54 [15349982.001]
  • [Cites] Diagn Cytopathol. 2004 Sep;31(3):159-63 [15349984.001]
  • [Cites] Diagn Cytopathol. 2005 May;32(5):281-6 [15830360.001]
  • [Cites] J Histochem Cytochem. 2005 Dec;53(12):1433-40 [15956022.001]
  • [Cites] Indian J Pathol Microbiol. 2004 Jul;47(3):309-18 [16295413.001]
  • [Cites] Eur J Cancer. 1991;27(6):762-5 [1676900.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):962-8 [16861966.001]
  • [Cites] Acta Cytol. 1990 Jan-Feb;34(1):79-83 [1688679.001]
  • [Cites] Cytojournal. 2006;3:24 [17069647.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):499-513 [1709557.001]
  • [Cites] Cancer. 2007 Feb 25;111(1):41-6 [17173322.001]
  • [Cites] Br J Cancer. 1991 Dec;64(6):1039-42 [1764365.001]
  • [Cites] Hum Mol Genet. 1997 Sep;6(9):1549-58 [9285793.001]
  • [Cites] Pathol Int. 1997 Sep;47(9):637-41 [9311017.001]
  • [Cites] N Engl J Med. 1998 Jan 15;338(3):153-60 [9428816.001]
  • [Cites] Am J Clin Pathol. 1998 May;109(5):625-30 [9576583.001]
  • [Cites] J Korean Med Sci. 1998 Aug;13(4):395-9 [9741544.001]
  • [Cites] Diagn Cytopathol. 1998 Nov;19(5):382-4 [9812236.001]
  • [Cites] Clin Cancer Res. 1998 Nov;4(11):2801-5 [9829745.001]
  • [Cites] Nature. 1978 Dec 21-28;276(5690):834-6 [31568.001]
  • [Cites] Acta Cytol. 1988 May-Jun;32(3):367-76 [3287819.001]
  • [Cites] Acta Cytol. 1988 Jan-Feb;32(1):1-10 [3336946.001]
  • [Cites] Am J Pathol. 1986 Mar;122(3):433-42 [3513600.001]
  • [Cites] Cancer. 1986 Feb 15;57(4):797-803 [3943013.001]
  • [Cites] Cancer. 1985 Sep 15;56(6):1490-2 [4027884.001]
  • [Cites] Am J Pathol. 1995 Dec;147(6):1584-91 [7495283.001]
  • [Cites] Am J Pathol. 1995 Dec;147(6):1799-810 [7495304.001]
  • [Cites] EMBO J. 1995 May 15;14(10):2333-40 [7539744.001]
  • [Cites] Am J Surg Pathol. 1995 Jun;19(6):659-65 [7755152.001]
  • [Cites] J Pathol. 1995 Apr;175(4):391-6 [7790992.001]
  • [Cites] Ann Clin Lab Sci. 1994 Jan-Feb;24(1):6-11 [8147568.001]
  • [Cites] Pathol Res Pract. 1993 Dec;189(10):111-36 [8183732.001]
  • [Cites] Acta Cytol. 1994 May-Jun;38(3):355-60 [8191824.001]
  • [Cites] Am J Pathol. 1994 Jun;144(6):1121-34 [8203453.001]
  • [Cites] Am J Surg Pathol. 1993 Jan;17(1):1-13 [8383465.001]
  • [Cites] Histopathology. 1993 Jul;23(1):93-7 [8396065.001]
  • [Cites] Diagn Cytopathol. 1995 Nov;13(4):310-5 [8599914.001]
  • [Cites] Int J Gynecol Pathol. 1995 Jul;14(3):260-5 [8600079.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1214-9 [8635146.001]
  • [Cites] J Pediatr Hematol Oncol. 1996 Aug;18(3):293-8 [8689345.001]
  • [Cites] Acta Cytol. 1997 Jul-Aug;41(4):1035-47 [9250296.001]
  • [Cites] Arch Pathol Lab Med. 1999 Mar;123(3):206-12 [10086508.001]
  • [Cites] Histopathology. 1999 Mar;34(3):205-10 [10217560.001]
  • [Cites] Diagn Cytopathol. 1999 May;20(5):271-7 [10319227.001]
  • [Cites] Diagn Cytopathol. 1999 May;20(5):278-84 [10319228.001]
  • [Cites] Am J Pathol. 1999 Jul;155(1):17-21 [10393831.001]
  • [Cites] Diagn Cytopathol. 1999 Aug;21(2):81-91 [10425044.001]
  • [Cites] Hum Pathol. 2000 Feb;31(2):246-50 [10685642.001]
  • [Cites] Diagn Cytopathol. 2000 Aug;23(2):118-23 [10888758.001]
  • [Cites] Acta Cytol. 2000 Jul-Aug;44(4):524-32 [10934943.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):776-81 [11395555.001]
  • [Cites] Biol Pharm Bull. 2004 Mar;27(3):315-8 [14993794.001]
  • [Cites] Cytometry B Clin Cytom. 2005 Mar;64(1):34-42 [15669024.001]
  • [Cites] Diagn Cytopathol. 2005 Apr;32(4):211-6 [15754373.001]
  • [Cites] Diagn Cytopathol. 2005 Jun;32(6):330-5 [15880716.001]
  • [Cites] Cytopathology. 2007 Aug;18(4):234-40 [17559565.001]
  • [Cites] Diagn Mol Pathol. 1995 Sep;4(3):162-73 [7493135.001]
  • [Cites] Acta Cytol. 1993 Jul-Aug;37(4):477-82 [8392251.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):406-12 [8604806.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1886-93 [1848471.001]
  • [Cites] Am J Pathol. 1991 Aug;139(2):317-25 [1867320.001]
  • [Cites] Diagn Cytopathol. 1991;7(5):451-61 [1954821.001]
  • [Cites] Cell. 1990 Feb 9;60(3):509-20 [2154335.001]
  • [Cites] Am J Pathol. 1990 Dec;137(6):1283-91 [2260621.001]
  • [Cites] Hum Pathol. 1986 Oct;17(10):996-1008 [2428727.001]
  • [Cites] Diagn Cytopathol. 1989;5(4):378-82 [2612314.001]
  • [Cites] Cancer. 1985 Apr 15;55(8):1805-17 [2983864.001]
  • [Cites] Diagn Cytopathol. 1997 Jun;16(6):513-7 [9181317.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1807-12 [9846971.001]
  • [Cites] Diagn Cytopathol. 1998 Dec;19(6):410-6 [9839129.001]
  • [Cites] J Surg Oncol. 1999 Aug;71(4):269-72 [10440769.001]
  • [Cites] Mod Pathol. 2000 May;13(5):482-8 [10824918.001]
  • [Cites] Acta Cytol. 2000 May-Jun;44(3):332-6 [10833987.001]
  • [Cites] Arch Pathol Lab Med. 2000 Dec;124(12):1792-9 [11100059.001]
  • [Cites] Diagn Cytopathol. 2001 Apr;24(4):233-9 [11285617.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Sep;9(3):255-60 [11556754.001]
  • [Cites] Anal Quant Cytol Histol. 2001 Dec;23(6):405-12 [11777275.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):135-40 [11782370.001]
  • [Cites] Cancer. 2002 Feb 25;96(1):21-31 [11836699.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):965-77 [12170083.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1175-83 [12218574.001]
  • [Cites] Diagn Cytopathol. 2003 May;28(5):232-8 [12722117.001]
  • [Cites] Acta Cytol. 1992 Jul-Aug;36(4):541-50 [1321999.001]
  • (PMID = 21938141.001).
  • [ISSN] 0970-9371
  • [Journal-full-title] Journal of cytology
  • [ISO-abbreviation] J Cytol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3167982
  • [Keywords] NOTNLM ; Fine needle aspiration cytology / ancillary techniques / malignant small round cell tumors
  •  go-up   go-down


80. Bartee E, McCormack A, Früh K: Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog; 2006 Oct;2(10):e107
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For instance, the K5 modulator of immune recognition (MIR2) from Kaposi sarcoma-associated herpesvirus prevents activation of cytotoxic T cells, natural killer cells, and natural killer T cells by downregulating major histocompatibility complex (MHC) class I molecules, the MHC-like molecule CD1, the cell adhesion molecules ICAM-1 and PECAM, and the co-stimulatory molecule B7.2.